Research Square

Preprints are preliminary reports that have not undergone peer review.
They should not be considered conclusive, used to inform clinical practice,
or referenced by the media as validated information.

Adjunctive use of a novel immunomodulatory treatment to standard protocol in dogs with clinical leishmaniosis: a prospective masked placebo-controlled longitudinal study

Marina Domínguez-Ruiz

mdominguez@uax.es

Facultad de Veterinaria, Universidad Alfonso X el Sabio (UAX). Avenida de la Universidad, 1. 28691 Villanueva de la Cañada. Madrid. España.

Rodolfo Oliveira Leal

CIISA – Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon/ Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS)

Pamela Campioli

Unidad de Investigación. Facultad de Veterinaria, Universidad Alfonso X el Sabio (UAX). Avenida de la Universidad, 1. 28691 Villanueva de la Cañada. Madrid. España.

Veronica Salazar-Nussio

Facultad de Veterinaria, Universidad Alfonso X el Sabio (UAX). Avenida de la Universidad, 1. 28691 Villanueva de la Cañada. Madrid. España.

Ana María Gutiérrez-Serrera

Facultad de Veterinaria, Universidad Alfonso X el Sabio (UAX). Avenida de la Universidad, 1. 28691 Villanueva de la Cañada. Madrid. España.

Gustavo Ortiz-Díez

Department of Animal Medicine and Surgery, Veterinary Medicine School, Complutense University of Madrid, Madrid, Spain.

Javier García-Castro

Unidad de Biotecnología Celular. Instituto de Salud Carlos III. Madrid. España

---

Research Article

Keywords: Canine leishmaniosis, Leishmania infantum, nutraceutical, immunomodulation, placebo-controlled study, cytokines, proteinuria, azotaemia, prognosis

Posted Date: August 10th, 2026

DOI: https://doi.org/10.21203/rs.3.rs-10554309/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License

Additional Declarations: Competing interest reported. The experimental work presented in this study was partially funded by Santander Universidades–Fundación Universidad Alfonso X el Sabio (FUAX) and by Omnifect Ibérica S.L.

Adjunctive use of a novel immunomodulatory treatment to standard protocol in dogs with clinical leishmaniosis: a prospective masked placebo-controlled longitudinal study

M. Domínguez-Ruiz[1], R. Oliveira Leal[2], P. Campioli[3], V. Salazar[1], A. Gutiérrez- Serrera[1], G. Ortiz-Díez[4], J. García-Castro[5]

[1]Facultad de Veterinaria, Universidad Alfonso X el Sabio (UAX). Avenida de la Universidad, 1. 28691 Villanueva de la Cañada. Madrid. España.

[2]CIISA – Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon/ Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS)

[3]Unidad de Investigación. Facultad de Veterinaria, Universidad Alfonso X el Sabio (UAX). Avenida de la Universidad, 1. 28691 Villanueva de la Cañada. Madrid. España.

[4]Department of Animal Medicine and Surgery, Veterinary Medicine School, Complutense University of Madrid, Madrid, Spain.

[5]Unidad de Biotecnología Celular. Instituto de Salud Carlos III. Madrid. España

Corresponding author: **mdominguez@uax.es**

Journal target: Parasites & Vectors, Research article.

Internal note: this version deliberately keeps the Declarations, Data availability, Funding, Competing interests, Authors' contributions and Acknowledgements as author-completion placeholders. Draft figures are inserted for review only and should be regenerated at final production quality before submission.

Abstract

Background: Although adjunctive immunomodulation has shown promise in canine leishmaniosis (CanL), evidence remains limited. We evaluated Omnifect® Proimmune (OP), a nutraceutical containing lyophilized inactive lipopolysaccharide from *Ochrobactrum intermedium* and antioxidants, as an adjunct to standard therapy (ST) in dogs with clinical CanL caused by *Leishmania infantum*.

Methods: In this prospective, 12-month, non-randomised, masked, placebo-controlled, parallel-group clinical study, 56 client-owned dogs with clinical CanL received conventional antileishmanial treatment plus either OP or placebo. Analyses followed an intention-to-treat approach. Longitudinal outcomes were assessed using mixed-effects models adjusted for grouped baseline LeishVet stage. Survival was evaluated using Kaplan–Meier and Cox proportional hazards models.

Results: Of the 56 dogs, 27 received OP + ST and 29 placebo + ST. Thirty-five completed scheduled follow-up, 16 died and five were withdrawn or did not complete the protocol. Clinical signs improved in both groups, but OP did not demonstrate overall superiority in LeishVet stage, serology, TaqMan qPCR, UPC or individual ELISA cytokine trajectories. Serum creatinine was lower in the OP group at day 180 [0.86 (0.76–1.00) vs 1.02 (0.84–1.40) mg/dl; nominal $p = 0.031$], but no corresponding between-group difference in UPC was detected. The pooled-serum membrane-array analysis showed its largest descriptive between-group difference in the growth/angiogenesis axis but, owing to pooling, lacked biological replication and did not permit individual-level inference (qFDR approximately 0.07). Treatment group was not independently associated with survival (placebo vs OP: hazard ratio [HR] 1.42, 95% confidence interval [CI] 0.49–4.11; $p = 0.518$), whereas higher baseline creatinine (HR 2.43, 95% CI 1.47–4.00; $p < 0.001$) was associated with a higher hazard of death/euthanasia and higher baseline albumin (HR 0.31, 95% CI 0.13–0.75; $p = 0.009$) with a lower hazard.

Conclusions: Adjunctive OP did not demonstrate overall superiority over placebo when added to ST for clinical CanL, and no safety concern attributable to OP was identified. The isolated between-group difference in serum creatinine at day 180 and the descriptive growth/angiogenesis pattern warrant further investigation but do not establish renal or immunological efficacy.

Keywords

Canine leishmaniosis; *Leishmania infantum*; nutraceutical; immunomodulation; placebo-controlled study; cytokines; proteinuria; azotaemia, prognosis

Background

Canine leishmaniosis (CanL) caused by *Leishmania infantum* is a vector-borne disease of major veterinary and One Health relevance. In endemic areas, dogs are the main domestic reservoir of *L. infantum* and may contribute to maintenance of transmission to phlebotomine sand flies and, indirectly, to the human disease burden (Baneth et al., 2008; Palatnik-de-Sousa & Day, 2011; Ribeiro et al., 2018). Clinical expression is heterogeneous, ranging from mild cutaneous or lymphoid disease to severe systemic illness with renal involvement (proteinuria, azotaemia), immune-complex disease and death (Koutinas & Koutinas, 2014; Solano-Gallego et al., 2011).

Diagnosis and monitoring require integration of compatible clinical signs and/or clinicopathological abnormalities with serological, parasitological or molecular evidence of infection (Paltrinieri et al., 2010; Solano-Gallego et al., 2011). LeishVet staging is widely used to classify clinical CanL, guide treatment, structure follow-up and estimate prognosis (Solano-Gallego et al., 2011). Renal status is particularly important since proteinuria, azotaemia and hypoalbuminaemia are strongly linked to disease severity and outcome (IRIS, 2024; Pereira et al., 2020; Roura et al., 2013; Sarquis et al., 2025).

Conventional treatment is based mainly on meglumine antimoniate or miltefosine combined with allopurinol (Manna et al., 2015; Miró et al., 2009; Solano-Gallego et al., 2011). These protocols usually induce clinical improvement and reduce parasite burden, but parasitological cure is uncommon, relapse may occur and drug-related adverse effects such as nephrotoxicity, gastrointestinal intolerance, xanthinuria or urolithiasis remain clinically relevant (Reguera et al., 2016; Torres et al., 2016).

Because the outcome of *Leishmania* spp. infection depends strongly on the host immune response, adjunctive immunomodulation has been proposed as a strategy to improve disease control. However, immune protection in leishmaniosis should not be reduced to a simple Th1-protective/Th2-pathogenic dichotomy. Recent work emphasises a more complex network involving macrophages, dendritic cells, neutrophils, natural killer cells, CD4 and CD8 T-cell subsets, B cells, regulatory circuits, tissue compartments and host-parasite context (Hosein et al., 2017; Paton et al., 2025; Toepp & Petersen, 2020).

Clinical studies have evaluated adjunctive immunomodulatory approaches in dogs, including domperidone and dietary nucleotides with active hexose correlated compound (AHCC), with variable product-specific results (Baxarias et al., 2023; Cavalera et al., 2021; Miró et al., 2024; Segarra et al., 2017, 2018). Omnifect Proimmune (OP) is a distinct complementary feed/nutraceutical containing an inactivated microbial wall extract with a Gram-negative LPS fraction, brewer's yeast-derived mannan-oligosaccharides, olive polyphenols, turmeric, clinoptilolite and vitamin B6. Product-specific evidence for this adjunct in naturally occurring clinical CanL is limited.

The aim of this study was to evaluate the clinical, renal, serological, molecular, immunological, survival and safety outcomes of adjunctive OP compared with placebo when added to standard treatment (ST) in client-owned dogs with naturally occurring clinical CanL.

Methods

Ethics approval, owner consent, study design and masking

This study involved client-owned dogs presented for clinical disease compatible with CanL. The clinical veterinary study and the use of anonymised clinical data were approved by the Bioethics Committee. Written informed consent was obtained from all owners before inclusion and use of anonymised clinical data for research purposes.

This was a prospective, non-randomised, masked, placebo-controlled, parallel-group clinical study in client-owned dogs with naturally occurring clinical CanL. Dogs were recruited between 2021 and 2024 and were followed for 12 months.

The study products were supplied in coded form as Product A and Product B. Dog owners, the principal clinician-investigator, all clinical and laboratory staff, and the statistician were masked to study-product identity throughout follow-up and statistical analysis. The allocation code was held by Omnifect Ibérica S.L. and was opened after database closure and completion of the statistical analyses. After code opening, Group A was identified as ST plus OP and Group B as ST plus placebo.

The study was not randomised because, owing to initial product availability, the first five dogs were assigned to Group A. Thereafter, eligible dogs were enrolled consecutively as they presented and their owners agreed to participate, with non-random allocation used to obtain two groups of similar size. No formal random sequence generation or allocation-concealment procedure was used. This non-random allocation may have introduced selection bias and was considered when interpreting between-group comparisons.

Study population, diagnostic criteria and eligibility

Client-owned dogs of any breed, sex or age were eligible if they had clinical signs and/or clinicopathological abnormalities compatible with clinical CanL and infection by *L. infantum* confirmed by at least one specific diagnostic method. CanL was confirmed by one or more of the following criteria: quantitative indirect immunofluorescence antibody test (IFI) titre > 1:100; visualisation of *L. infantum* amastigotes by cytology or histopathology from clinically relevant tissues; or positive quantitative polymerase chain reaction (qPCR) for *L. infantum* in peripheral blood or another clinically relevant sample.

In dogs previously vaccinated against *L. infantum*, inclusion required compatible clinical disease and confirmation of infection using diagnostic criteria considered appropriate for the vaccine background, including direct parasite detection or qPCR when serological interpretation could be affected. At baseline, dogs were clinically staged according to the LeishVet system. For adjusted longitudinal analyses, baseline clinical severity was also grouped as LeishVet stages I-II versus III-IV.

Dogs were not eligible if clinical CanL was not confirmed, if they had received another immunomodulatory product, including domperidone or nucleotide/AHCC-based products, within one month before diagnosis, or if they had received systemic immunosuppressive drugs other than clinically indicated glucocorticoids within one month before inclusion. Previous vaccination status, baseline glucocorticoid use and all relevant concomitant treatments were recorded.

Interventions and concomitant treatments

All dogs were prescribed conventional antileishmanial treatment under routine clinical conditions. The prescribed regimen consisted of meglumine antimoniate (50 mg/kg subcutaneously every 12 h for 28 days) or miltefosine (2 mg/kg orally every 24 h for 28 days), combined with allopurinol (10 mg/kg orally every 12 h for 12 months). Actual treatment use, protocol deviations and unavailable treatment records are summarised in Table 1 and Supplementary Table S2.

Group A received ST plus OP and Group B received ST plus placebo. OP was administered orally once daily at the commercially recommended dose according to the manufacturer's body-weight dosing instructions. The product was a complementary feed/nutraceutical containing an inactivated microbial wall extract with a Gram-negative LPS fraction, brewer's yeast-derived mannan-oligosaccharides, olive polyphenols, turmeric, clinoptilolite and vitamin B6. The placebo matched to OP in appearance, packaging and administration schedule. It contained no known immunomodulatory or antileishmanial ingredients.

Concomitant treatments were allowed when clinically indicated, provided that they did not include additional immunomodulators or prohibited immunosuppressive drugs. Permitted treatments included fluid therapy, topical treatments without glucocorticoids, probiotics, gastroprotectants, antiemetics, analgesics, antihypertensive drugs, antithrombotic drugs, renin-angiotensin-aldosterone system inhibitors, antibiotics, renal diets and glucocorticoids. Systemic glucocorticoid treatment was recorded, including the drug, dose, indication and duration. Glucocorticoid use was permitted when clinically indicated and the dose was gradually tapered before the next follow up. Glucocorticoid treatment was considered when interpreting inflammatory and immunological outcomes.

Follow-up, clinical staging and outcomes

Dogs were evaluated at baseline (day 0), day 90, day 180 and day 360. At each visit, the following procedures were performed when clinically feasible: history, physical examination, LeishVet clinical staging, systemic arterial blood pressure measurement, complete blood count, serum biochemistry, serum protein electrophoresis, C-reactive protein, IFI, urinalysis including urinary protein-to-creatinine ratio (UPC), and qPCR for *L. infantum* in peripheral blood.

Dogs were staged using the LeishVet clinical staging system for CanL, retaining the creatinine and UPC thresholds originally used during the study. Dogs were not retrospectively reclassified according to later IRIS creatinine cut-offs because LeishVet stage was the predefined clinical staging system for CanL in the thesis and study analysis. IRIS staging was used only as a renal classification framework when required for renal interpretation and was kept conceptually separate from LeishVet clinical staging.

The primary clinical outcome was the longitudinal evolution of LeishVet stage. Secondary outcomes included individual clinical signs, haematological variables, serum biochemical variables, serum albumin, serum creatinine, C-reactive protein, urinalysis variables, UPC, IFI, qPCR results, individual plasma cytokine concentrations, exploratory membrane-array trends, survival and safety. IFI titres were grouped into clinically interpretable categories: low (≤ 1:800), intermediate (1:1600-1:3200) and high (≥ 1:6400). Potential adverse events reported by owners or identified during scheduled clinical follow-up were recorded descriptively. Adverse events were actively solicited at each visit along with all treatments, to assess the potential relationship with the study product.

Molecular assays

DNA was extracted from 100 µl of EDTA-anticoagulated peripheral blood using the Speedtools DNA extraction kit (Biotools B&M Labs S.A., Madrid, Spain), according to the manufacturer's instructions. Two real-time qPCR assays targeting *L. infantum* kinetoplast DNA were performed. The TaqMan assay used primers Leish-F 5′-CAAACCTATGCTCACTATC-3′ and Leish-R 5′-GGTATGGGTATTCTTTATGG-3′, and probe 5′-FAM-CAACCACCACCATCAAATCC-3′-IABkFQ. The SYBR Green assay used primers JW11-F 5′-CCTATTTTACACCAACCCCCAGT-3′ and JW12-R 5′-GGGTAGGGGCGTTCTGCGAAA-3′.

Amplifications were performed in triplicate using a CFX Real-Time PCR System (Bio-Rad Laboratories Inc., Richmond, WA, USA). Each run included positive and negative controls and amplification of beta-actin as an internal control. When amplification was not detected, Ct = 40 was assigned for Ct-based analytical summaries. TaqMan qPCR was considered positive when Ct was < 35 and negative when Ct was ≥ 35 or amplification was not detected. SYBR Green qPCR was considered positive when Ct was < 38 and negative when Ct was ≥ 38 or amplification was not detected. TaqMan qPCR was predefined as the primary molecular endpoint; SYBR Green qPCR was considered complementary.

The TaqMan reaction was performed in a final volume of 20 µL containing 10 µL of Quantimix Easy Probes master mix, 2.5 µL of DNA template, primers at 0.4 µM and probe at 0.3 µM. SYBR Green reactions were performed in a final volume of 20 µL containing 10 µL of GoTaq Hot Start Green Master Mix 2×, 2.5 µL of DNA template and each primer at 0.4 µM. Amplification consisted of an initial incubation at 95 °C for 10 min, followed by 44 cycles at 95 °C for 5 s and 55 °C for 40 s. The TaqMan standard curve was generated from six serial logarithmic dilutions of a culture containing 2×10^6 L. infantum promastigotes/mL and yielded an amplification efficiency of 98.5% ($R^2 = 0.99$).

Cytokine substudies

Plasma IFN-gamma, IL-12, IL-4, IL-10, IL-17 and IL-21 concentrations were measured using commercial ELISA kits according to the manufacturers' protocols. IFN-gamma and IL-10 were measured using kits from R&D Systems, IL-12 using a kit from Invitrogen, and IL-4, IL-17 and IL-21 using kits from MyBioSource. Absorbance was read at 450 nm using a Varioskan LUX plate reader, and results were processed using SkanIt software. The analytical range and lower limit of quantification were recorded for each ELISA kit. Values below the lower limit of quantification were assigned a prespecified assay-specific value for analysis

IFN-gamma, IL-10 and IL-12 were analyzed at baseline and day 90. IL-4, IL-17 and IL-21 were available at baseline, day 90 and day 180. Data availability by analyte and visit is reported in Supplementary Table S1.

An exploratory membrane-array substudy was performed using Canine Cytokine Array C1 membranes (RayBiotech, Norcross, GA, USA). For each treatment group, one pooled serum sample was prepared from six dogs at baseline and one pooled serum sample from six dogs at day 90. Each pooled sample was hybridised to one membrane, and signal intensity was quantified by densitometry according to the manufacturer's instructions. Signals were normalised to internal controls. For each analyte and treatment group, within-group change between day 90 and baseline was calculated as fold change and transformed to the log2 scale. The between-group difference in change was expressed as Delta-Delta = log2FC Group B - log2FC Group A. Directionality within prespecified functional axes was assessed using a binomial test, and multiplicity was controlled at axis level using the Benjamini-Hochberg false-discovery-rate procedure. Because the membrane-array substudy was based on one pooled serum sample per treatment group and time point, it did not provide

biological replication or allow individual-level inference. Results were therefore interpreted descriptively as exploratory patterns requiring confirmation in individual samples.

Sample size and statistical analysis

The sample size was determined by clinical feasibility, and no formal sample-size calculation was performed. Effect estimates, 95% confidence intervals and the consistency of findings across outcomes were therefore prioritised when interpreting the precision and clinical relevance of the results. After database closure, a sensitivity calculation was performed to contextualise the magnitude of effects that the study could detect, not to claim post hoc power. With 27 and 29 dogs per group, a two-sided alpha level of 0.05 and 80% power, the available sample could detect an approximate standardised between-group difference of 0.75 SD in a simple two-arm comparison of a continuous endpoint. For survival analyses, the number of events provided precision only for large effects and was used to contextualise interpretation.

The main analysis followed an intention-to-treat framework: all enrolled dogs were retained in the analytical cohort and analysed according to their assigned study product, irrespective of treatment discontinuation, death, withdrawal or incomplete follow-up. Missing values were not imputed, and each longitudinal model used all available observations for the corresponding outcome and visit. Continuous variables were summarised as mean ± standard deviation or median and interquartile range, according to distribution. Categorical variables were summarised as absolute and relative frequencies. Baseline comparisons between groups used Student's t test or the Mann-Whitney U test for continuous variables, and the chi-square test or Fisher's exact test for categorical variables, as appropriate. Baseline comparisons were interpreted descriptively and were not used as evidence of successful randomisation.

Repeated continuous outcomes were analysed using linear mixed-effects models with a random intercept for dog and fixed effects for treatment group, time and group-by-time interaction. Time was treated as a categorical variable. Models were adjusted for baseline clinical severity grouped as LeishVet stages I–II versus III–IV. UPC was analysed primarily on the logarithmic scale. For the log-transformed UPC outcome, a PP-lite sensitivity analysis was performed in dogs with at least one post-baseline visit. Repeated binary outcomes were analysed using mixed-effects logistic regression adjusted for grouped baseline LeishVet stage when model estimation was stable. Longitudinal LeishVet stage, the primary outcome, was analysed using an ordinal repeated-measures model. A mixed-effects model was used as a sensitivity analysis.

The Kaplan–Meier analysis included all 56 dogs in the intention-to-treat cohort. Survival time was calculated from inclusion to death/euthanasia. Dogs without an event were censored at the last reliable follow-up date, with administrative censoring at day 360. All 16 recorded deaths/euthanasias were included as events in the Kaplan–Meier analysis and the main Cox model. The proportional-hazards assumption was assessed using Schoenfeld residuals. The main Cox proportional-hazards model included treatment group, baseline serum creatinine and baseline serum albumin; it included 55 dogs because baseline serum albumin was unavailable in one dog. Ties were handled using the Efron method. Complementary Cox models explored grouped baseline LeishVet stage and baseline UPC. Statistical tests were two-sided, and $p < 0.05$ was considered statistically significant. Analyses were performed using Stata version 15. Multiplicity adjustment using the Benjamini–Hochberg false-discovery-rate procedure was applied only to the exploratory membrane-array analysis. Results from the remaining secondary outcomes were interpreted as exploratory, considering effect estimates, 95% confidence intervals, consistency across visits and clinical plausibility.

Results

Study population, cohort flow and analytical datasets

Fifty-six client-owned dogs with naturally occurring clinical CanL were included in the intention-to-treat cohort. After code opening, Group A corresponded to ST plus OP (n = 27), and Group B to ST plus placebo (n = 29).

At study closure, 35/56 dogs (62.5%) had completed the scheduled follow-up, 16/56 (28.6%) had died and 5/56 (8.9%) had been withdrawn or had not completed the planned protocol because of protocol non-adherence. In the OP group, 18/27 dogs (66.7%) completed follow-up, 7/27 (25.9%) died and 2/27 (7.4%) did not complete the protocol. In the placebo group, the corresponding figures were 17/29 (58.6%), 9/29 (31.0%) and 3/29 (10.3%), respectively (Fig. 1). Deaths were clinically attributed to uraemic syndrome in dogs with chronic kidney disease, acute glomerulonephritis or sudden death.




Figure 1. Flow of the intention-to-treat cohort and time-to-event analysis. Fifty-six dogs with clinical canine leishmaniosis were included in the intention-to-treat cohort. After code opening, Group A was identified as conventional treatment plus Omnifect Proimmune (n = 27) and Group B as conventional treatment plus placebo (n = 29). Overall, 35 dogs completed the scheduled follow-up, 16 died and five were withdrawn or did not complete the planned

protocol. All 56 dogs and all 16 recorded death/euthanasia events were included in the Kaplan–Meier analysis. The main Cox proportional-hazards model included 55 dogs because baseline serum albumin was unavailable in one dog.

All 56 dogs in the intention-to-treat cohort were included in the Kaplan–Meier analysis, with 16 death/euthanasia events. The final Cox model included 55 dogs and 16 events because baseline serum albumin was unavailable in one dog.

Data availability varied by variable and visit and is summarised in Supplementary Table S1. The numbers of available observations at baseline, day 90, day 180 and day 360 were 56, 38, 37 and 31 for LeishVet stage; 55, 38, 37 and 31 for serum albumin; 56, 38, 37 and 31 for serum creatinine; and 56, 38, 37 and 30 for UPC. For immunoparasitological endpoints, the corresponding numbers were 54, 38, 37 and 31 for IFI, 43, 27, 20 and 18 for TaqMan qPCR, and 39, 23, 20 and 18 for SYBR Green qPCR. ELISA availability differed by cytokine and visit, and no ELISA determinations were available at day 360.

Baseline characteristics

Baseline characteristics of the intention-to-treat cohort are summarised in Table 1, and the complete baseline dataset is provided in Supplementary Table S2. Given the non-random allocation, between-group baseline comparisons were interpreted descriptively and were not used to infer group comparability.

Nominal baseline imbalances were observed for vomiting, which was more frequent in the OP group; alopecia, which was more frequent in the placebo group; urine dipstick blood positivity, which was more frequent in the OP group; and SYBR Green qPCR positivity, which was higher in the placebo group. The SYBR Green imbalance was not reproduced by TaqMan qPCR, the predefined primary molecular assay. Baseline comparisons were interpreted descriptively.

Table 1. Baseline characteristics of the intention-to-treat cohort

Characteristic	Omnifect Proimmune group (n = 27)	Placebo group (n = 29)
Age, years	6.4 ± 3.7	7.2 ± 2.5
Body weight, kg	23.6 (11.2–34.0)	30.6 (17.8–36.4)
Male sex	15/27 (55.6%)	17/29 (58.6%)
Neutered	11/27 (40.7%)	14/29 (48.3%)
Previous vaccination against *L. infantum*	3/27 (11.1%)	7/29 (24.1%)
Concurrent disease at baseline	12/27 (44.4%)	11/29 (37.9%)
Meglumine antimoniate	19/26 (73.1%)	21/29 (72.4%)
Allopurinol	26/27 (96.3%)	28/29 (96.6%)
Glucocorticoids	12/27 (44.4%)	14/29 (48.3%)
Clopidogrel	9/27 (33.3%)	8/29 (27.6%)
Renal diet	9/27 (33.3%)	5/29 (17.2%)
LeishVet stage I–II	11/27 (40.7%)	17/29 (58.6%)
LeishVet stage III–IV	16/27 (59.3%)	12/29 (41.4%)
IRIS stage 1	6/27 (22.2%)	9/29 (31.0%)
IRIS stage 2	6/27 (22.2%)	8/29 (27.6%)
IRIS stage 3	6/27 (22.2%)	7/29 (24.1%)
IRIS stage 4	9/27 (33.3%)	5/29 (17.2%)
Hypertensive category at baseline	13/26 (50.0%)	11/28 (39.3%)

Characteristic	Omnifect Proimmune group (n = 27)	Placebo group (n = 29)
Systolic arterial pressure, mmHg	157.6 ± 30.8	155.4 ± 23.0
General clinical signs present	25/27 (92.6%)	27/29 (93.1%)
Generalised lymphadenomegaly	20/27 (74.1%)	19/29 (65.5%)
Weight loss	14/27 (51.9%)	16/29 (55.2%)
Lethargy	11/27 (40.7%)	14/29 (48.3%)
Reduced appetite	11/27 (40.7%)	12/29 (41.4%)
Polyuria/polydipsia	10/27 (37.0%)	9/29 (31.0%)
Vomiting	6/27 (22.2%)	1/29 (3.4%)
Cutaneous signs present	8/27 (29.6%)	15/29 (51.7%)
Alopecia	1/27 (3.7%)	7/29 (24.1%)
Ocular signs	2/27 (7.4%)	4/29 (13.8%)
Neurological signs	2/27 (7.4%)	1/29 (3.4%)
Haematocrit, %	38.5 ± 9.49	37.5 ± 8.27
Platelets, ×10³/µl	214.0 (157.0–289.0)	226.0 (124.0–286.0)
Total protein, g/dl	7.1 ± 1.71	7.3 ± 1.54
Albumin, g/dl	2.6 ± 0.78	2.7 ± 0.83
Globulins, g/dl	4.5 ± 1.89	4.6 ± 1.77
Creatinine, mg/dl	1.0 (0.8–1.7)	1.1 (0.8–1.3)
UPC	1.08 (0.18–5.32)	0.36 (0.16–3.03)
Urine dipstick blood positive	15/26 (57.7%)	11/29 (37.9%)
Positive urine culture	3/27 (11.1%)	3/29 (10.3%)
Xanthine crystals	2/27 (7.4%)	0/29 (0.0%)
C-reactive protein, mg/l	8.3 (2.2–63.7)	13.0 (2.1–48.7)
TaqMan qPCR positive	19/21 (90.5%)	17/22 (77.3%)
TaqMan qPCR Ct	33.2 ± 2.38	33.39 ± 2.88
SYBR Green qPCR positive	9/19 (47.4%)	16/20 (80.0%)
SYBR Green qPCR Ct	34.67 ± 3.68	34.64 ± 3.45

Values are reported as n/N (%), mean ± standard deviation or median (interquartile range), according to distribution and source reporting. Baseline comparisons were descriptive and are provided in Supplementary Table S2. IRIS, International Renal Interest Society; UPC, urinary protein-to-creatinine ratio; qPCR, quantitative polymerase chain reaction; Ct, cycle threshold. Miltefosine use was recorded only in free-text clinical records and was not available as a structured baseline variable; it is therefore not reported separately.

Clinical evolution and LeishVet stage

The main longitudinal clinical, clinicopathological, molecular and immunological outcomes are summarised in Table 2. Complete observed trajectories and denominators are reported in Supplementary Tables S3 and S4.

Table 2. Main longitudinal clinical, clinicopathological, molecular and immunological outcomes

Domain	Outcome	Main analysis / reporting scale	Available observations	Main result	Interpretation
Clinical stage	LeishVet clinical stage	Repeated ordinal analysis and mixed-effects sensitivity model,	56 / 38 / 37 / 31	Ordinal global analysis p = 0.157; mixed-model group × time interaction p = 0.173	No differential global clinical-stage trajectory

Domain	Outcome	Main analysis / reporting scale	Available observations	Main result	Interpretation
		adjusted for grouped baseline LeishVet stage			was detected between groups
Clinical signs	Lethargy, generalised lymphadenomegaly, weight loss and alopecia	Mixed-effects logistic regression for repeated binary signs, adjusted for grouped baseline LeishVet stage	Full trajectories in Supplementary Table S3 and Supplementary Fig. S1	Significant group × time interactions for lethargy ($p = 0.018$), lymphadenomegaly ($p < 0.001$), weight loss ($p = 0.022$) and alopecia ($p = 0.036$)	Sign-level interactions observed, but frequencies decreased in both groups and did not translate into superior global LeishVet evolution
Haematology	Platelet count	Linear mixed-effects model	Full longitudinal summaries in Supplementary Table S3	Group × time interaction $p = 0.017$; platelet counts increased over time in both groups	Isolated laboratory interaction without a clinically decisive treatment signal
Renal / biochemical	Serum creatinine	Linear mixed-effects model; observed values reported as median (IQR)	56 / 38 / 37 / 31	Day 180: 0.86 (0.76–1.00) mg/dl in Omnifect Proimmune vs 1.02 (0.84–1.40) mg/dl in placebo; nominal $p = 0.031$	Isolated between-group difference at day 180; insufficient to establish renal efficacy
Protein / renal	Serum albumin	Linear mixed-effects model; observed values reported as mean ± SD	55 / 38 / 37 / 31	Between-group differences at day 90 and day 180; no significant separation at day 360	Transient differences without a sustained directional treatment effect
Proteinuria	UPC / log_UPC	Linear mixed-effects model; UPC analysed primarily on logarithmic scale	56 / 38 / 37 / 30	No significant between-group differences at day 90 ($p = 0.587$), day 180 ($p = 0.983$) or day 360 ($p = 0.708$). PP-lite day-90 adjusted contrast for log_UPC: $\beta = 0.093$, 95% CI −0.185 to 0.372; ITT: $\beta = 0.109$, 95% CI −0.135 to 0.353	No sustained between-group separation in proteinuria; the sensitivity analysis did not alter the interpretation
Inflammation	C-reactive protein	Linear mixed-effects model; observed values reported as median (IQR)	42 / 36 / 34 / 29	CRP decreased descriptively after baseline in both groups; adjusted longitudinal analysis did not show differential group trajectories	No evidence of differential systemic inflammatory response
Serology	IFI titre / IFI clinical categories	Repeated categorical analysis; titres grouped as low, intermediate and high	54 / 38 / 37 / 31	No significant treatment-related longitudinal difference in IFI evolution	Similar serological trajectory in both groups
Molecular parasitology	TaqMan qPCR	Primary molecular endpoint; positivity and Ct values assessed longitudinally	43 / 27 / 20 / 18	No significant between-group differences in TaqMan qPCR positivity or Ct values during follow-up	No differential peripheral-blood TaqMan qPCR trajectory was detected between groups

Domain	Outcome	Main analysis / reporting scale	Available observations	Main result	Interpretation
Molecular parasitology	SYBR Green qPCR	Complementary molecular endpoint	39 / 23 / 20 / 18	Baseline imbalance and an isolated between-group difference in positivity and Ct values at day 360; neither finding was reproduced by TaqMan qPCR	Complementary finding only; does not modify the primary molecular interpretation
Individual cytokines	IFN-γ, IL-12, IL-4, IL-10, IL-17 and IL-21	Individual ELISA; mixed-effects models when estimable	Variable by cytokine and visit; no day-360 ELISA data	No significant group × time interaction for any individually measured cytokine	No evidence of differential systemic cytokine modulation by ELISA
Exploratory cytokine array	Growth / angiogenesis functional axis	Pooled-serum membrane array; Delta-Delta = log2FC placebo − log2FC Omnifect Proimmune; FDR correction by functional axis	Pools from six dogs per group at baseline and day 90	Largest descriptive between-group difference: median Delta-Delta −0.98 (IQR −1.96 to −0.71)	Exploratory pooled-sample pattern without biological replication; hypothesis-generating only and requiring confirmation in individual samples

Group A received conventional treatment plus Omnifect Proimmune; Group B received conventional treatment plus placebo. Available observations are shown as day 0 / day 90 / day 180 / day 360 when applicable. TaqMan qPCR was predefined as the primary molecular endpoint; SYBR Green qPCR was interpreted as complementary. The membrane-array substudy was based on pooled sera and did not allow individual-level inference.

The frequency of several clinical signs decreased during follow-up in both groups. Significant group-by-time interactions were observed for lethargy, generalised lymphadenomegaly, weight loss and alopecia (Supplementary Fig. S1; Table 2). These interactions were interpreted together with the absolute trajectories, which showed decreasing frequencies in both groups. LeishVet stage did not show evidence of a differential longitudinal evolution attributable to treatment group. The repeated ordinal model did not reach statistical significance ($p = 0.157$), and the mixed-model sensitivity analysis did not show a significant treatment-by-time interaction ($p = 0.173$).

Clinicopathological, inflammatory and renal-related trajectories

Most haematological, biochemical and urinary variables showed broadly parallel trajectories in both groups during follow-up (Table 2; Supplementary Table S3). Platelet count was the only haematological variable with a significant group-by-time interaction ($p = 0.017$), although platelet counts increased over time in both groups.

At day 180, serum creatinine was lower in the OP group than in the placebo group [0.86 (0.76–1.00) vs 1.02 (0.84–1.40) mg/dl; nominal $p = 0.031$]. This isolated between-group difference in serum creatinine was not accompanied by between-group differences in UPC, which did not differ between groups at day 90 ($p = 0.587$), day 180 ($p = 0.983$) or day 360 ($p = 0.708$), despite a descriptive decrease in UPC in both groups during follow-up (Fig. 2).




Figure 2. Renal trajectories during 12-month follow-up.

Serum creatinine (A), serum albumin (B) and urinary protein-to-creatinine ratio (UPC) (C) by treatment group at days 0, 90, 180 and 360. Points represent medians and shaded areas represent group-specific interquartile ranges calculated from the available observations at each visit; darker shading indicates overlap between the two group-specific interquartile ranges. UPC is displayed on a logarithmic scale. Dotted horizontal lines indicate the serum creatinine threshold of 1.4 mg/dl and selected UPC thresholds of 0.5, 1 and 5 used in the LeishVet staging framework.

Serum albumin differed between groups at day 90 and day 180 but not at day 360, and the pattern did not support a sustained directional treatment effect. C-reactive protein concentrations decreased descriptively after baseline in both groups, but adjusted longitudinal analyses did not show differential trajectories between groups.

Serology, molecular parasitology and cytokines

The evolution of IFI titre categories was similar in both groups, with no significant group-by-time effect (Table 2; Supplementary Table S4). TaqMan qPCR, predefined as the main molecular endpoint, did not show significant between-group differences during follow-up, either in qPCR positivity or in Ct values.

SYBR Green qPCR was analysed as a complementary assay. Positivity was higher in the placebo group at baseline, and an isolated between-group difference in both positivity and Ct values was observed at day 360. Neither finding was reproduced by TaqMan qPCR. The molecular interpretation was therefore based on the predefined primary TaqMan assay.

Individual plasma IFN-gamma, IL-12, IL-4, IL-10, IL-17 and IL-21 concentrations did not show significant treatment-by-time interactions in adjusted longitudinal models (Table 2; Supplementary Table S4). IFN-gamma and IL-10 concentrations were very low or undetectable in most available determinations. IL-12 showed numerical baseline differences between groups, but its adjusted longitudinal evolution was not significantly different. IL-4, IL-17 and IL-21 remained globally stable and followed comparable trajectories between groups.

Exploratory membrane-array substudy

The exploratory membrane-array substudy was based on one pooled serum sample from six dogs per treatment group at baseline and day 90. The growth/angiogenesis axis showed the largest descriptive between-group difference [median Delta-Delta −0.98, IQR −1.96 to −0.71; nominal p = 0.0078; qFDR approximately 0.07] (Supplementary Table S5; Supplementary Fig. S2). Because no biological replicates were available, the analysis did not permit estimation of interindividual variability or formal between-group inference and was considered hypothesis-generating.

Survival, sensitivity analysis and safety

Kaplan–Meier curves for the intention-to-treat cohort, with administrative censoring at day 360, are shown in Fig. 3A. In the main Cox proportional-hazards model, including treatment group, baseline serum creatinine and baseline serum albumin, treatment group was not independently associated with survival. The hazard ratio for placebo versus OP was 1.42 (95% CI 0.49–4.11; p = 0.518). Higher baseline serum creatinine was associated with a higher hazard of death/euthanasia (HR 2.43, 95% CI 1.47–4.00; p < 0.001), whereas higher baseline serum albumin was associated with a lower hazard (HR 0.31, 95% CI 0.13–0.75; p = 0.009) (Table 3; Fig. 3B).




Figure 3. Survival by treatment group and main Cox proportional-hazards model. (A) Kaplan–Meier curves for all 56 dogs included in the intention-to-treat cohort, comprising 16 death/euthanasia events. Follow-up was administratively censored at day 360. Censoring times are indicated by tick marks, and numbers at risk are shown at 0, 90, 180 and 360 days. The Omnifect Proimmune group included 27 dogs and seven events, and the placebo group included 29 dogs and nine events. (B) Forest plot of the main Cox proportional-hazards model including treatment group, baseline serum creatinine and baseline serum albumin. The model included 55 dogs and 16 events because baseline serum albumin was unavailable in one dog. Points represent hazard ratios

and horizontal bars represent 95% confidence intervals. Omnifect Proimmune was the reference treatment category. Hazard ratios for serum creatinine and serum albumin refer to increases of 1 mg/dl and 1 g/dl, respectively. Corresponding p values are reported in Table 3.

Table 3. Main Cox proportional-hazards model for death/euthanasia

Variable	Hazard ratio	95% CI	p value
Treatment group: placebo vs Omnifect Proimmune	1.42	0.49–4.11	0.518
Baseline serum creatinine, per 1 mg/dl increase	2.43	1.47–4.00	< 0.001
Baseline serum albumin, per 1 g/dl increase	0.31	0.13–0.75	0.009

The Cox model included treatment group, baseline serum creatinine and baseline serum albumin. Omnifect Proimmune was the reference treatment category. The model included 55 dogs and 16 death/euthanasia events; one dog was excluded because baseline serum albumin was unavailable. Ties were handled using the Efron method. Hazard ratios for serum creatinine and albumin refer to increases of 1 mg/dl and 1 g/dl, respectively. Given the limited number of events, the estimates should be interpreted as exploratory. CI, confidence interval

In the complementary Cox models, baseline albumin remained associated with survival, and baseline creatinine remained associated when included. Grouped baseline LeishVet stage and baseline UPC were not independently associated with survival in these models. Given the limited number of events, these analyses were considered exploratory.

A PP-lite sensitivity analysis restricted to 39 dogs with at least one post-baseline visit yielded an adjusted day-90 between-group contrast for log-transformed UPC of $\beta = 0.093$ (95% CI −0.185 to 0.372), compared with $\beta = 0.109$ (95% CI −0.135 to 0.353) in the intention-to-treat analysis. Both confidence intervals included zero, and the overall interpretation was unchanged (Supplementary Table S6). No safety concern attributable to OP was identified during the study.

Discussion

This prospective, 12-month, masked, placebo-controlled, parallel-group clinical study provides a deliberately cautious assessment of adjunctive OP in dogs with naturally occurring clinical CanL. The main finding was that no safety concern attributable to OP was identified during follow-up, but the adjunctive product did not demonstrate robust overall superiority over placebo across the main clinical, renal, serological, molecular, individual cytokine or survival outcomes. Clinical improvement occurred in both groups, which is consistent with the expected effect of conventional treatment in dogs with clinical CanL. The most reproducible prognostic information came from baseline renal and protein status, rather than from treatment group.

The clinical results should therefore be interpreted as evidence of improvement under a conventional-treatment framework, not as evidence of a clear incremental clinical effect of the adjunctive product. Several individual clinical signs decreased during follow-up, including lethargy, generalised lymphadenomegaly and weight loss. Some signs showed significant group-by-time interactions, but their absolute trajectories decreased in both groups and did not translate into a differential evolution of global LeishVet stage. This distinction is important because LeishVet staging integrates clinical expression, clinicopathological abnormalities and renal involvement, and is therefore more informative than isolated sign-level changes.

Renal involvement is central to the prognosis of CanL, and the renal-related findings were therefore of particular interest. Serum creatinine was lower in the OP group at day 180. However, this isolated between-group difference was not accompanied by statistical significance in UPC among these groups, and albumin differences were transient. Therefore, these findings should not be interpreted as evidence of improved renal function. Confirmation would require a study with a predefined renal endpoint and prospectively defined renal phenotypes. For this reason, the present data should not be interpreted as demonstrating renal protection. A conservative interpretation is that this isolated creatinine difference warrants prospective evaluation in dogs with predefined renal phenotypes, but the current study does not establish improvement in renal function or proteinuria.

Direct comparison with Miró et al. (2024) is limited by differences in product composition, allocation procedure, sample size, multicenter design, follow-up duration, outcome hierarchy and analytical population. Their study evaluated a different supplement in a larger randomised trial and reported additional renal and molecular effects. The present findings should therefore be interpreted as product-specific evidence rather than as confirmation or refutation of those results. By contrast, the present study was smaller, had a more pragmatic single-cohort clinical setting, lacked independently verifiable formal randomisation, included a heterogeneous clinical population and evaluated a different product. These differences in product, design, sample size, follow-up, outcome hierarchy and analytical population are sufficient to explain why the conclusions should not be parallel. The present study is therefore not a negative replication of Miró et al.; rather, it provides product-specific evidence showing that no attributable safety concern was identified, while the same robust additive effect was not demonstrated in this cohort.

The molecular results also support a cautious interpretation. Peripheral-blood TaqMan qPCR was predefined as the primary molecular endpoint and did not show a differential treatment effect in positivity or Ct values during follow-up. SYBR Green qPCR provided complementary information and showed an isolated signal, but this was not reproduced by TaqMan. The molecular conclusion should therefore be based primarily on TaqMan qPCR. In addition, peripheral blood is a practical and minimally invasive sample for longitudinal monitoring, but it is less sensitive than tissue-based or cellular targets such as bone marrow, lymph node, spleen, skin or conjunctival swabs for detecting *L. infantum* infection (Fisa et al., 2001; Solano-Gallego et al., 2011).

The individual cytokine ELISA panel did not show evidence of differential systemic cytokine modulation. IFN-gamma and IL-10 were very low or undetectable in many available samples, IL-12 showed numerical baseline differences without a significant adjusted longitudinal treatment effect, and IL-4, IL-17 and IL-21 remained broadly stable. These results do not support a claim that OP induced a measurable systemic Th1/Th2 shift in this cohort. However, the absence of an ELISA signal should not be overextended into proof that no immunological effect occurred. The immune response to *L. infantum* infection is compartmentalised, cell-specific and context-dependent (Paton et al., 2025). The appropriate conclusion is that the study did not document a differential circulating soluble-cytokine response by ELISA.

The exploratory membrane-array substudy showed its largest descriptive between-group difference in the growth/angiogenesis functional axis. However, the analysis was based on one pooled serum sample per group and time point and therefore did not allow estimation of interindividual variability or formal treatment-group inference. This pattern should be considered hypothesis-generating and requires confirmation using individual samples before any biological or clinical interpretation is made.

In this cohort, higher baseline serum creatinine was associated with a higher hazard of death/euthanasia, whereas higher baseline serum albumin was associated with a lower hazard. Treatment group was not independently associated with survival. Grouped baseline LeishVet stage and baseline UPC were not independently associated with survival in the complementary models; however, given the limited number of events, these findings should be considered exploratory and should not be interpreted as evidence that LeishVet stage or proteinuria lack prognostic relevance in CanL.

No adverse events considered attributable to OP were identified during follow-up. This finding supports an acceptable tolerability profile in the study cohort, particularly because adjunctive products intended for prolonged use should not add toxicity to conventional treatment in dogs with concurrent renal disease or receiving multiple treatments. However, tolerability should not be conflated with efficacy, and the absence of product-attributable adverse events does not alter the lack of robust overall superiority in the main outcomes.

This study has several strengths. A major strength of this study was the prospective 12-month follow-up of client-owned dogs with naturally occurring clinical CanL, a setting in which repeated sampling, protocol adherence and long-term retention are particularly challenging. Additional strengths included the masked placebo-controlled design, the intention-to-treat framework and the integrated assessment of clinical, renal, molecular, immunological and survival outcomes.

The limitations are also important. The effective sample size decreased during follow-up because of death, withdrawal and incomplete data availability. As some missing observations were related to clinical deterioration or death, the missing-data mechanism may have been informative, and analyses based on available observations could not completely exclude attrition bias. Therefore, non-significant between-group findings should not be interpreted as evidence of treatment equivalence.

The study was not randomised. Owing to the initial availability of OP, the first five dogs were assigned to Group A; dogs were subsequently enrolled in Group B, and recruitment continued until groups of similar size were obtained. This non-random allocation may have introduced selection bias, and residual baseline differences between groups cannot be excluded.

Conventional antileishmanial treatment and concomitant clinical management were not fully standardised. Dogs received either meglumine antimoniate or miltefosine, together with allopurinol, and some also received glucocorticoids, antithrombotic treatment, renal diets or other supportive therapies. This pragmatic approach increases clinical applicability but may have confounded renal, inflammatory and immunological outcomes and reduced the ability to isolate the adjunctive effect of OP.

Overall, adjunctive OP did not demonstrate robust overall superiority over placebo in this heterogeneous cohort of dogs with clinical CanL. No adverse events considered attributable to the product were identified. The isolated day-180 difference in serum creatinine and the descriptive growth/angiogenesis pattern observed in pooled sera require confirmation in studies with predefined renal endpoints and individual-level immune measurements. Future studies should use fully documented randomisation and allocation concealment and prioritise clinically relevant outcomes, including relapse, renal progression and survival.

Conclusions

In this prospective 12-month masked placebo-controlled study, adjunctive OP did not demonstrate robust overall superiority over placebo when added to conventional treatment for clinical CanL. No adverse events considered attributable to OP were identified during follow-up. The isolated between-group difference in serum creatinine at day 180 and the descriptive growth/angiogenesis pattern observed in pooled sera were exploratory and do not establish renal or immunological efficacy. In this cohort, higher baseline creatinine was associated with a higher hazard of death/euthanasia and higher baseline albumin with a lower hazard, whereas treatment group was not independently associated with survival. Future studies should use fully documented randomisation and allocation concealment, predefined renal endpoints and individual-level immune biomarkers.

List of abbreviations

AHCC, active hexose correlated compound; CanL, canine leishmaniosis; CI, confidence interval; Ct, cycle threshold; ELISA, enzyme-linked immunosorbent assay; FDR, false discovery rate; HR, hazard ratio; IFI, indirect immunofluorescence antibody test; IRIS, International Renal Interest Society; IQR, interquartile range; OP, Omnifect Proimmune; qPCR, quantitative polymerase chain reaction; SD, standard deviation; SDMA, symmetric dimethylarginine; ST, standard treatment; UPC, urinary protein-to-creatinine ratio.

Declarations

Ethics approval and consent to participate

The study protocol was reviewed and approved by the Bioethics Committee of Universidad Alfonso X el Sabio (UAX), Madrid, Spain (approval number: [2024_09/292]). Written informed consent was obtained from the owners or legal guardians of all animals before enrolment in the study. All animals were managed according to the applicable animal welfare regulations and institutional ethical guidelines.

Consent for publication

Not applicable.

Availability of data and materials

The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that this work was supported by Santander Universidades–Fundación Universidad Alfonso X el Sabio (FUAX) and by Omnifect Ibérica S.L.

Funding

The experimental work presented in this study was partially funded by Santander Universidades–Fundación Universidad Alfonso X el Sabio (FUAX) and by Omnifect Ibérica S.L.

Authors' contributions

M.D.R. made substatial contributions to the conception and design of the work, acquisition, analysis and interpretation of the data and drafting and revision of the document. R.O.L. contributed to the design of the work, analysis and interpretation of data and drafting and revision of the document. P.C. contributed to membrane-array and cytokines analyses and interpretation and revision of the document. V.S. contributed to cytokines analyses and interpretation and revision of the document. A.G.S contributed to analysis and interpretation of the data. G.D.O contributed to the analysis and interpretation of the data, performed the statistical analysis, and contributed to draft and revision of the document. J.G.C_contributed to the design of the work, analysis and interpretation of data and drafting and revision of the document.

Acknowledgements

This work was supported by Santander Universidades–Fundación Universidad Alfonso X el Sabio (FUAX) and by Omnifect Ibérica S.L.

Authors' information

[1]Facultad de Veterinaria, Universidad Alfonso X el Sabio (UAX). Avenida de la Universidad, 1. 28691 Villanueva de la Cañada. Madrid. España. [2]CIISA – Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon/Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS). [3]Unidad de Investigación. Facultad de Veterinaria, Universidad Alfonso X el Sabio (UAX). Avenida de la Universidad, 1. 28691 Villanueva de la Cañada. Madrid. España. [4]Department of Animal Medicine and Surgery, Veterinary Medicine School, Complutense University of Madrid, Madrid, Spain.[5]Unidad de Biotecnología Celular. Instituto de Salud Carlos III. Madrid. España.

Supplementary material proposed

Additional file 1. Supplementary Table S1. Analytical populations and data availability by visit and treatment group. Format: XLSX.

Additional file 2. Supplementary Table S2. Full baseline characteristics of the intention-to-treat cohort. Format: XLSX.

Additional file 3. Supplementary Table S3. Full longitudinal clinical, haematological, biochemical and urinary outcomes. Format: XLSX.

Additional file 4. Supplementary Table S4. Full serological, molecular and individual cytokine outcomes. Format: XLSX.

Additional file 5. Supplementary Table S5. Exploratory membrane-array substudy. Format: XLSX.

Additional file 6. Supplementary Table S6. Complementary survival and sensitivity analyses. Format: XLSX.

Additional file 7. Supplementary Figure S1. Clinical signs with significant group-by-time interaction. Format: PNG/PDF.

Additional file 8. Supplementary Figure S2. Exploratory membrane-array functional axes. Format: PNG/PDF.

References

1. Baneth, G., Koutinas, A. F., Solano-Gallego, L., Bourdeau, P., & Ferrer, L. (2008). Canine leishmaniosis — new concepts and insights on an expanding zoonosis: Part one. *Trends in Parasitology, 24*, 324–330. https://doi.org/10.1016/j.pt.2008.04.001
2. Baxarias, M., Donato, G., Mateu, C., Salichs, M., Homedes, J., Miró, G., Pennisi, M. G., & Solano-Gallego, L. (2023). A blinded, randomized and controlled multicenter clinical trial to assess the efficacy and safety of Leisguard® as an immunotherapeutic treatment for healthy *Leishmania infantum*-seropositive dogs. *Parasites & Vectors, 16*, 344. https://doi.org/10.1186/s13071-023-05903-0
3. Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society: Series B, 57*, 289–300.
4. Cavalera, M. A., Gernone, F., Uva, A., D'Ippolito, P., Roura, X., Paltrinieri, S., & Zatelli, A. (2021). Effect of domperidone (Leisguard®) on antibody titres, inflammatory markers and creatinine in dogs with leishmaniosis and chronic kidney disease. *Parasites & Vectors, 14*, 525. https://doi.org/10.1186/s13071-021-05013-6
5. Cerón, J. J., Pardo-Marín, L., Caldin, M., Furlanello, T., Solano-Gallego, L., Tecles, F., et al. (2018). Use of acute phase proteins for the clinical assessment and management of canine leishmaniosis: General recommendations. *BMC Veterinary Research, 14*, 196. https://doi.org/10.1186/s12917-018-1524-y
6. Fisa, R., Riera, C., Gállego, M., Manubens, J., & Portús, M. (2001). Nested PCR for diagnosis of canine leishmaniosis in peripheral blood, lymph node and bone marrow aspirates. *Veterinary Parasitology, 99*, 105–111. https://doi.org/10.1016/S0304-4017(01)00447-2

7. Francino, O., Altet, L., Sánchez-Robert, E., Rodriguez, A., Solano-Gallego, L., Alberola, J., et al. (2006). Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis. *Veterinary Parasitology, 137*, 214–221.
8. Hosein, S., Blake, D. P., & Solano-Gallego, L. (2017). Insights on adaptive and innate immunity in canine leishmaniosis. *Parasitology, 144*, 95–115.
9. International Renal Interest Society. (2024). *IRIS staging of chronic kidney disease*. http://www.iris-kidney.com/guidelines/staging.html
10. Koutinas, A. F., & Koutinas, C. K. (2014). Pathologic mechanisms underlying the clinical findings in canine leishmaniasis due to *Leishmania infantum/chagasi*. *Veterinary Pathology, 51*, 527–538. https://doi.org/10.1177/0300985814521248
11. Manna, L., Corso, R., Galiero, G., Cerrone, A., Muzj, P., & Gravino, A. E. (2015). Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol. *Parasites & Vectors, 8*, 289. https://doi.org/10.1186/s13071-015-0896-0
12. Martínez-Orellana, P., Marí-Martorell, D., Montserrat-Sangrà, S., Ordeix, L., Baneth, G., & Solano-Gallego, L. (2017). *Leishmania infantum*-specific IFN-γ production in stimulated blood from dogs with clinical leishmaniosis at diagnosis and during treatment. *Veterinary Parasitology, 248*, 39–47.
13. Miró, G., Oliva, G., Cruz, I., Cañavate, C., Mortarino, M., Vischer, C., et al. (2009). Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. *Veterinary Dermatology, 20*, 397–404.
14. Miró, G., Segarra, S., Cerón, J. J., Ferrer, L., Solano-Gallego, L., Montell, L., et al. (2024). New immunomodulatory treatment protocol for canine leishmaniosis reduces parasitemia and proteinuria. *PLOS Neglected Tropical Diseases, 18*, e0012712. https://doi.org/10.1371/journal.pntd.0012712
15. Palatnik-de-Sousa, C. B., & Day, M. J. (2011). One Health: The global challenge of epidemic and endemic leishmaniasis. *Parasites & Vectors, 4*, 197. https://doi.org/10.1186/1756-3305-4-197
16. Paltrinieri, S., Solano-Gallego, L., Fondati, A., Lubas, G., Gradoni, L., Castagnaro, M., et al. (2010). Guidelines for diagnosis and clinical classification of leishmaniasis in dogs. *Journal of the American Veterinary Medical Association, 236*, 1184–1191.
17. Paton, H., Sarkar, P., & Gurung, P. (2025). An overview of host immune responses against *Leishmania* spp. infections. *Human Molecular Genetics, 34*, R83–R109. https://doi.org/10.1093/hmg/ddaf043
18. Pereira, M. A., Santos, R., Oliveira, R., Costa, L., Prata, A., Gonçalves, V., et al. (2020). Prognostic factors and life expectancy in canine leishmaniosis. *Veterinary Sciences, 7*, 128. https://doi.org/10.3390/vetsci7030128
19. Peris, M. P., Esteban-Gil, A., Ortega-Hernández, P., Morales, M., Halaihel, N., & Castillo, J. A. (2021). Comparative study of real-time PCR (TaqMan probe and SYBR Green), serological techniques and clinical signs evaluation for the diagnosis of canine leishmaniasis in experimentally infected dogs. *Microorganisms, 9*, 262.
20. Reguera, R. M., Morán, M., Pérez-Pertejo, Y., García-Estrada, C., & Balaña-Fouce, R. (2016). Current status on prevention and treatment of canine leishmaniasis. *Veterinary Parasitology, 227*, 98–114.
21. Ribeiro, R. R., Michalick, M. S. M., da Silva, M. E., dos Santos, C. C. P., Frézard, F. J. G., & da Silva, S. M. (2018). Canine leishmaniasis: An overview of the current status and strategies for control. *BioMed Research International, 2018*, 3296893. https://doi.org/10.1155/2018/3296893
22. Roura, X., Fondati, A., Lubas, G., Gradoni, L., Maroli, M., Oliva, G., et al. (2013). Prognosis and monitoring of leishmaniasis in dogs: A working group report. *The Veterinary Journal, 198*, 43–47.

23. Saridomichelakis, M. N., Baneth, G., Colombo, S., Dantas-Torres, F., Ferrer, L., Fondati, A., et al. (2025). World Association for Veterinary Dermatology consensus statement for diagnosis, and evidence-based clinical practice guidelines for treatment and prevention of canine leishmaniosis. *Veterinary Dermatology, 36*, 723–787.
24. Sarquis, J., Sanz, C. R., Raposo, L. M., Montoya, A., Checa, R., Barrera, J. P., Gómez-Velasco, C., Estevez Sánchez, E., & Miró, G. (2025). Unveiling prognostic indicators in canine leishmaniosis: Two decades of evidence. *Parasites & Vectors, 18*, 467. https://doi.org/10.1186/s13071-025-06731-0
25. Segarra, S., Miró, G., Montoya, A., Pardo-Marín, L., Boqué, N., Ferrer, L., et al. (2017). Randomized, allopurinol-controlled trial of the effects of dietary nucleotides and active hexose correlated compound in the treatment of canine leishmaniosis. *Veterinary Parasitology, 239*, 50–56.
26. Segarra, S., Miró, G., Montoya, A., Pardo-Marín, L., Teichenné, J., Ferrer, L., & Cerón, J. J. (2018). Prevention of disease progression in *Leishmania infantum*-infected dogs with dietary nucleotides and active hexose correlated compound. *Parasites & Vectors, 11*, 103. https://doi.org/10.1186/s13071-018-2705-z
27. Solano-Gallego, L., Miró, G., Koutinas, A., Cardoso, L., Pennisi, M. G., Ferrer, L., et al. (2011). LeishVet guidelines for the practical management of canine leishmaniosis. *Parasites & Vectors, 4*, 86. https://doi.org/10.1186/1756-3305-4-86
28. Solano-Gallego, L., Di Filippo, L., Ordeix, L., Planellas, M., Roura, X., Altet, L., et al. (2016). Early reduction of *Leishmania infantum*-specific antibodies and blood parasitemia during treatment in dogs with moderate or severe disease. *Parasites & Vectors, 9*, 235.
29. Solano-Gallego, L., Cardoso, L., Pennisi, M. G., Petersen, C., Bourdeau, P., Oliva, G., et al. (2017). Diagnostic challenges in the era of canine *Leishmania infantum* vaccines. *Trends in Parasitology, 33*, 706–717.
30. Toepp, A. J., & Petersen, C. A. (2020). The balancing act: Immunology of leishmaniosis. *Research in Veterinary Science, 130*, 19–25.
31. Torres, M., Pastor, J., Roura, X., Tabar, M. D., Espada, Y., Font, A., et al. (2016). Adverse urinary effects of allopurinol in dogs with leishmaniasis. *Journal of Small Animal Practice, 57*, 299–304.

Supplementary Tables

Supplementary Table S1. Analytical populations (section A) and data availability (section B) by visit and treatment group

Section A.	**Analytical populations**						
Population / set	**Total dogs**	**Total events**	**Omnifect Proimmune dogs**	**Omnifect events**	**Placebo dogs**	**Placebo events**	**Operational definition**
Intention-to-treat cohort	56		27		29		All enrolled dogs analysed according to assigned study product.
Completed scheduled follow-up	35		18		17		Dogs with scheduled 12-month follow-up completed.
Death/euthanasia during follow-up	16	16	7	7	9	9	All recorded death/euthanasia events.
Withdrawn / did not complete planned protocol	5		2		3		Withdrawn or protocol not completed for reasons other than death/euthanasia.
Kaplan–Meier survival analysis	56	16	27	7	29	9	All enrolled dogs with valid inclusion date and documented event/censoring date; administrative censoring at day 360.
Main Cox proportional-hazards model	55	16	27	7	28	9	Kaplan–Meier analysis set restricted to dogs with baseline serum albumin available.
PP-lite UPC sensitivity analysis	39						Dogs with at least one post-baseline visit; used only for UPC sensitivity analysis.

Section B.	Data availability by visit and treatment group					
Domain	**Outcome**	**Variable**	**Visit**	**N available - Total**	**N available - Omnifect Proimmune**	**N available - Placebo**
Clinical stage	LeishVet stage	Estad_Leish_d0	Day 0	56	27	29
Clinical stage	LeishVet stage	Estad_Leish_d90	Day 90	38	19	19
Clinical stage	LeishVet stage	Estad_Leish_d180	Day 180	37	19	18
Clinical stage	LeishVet stage	Estad_Leish_d360	Day 360	31	16	15
Renal/biochemistry	Serum albumin	Alb_d0	Day 0	55	27	28
Renal/biochemistry	Serum albumin	Alb_d90	Day 90	38	19	19
Renal/biochemistry	Serum albumin	Alb_d180	Day 180	37	19	18
Renal/biochemistry	Serum albumin	Alb_d360	Day 360	31	16	15
Renal/biochemistry	Serum creatinine	Creat_d0	Day 0	56	27	29
Renal/biochemistry	Serum creatinine	Creat_d90	Day 90	38	19	19
Renal/biochemistry	Serum creatinine	Creat_d180	Day 180	37	19	18
Renal/biochemistry	Serum creatinine	Creat_d360	Day 360	31	16	15
Proteinuria	UPC	UPC_d0	Day 0	56	27	29
Proteinuria	UPC	UPC_d90	Day 90	38	19	19
Proteinuria	UPC	UPC_d180	Day 180	37	19	18
Proteinuria	UPC	UPC_d360	Day 360	30	16	14
Serology	IFI	IFI_leish_d0	Day 0	54	26	28
Serology	IFI	IFI_leish_d90	Day 90	38	19	19
Serology	IFI	IFI_leish_d180	Day 180	37	19	18
Serology	IFI	IFI_leish_d360	Day 360	31	16	15
Molecular	TaqMan qPCR result recorded	qPCRLeish_SND_d0	Day 0	43	22	21

Molecular	TaqMan qPCR result recorded	qPCRLeish_SND_d90	Day 90	37	19	18
Molecular	TaqMan qPCR result recorded	qPCRLeish_SND_d180	Day 180	37	19	18
Molecular	TaqMan qPCR result recorded	qPCRLeish_SND_d360	Day 360	37	19	18
Molecular	TaqMan qPCR Ct / binary classification recorded	NºCtqPCR_SND_d0	Day 0	36	17	19
Molecular	TaqMan qPCR Ct / binary classification recorded	NºCtqPCR_SND_d90	Day 90	27	15	12
Molecular	TaqMan qPCR Ct / binary classification recorded	NºCtqPCR_SND_d180	Day 180	20	12	8
Molecular	TaqMan qPCR Ct / binary classification recorded	NºCtqPCR_SND_d360	Day 360	18	9	9
Molecular	SYBR Green qPCR result recorded	qPCRLeish_SYB_d0	Day 0	39	19	20
Molecular	SYBR Green qPCR result recorded	qPCRLeish_SYB_d90	Day 90	37	19	18
Molecular	SYBR Green qPCR result recorded	qPCRLeish_SYB_d180	Day 180	37	19	18
Molecular	SYBR Green qPCR result recorded	qPCRLeish_SYB_d360	Day 360	37	19	18

Molecular	SYBR Green qPCR Ct / binary classification recorded	NºCtqPCR_SYB_d0	Day 0	25	9	16
Molecular	SYBR Green qPCR Ct / binary classification recorded	NºCtqPCR_SYB_d90	Day 90	23	10	13
Molecular	SYBR Green qPCR Ct / binary classification recorded	NºCtqPCR_SYB_d180	Day 180	20	12	8
Molecular	SYBR Green qPCR Ct / binary classification recorded	NºCtqPCR_SYB_d360	Day 360	18	9	9
Individual ELISA	IFN-gamma	IFN_d0	Day 0	20	10	10
Individual ELISA	IFN-gamma	IFN_90	Day 90	19	10	9
Individual ELISA	IFN-gamma	IFN_180	Day 180	0	0	0
Individual ELISA	IFN-gamma	IFN_360	Day 360	0	0	0
Individual ELISA	IL-12	IL12_d0	Day 0	20	10	10
Individual ELISA	IL-12	IL12_90	Day 90	20	10	10
Individual ELISA	IL-12	IL12_180	Day 180	0	0	0
Individual ELISA	IL-12	IL12_360	Day 360	0	0	0
Individual ELISA	IL-4	IL4_d0	Day 0	27	14	13
Individual ELISA	IL-4	IL4_90	Day 90	26	14	12
Individual ELISA	IL-4	IL4_180	Day 180	26	15	11
Individual ELISA	IL-4	IL4_360	Day 360	0	0	0
Individual ELISA	IL-10	IL10_d0	Day 0	20	10	10
Individual ELISA	IL-10	IL10_90	Day 90	19	10	9
Individual ELISA	IL-10	IL10_180	Day 180	0	0	0
Individual ELISA	IL-10	IL10_360	Day 360	0	0	0
Individual ELISA	IL-17	IL17_d0	Day 0	25	12	13
Individual ELISA	IL-17	IL17_d90	Day 90	29	15	14

Individual ELISA	IL-17	IL17_180	Day 180	34	18	16
Individual ELISA	IL-17	IL17_360	Day 360	0	0	0
Individual ELISA	IL-21	IL21_d0	Day 0	35	18	17
Individual ELISA	IL-21	IL21_d90	Day 90	34	18	16
Individual ELISA	IL-21	IL21_d180	Day 180	34	18	16
Individual ELISA	IL-21	IL21_d360	Day 360	0	0	0

Note. Data availability counts reflect dogs with recorded data for each variable and visit. The Kaplan–Meier analysis included all 56 dogs and 16 death/euthanasia events; the main Cox model included 55 dogs and 16 events because baseline serum albumin was unavailable in one dog. OP, Omnifect Proimmune; IFI, indirect immunofluorescence antibody test; qPCR, quantitative polymerase chain reaction; UPC, urinary protein-to-creatinine ratio.

Supplementary Table S2. Full baseline characteristics of the intention-to-treat cohort

Domain	**Characteristic**	**Omnifect Proimmune group (n = 27)**	**Placebo group (n = 29)**	**Descriptive p value**	**Notes**
Demographics and history	Age, years	6.4 ± 3.7	7.2 ± 2.5	0.343	Mean ± SD.
Demographics and history	Body weight, kg	23.6 (11.2–34.0)	30.6 (17.8–36.4)	0.337	Median (IQR).
Demographics and history	Male sex	15/27 (55.6%)	17/29 (58.6%)	0.817	
Demographics and history	Neutered	11/27 (40.7%)	14/29 (48.3%)	0.571	
Demographics and history	Previous vaccination against L. infantum	3/27 (11.1%)	7/29 (24.1%)	0.203	
Demographics and history	Concurrent disease at baseline	12/27 (44.4%)	11/29 (37.9%)	0.783	
Conventional and concomitant treatment	Meglumine antimoniate	19/26 (73.1%)	21/29 (72.4%)	0.956	Denominators reflect available structured treatment records.
Conventional and concomitant treatment	Allopurinol	26/27 (96.3%)	28/29 (96.6%)	0.959	
Conventional and concomitant treatment	Glucocorticoids	12/27 (44.4%)	14/29 (48.3%)	0.774	
Conventional and concomitant treatment	Clopidogrel	9/27 (33.3%)	8/29 (27.6%)	0.640	
Conventional and concomitant treatment	Renal diet	9/27 (33.3%)	5/29 (17.2%)	0.165	
Clinical severity	LeishVet stage I–II	11/27 (40.7%)	17/29 (58.6%)	0.656	Grouped baseline LeishVet stage.

Clinical severity	LeishVet stage III–IV	16/27 (59.3%)	12/29 (41.4%)	0.656	Grouped baseline LeishVet stage.
Clinical severity	IRIS stage 1	6/27 (22.2%)	9/29 (31.0%)	0.565	Overall comparison across IRIS categories.
Clinical severity	IRIS stage 2	6/27 (22.2%)	8/29 (27.6%)	0.565	Overall comparison across IRIS categories.
Clinical severity	IRIS stage 3	6/27 (22.2%)	7/29 (24.1%)	0.565	Overall comparison across IRIS categories.
Clinical severity	IRIS stage 4	9/27 (33.3%)	5/29 (17.2%)	0.565	Overall comparison across IRIS categories.
Blood pressure	Normotensive	13/26 (50.0%)	17/28 (60.7%)	0.113	Overall comparison of baseline blood-pressure category.
Blood pressure	Hypertensive	13/26 (50.0%)	11/28 (39.3%)	0.113	Overall comparison of baseline blood-pressure category.
Blood pressure	Systolic arterial pressure, mmHg	157.6 ± 30.8	155.4 ± 23.0	0.690	Mean ± SD.
Blood pressure	Mean arterial pressure, mmHg	113.6 ± 33.1	110.4 ± 12.4	0.561	Mean ± SD.
Blood pressure	Diastolic arterial pressure, mmHg	103.1 ± 29.4	99.5 ± 12.6	0.473	Mean ± SD.
Clinical signs	General clinical signs present	25/27 (92.6%)	27/29 (93.1%)	0.941	
Clinical signs	Generalised lymphadenomegaly	20/27 (74.1%)	19/29 (65.5%)	0.487	
Clinical signs	Weight loss	14/27 (51.9%)	16/29 (55.2%)	0.803	
Clinical signs	Lethargy	11/27 (40.7%)	14/29 (48.3%)	0.571	
Clinical signs	Reduced appetite	11/27 (40.7%)	12/29 (41.4%)	0.961	
Clinical signs	Polyuria/polydipsia	10/27 (37.0%)	9/29 (31.0%)	0.636	
Clinical signs	Vomiting	6/27 (22.2%)	1/29 (3.4%)	0.034	Nominal baseline imbalance.
Clinical signs	Cutaneous signs present	8/27 (29.6%)	15/29 (51.7%)	0.093	
Clinical signs	Alopecia	1/27 (3.7%)	7/29 (24.1%)	0.029	Nominal baseline imbalance.
Clinical signs	Ocular signs	2/27 (7.4%)	4/29 (13.8%)	0.440	
Clinical signs	Neurological signs	2/27 (7.4%)	1/29 (3.4%)	0.511	
Haematology and serum biochemistry	Haematocrit, %	38.5 ± 9.49	37.5 ± 8.27	0.675	
Haematology and serum biochemistry	Haemoglobin, g/dl	13.1 ± 3.48	12.6 ± 3.07	0.533	
Haematology and serum biochemistry	Leukocytes, $\times 10^3/\mu l$	10.6 (7.3–14.0)	7.3 (6.6–10.2)	0.154	Median (IQR).
Haematology and serum biochemistry	Platelets, $\times 10^3/\mu l$	214.0 (157.0–289.0)	226.0 (124.0–286.0)	0.857	Median (IQR).
Haematology and serum biochemistry	Total protein, g/dl	7.1 ± 1.71	7.3 ± 1.54	0.678	
Haematology and serum biochemistry	Albumin, g/dl	2.6 ± 0.78	2.7 ± 0.83	0.701	

Haematology and serum biochemistry	Globulins, g/dl	4.5 ± 1.89	4.6 ± 1.77	0.834	
Haematology and serum biochemistry	Phosphorus, mg/dl	4.4 (3.5–5.9)	4.1 (3.4–5.2)	0.556	Median (IQR).
Haematology and serum biochemistry	Urea, mg/dl	39.1 (23.5–84.0)	33.4 (28.0–51.5)	0.617	Median (IQR).
Haematology and serum biochemistry	BUN, mg/dl	18.3 (11.0–39.3)	15.7 (13.3–24.1)	0.870	Median (IQR).
Haematology and serum biochemistry	Creatinine, mg/dl	1.0 (0.8–1.7)	1.1 (0.8–1.3)	0.718	Median (IQR).
Haematology and serum biochemistry	Alkaline phosphatase, U/l	49.1 (36.8–69.3)	49.5 (38.6–86.5)	0.616	Median (IQR).
Haematology and serum biochemistry	ALT, U/l	39.7 (27.9–55.8)	35.1 (23.6–48.4)	0.363	Median (IQR).
Haematology and serum biochemistry	AST, U/l	33.6 (22.4–56.3)	38.0 (27.8–60.7)	0.534	Median (IQR).
Urinalysis	Urine specific gravity	1025 ± 13.38	1027.59 ± 12.84	0.468	
Urinalysis	Urine pH	6.54 ± 0.75	6.67 ± 0.96	0.569	
Urinalysis	UPC	1.08 (0.18–5.32)	0.36 (0.16–3.03)	0.417	Median (IQR).
Urinalysis	Urine dipstick blood positive	15/26 (57.7%)	11/29 (37.9%)	0.011	Nominal baseline imbalance reported in the study analysis.
Urinalysis	Positive urine culture	3/27 (11.1%)	3/29 (10.3%)	0.926	
Urinalysis	Xanthine crystals	2/27 (7.4%)	0/29 (0.0%)	0.314	
Inflammation	C-reactive protein, mg/l	8.3 (2.2–63.7)	13.0 (2.1–48.7)	0.880	Median (IQR).
Molecular parasitology	TaqMan qPCR positive	19/21 (90.5%)	17/22 (77.3%)	0.412	TaqMan qPCR was the predefined primary molecular endpoint.
Molecular parasitology	TaqMan qPCR Ct	33.2 ± 2.38	33.39 ± 2.88	0.834	
Molecular parasitology	SYBR Green qPCR positive	9/19 (47.4%)	16/20 (80.0%)	0.048	Complementary molecular assay; nominal baseline imbalance.
Molecular parasitology	SYBR Green qPCR Ct	34.67 ± 3.68	34.64 ± 3.45	0.987	

Note. Values are reported as n/N (%), mean ± standard deviation or median (interquartile range), according to source reporting. Baseline p values are descriptive and were not used to infer successful randomisation. OP, Omnifect Proimmune; IRIS, International Renal Interest Society; UPC, urinary protein-to-creatinine ratio; qPCR, quantitative polymerase chain reaction; Ct, cycle threshold; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen.

1 Supplementary Table S3. Full longitudinal clinical, haematological, biochemical and urinary outcomes

Domain	Outcome	Scale	Variable	Visit	Treatment group	n	mean	sd	median	q1	q3	min	max	n_positive	percent_positive	formatted
Clinical	Body weight, kg	continuous	Peso_d0	Day 0	Total	56	26,08	14,86	26,00	14,58	34,85	2,30	68,60			
Clinical	Body weight, kg	continuous	Peso_d0	Day 0	Omnifect Proimmune	27	25,13	16,48	23,60	12,60	32,70	6,60	68,60			
Clinical	Body weight, kg	continuous	Peso_d0	Day 0	Placebo	29	26,96	13,42	30,60	17,80	36,40	2,30	49,00			
Clinical	Body weight, kg	continuous	Peso_d90	Day 90	Total	38	27,22	14,13	27,70	14,48	36,08	4,90	60,80			
Clinical	Body weight, kg	continuous	Peso_d90	Day 90	Omnifect Proimmune	19	25,54	15,56	22,80	13,10	32,60	8,50	60,80			
Clinical	Body weight, kg	continuous	Peso_d90	Day 90	Placebo	19	28,89	12,74	32,00	19,10	37,40	4,90	49,00			
Clinical	Body weight, kg	continuous	Peso_d180	Day 180	Total	36	26,55	14,31	25,95	13,75	36,30	5,20	60,80			
Clinical	Body weight, kg	continuous	Peso_d180	Day 180	Omnifect Proimmune	18	24,58	15,53	19,20	12,70	29,95	9,00	60,80			
Clinical	Body weight, kg	continuous	Peso_d180	Day 180	Placebo	18	28,52	13,13	32,45	18,23	37,35	5,20	48,40			
Clinical	Body weight, kg	continuous	Peso_d360	Day 360	Total	28	30,37	14,15	30,75	19,48	37,40	8,50	61,00			
Clinical	Body weight, kg	continuous	Peso_d360	Day 360	Omnifect Proimmune	13	29,22	16,38	27,10	15,50	34,40	11,40	61,00			

Clinical	Body weight, kg	continuous	Peso_d360	Day 360	Placebo	15	31,37	12,39	35,20	24,40	37,80	8,50	48,20			
Blood pressure	Systolic arterial pressure, mmHg	continuous	PAS_d0	Day 0	Total	26	157,58	27,89	150,50	138,00	174,75	110,00	234,00			
Blood pressure	Systolic arterial pressure, mmHg	continuous	PAS_d0	Day 0	Omnifect Proimmune	14	156,64	30,76	152,50	135,75	172,25	110,00	234,00			
Blood pressure	Systolic arterial pressure, mmHg	continuous	PAS_d0	Day 0	Placebo	12	158,67	25,44	148,50	139,50	176,25	125,00	205,00			
Blood pressure	Systolic arterial pressure, mmHg	continuous	PAS_d90	Day 90	Total	8	159,13	34,19	149,50	132,00	184,50	126,00	218,00			
Blood pressure	Systolic arterial pressure, mmHg	continuous	PAS_d90	Day 90	Omnifect Proimmune	5	165,00	37,60	163,00	134,00	184,00	126,00	218,00			
Blood pressure	Systolic arterial pressure, mmHg	continuous	PAS_d90	Day 90	Placebo	3	149,33	32,15	136,00	131,00	161,00	126,00	186,00			
Blood pressure	Systolic arterial pressure, mmHg	continuous	PAS_d180	Day 180	Total	7	164,14	23,34	169,00	155,00	177,50	122,00	193,00			
Blood pressure	Systolic arterial pressure, mmHg	continuous	PAS_d180	Day 180	Omnifect Proimmune	3	159,00	32,36	173,00	147,50	177,50	122,00	182,00			
Blood pressure	Systolic arterial	continuous	PAS_d180	Day 180	Placebo	4	168,00	18,58	165,00	158,00	175,00	149,00	193,00			

	pressure, mmHg															
Blood pressure	Systolic arterial pressure, mmHg	continuous	PAS_d360	Day 360	Total	8	159,25	18,44	159,00	150,25	165,50	136,00	195,00			
Blood pressure	Systolic arterial pressure, mmHg	continuous	PAS_d360	Day 360	Omnifect Proimmune	3	171,00	21,17	163,00	159,00	179,00	155,00	195,00			
Blood pressure	Systolic arterial pressure, mmHg	continuous	PAS_d360	Day 360	Placebo	5	152,20	14,34	154,00	139,00	165,00	136,00	167,00			
Blood pressure	Diastolic arterial pressure, mmHg	continuous	PAD_d0	Day 0	Total	25	103,24	24,75	101,00	89,00	114,00	58,00	177,00			
Blood pressure	Diastolic arterial pressure, mmHg	continuous	PAD_d0	Day 0	Omnifect Proimmune	14	102,71	29,10	100,00	88,00	112,75	58,00	177,00			
Blood pressure	Diastolic arterial pressure, mmHg	continuous	PAD_d0	Day 0	Placebo	11	103,91	19,18	101,00	91,50	113,00	78,00	148,00			
Blood pressure	Diastolic arterial pressure, mmHg	continuous	PAD_d90	Day 90	Total	8	102,38	28,84	95,00	80,75	121,00	69,00	149,00			
Blood pressure	Diastolic arterial pressure, mmHg	continuous	PAD_d90	Day 90	Omnifect Proimmune	5	103,20	31,19	100,00	82,00	116,00	69,00	149,00			
Blood pressure	Diastolic arterial	continuous	PAD_d90	Day 90	Placebo	3	101,00	31,00	90,00	83,50	113,00	77,00	136,00			

	pressure, mmHg															
Blood pressure	Diastolic arterial pressure, mmHg	continuous	PAD_d180	Day 180	Total	7	104,14	22,22	103,00	95,00	107,50	74,00	147,00			
Blood pressure	Diastolic arterial pressure, mmHg	continuous	PAD_d180	Day 180	Omnifect Proimmune	3	90,67	15,28	94,00	84,00	99,00	74,00	104,00			
Blood pressure	Diastolic arterial pressure, mmHg	continuous	PAD_d180	Day 180	Placebo	4	114,25	22,68	107,00	101,25	120,00	96,00	147,00			
Blood pressure	Diastolic arterial pressure, mmHg	continuous	PAD_d360	Day 360	Total	8	98,75	13,20	101,00	91,50	105,50	76,00	116,00			
Blood pressure	Diastolic arterial pressure, mmHg	continuous	PAD_d360	Day 360	Omnifect Proimmune	3	92,00	19,00	87,00	81,50	100,00	76,00	113,00			
Blood pressure	Diastolic arterial pressure, mmHg	continuous	PAD_d360	Day 360	Placebo	5	102,80	8,35	102,00	100,00	103,00	93,00	116,00			
Blood pressure	Mean arterial pressure, mmHg	continuous	PAM_d0	Day 0	Total	25	111,28	26,65	110,00	97,00	123,00	71,00	209,00			
Blood pressure	Mean arterial pressure, mmHg	continuous	PAM_d0	Day 0	Omnifect Proimmune	14	110,86	34,33	106,50	95,25	121,50	71,00	209,00			
Blood pressure	Mean arterial	continuous	PAM_d0	Day 0	Placebo	11	111,82	13,08	114,00	100,50	122,50	92,00	128,00			

	pressure, mmHg															
Blood pressure	Mean arterial pressure, mmHg	continuous	PAM_d90	Day 90	Total	8	113,75	27,88	106,50	94,50	133,50	79,00	158,00			
Blood pressure	Mean arterial pressure, mmHg	continuous	PAM_d90	Day 90	Omnifect Proimmune	5	115,40	30,54	114,00	96,00	130,00	79,00	158,00			
Blood pressure	Mean arterial pressure, mmHg	continuous	PAM_d90	Day 90	Placebo	3	111,00	28,93	99,00	94,50	121,50	90,00	144,00			
Blood pressure	Mean arterial pressure, mmHg	continuous	PAM_d180	Day 180	Total	7	112,14	25,51	113,00	100,50	120,50	75,00	155,00			
Blood pressure	Mean arterial pressure, mmHg	continuous	PAM_d180	Day 180	Omnifect Proimmune	3	106,33	15,31	112,00	100,50	115,00	89,00	118,00			
Blood pressure	Mean arterial pressure, mmHg	continuous	PAM_d180	Day 180	Placebo	4	116,50	32,96	118,00	103,50	131,00	75,00	155,00			
Blood pressure	Mean arterial pressure, mmHg	continuous	PAM_d360	Day 360	Total	8	110,88	11,68	108,00	106,25	114,25	94,00	129,00			
Blood pressure	Mean arterial pressure, mmHg	continuous	PAM_d360	Day 360	Omnifect Proimmune	3	110,00	17,69	107,00	100,50	118,00	94,00	129,00			
Blood pressure	Mean arterial	continuous	PAM_d360	Day 360	Placebo	5	111,40	9,02	109,00	107,00	110,00	104,00	127,00			

	pressure, mmHg															
Haematology	Haematocrit, %	continuous	Hct_d0	Day 0	Total	56	38,01	8,81	38,83	32,83	44,88	11,80	55,70			
Haematology	Haematocrit, %	continuous	Hct_d0	Day 0	Omnifect Proimmune	27	38,53	9,49	38,80	34,60	44,15	11,80	55,70			
Haematology	Haematocrit, %	continuous	Hct_d0	Day 0	Placebo	29	37,53	8,27	38,85	30,20	45,10	22,40	51,50			
Haematology	Haematocrit, %	continuous	Hct_d90	Day 90	Total	38	44,13	7,71	45,00	39,15	49,25	29,80	58,30			
Haematology	Haematocrit, %	continuous	Hct_d90	Day 90	Omnifect Proimmune	19	44,11	8,50	42,70	39,05	51,65	29,80	58,30			
Haematology	Haematocrit, %	continuous	Hct_d90	Day 90	Placebo	19	44,15	7,06	45,60	40,55	49,10	30,30	55,10			
Haematology	Haematocrit, %	continuous	Hct_d180	Day 180	Total	37	43,06	8,42	42,70	38,50	49,10	16,40	58,20			
Haematology	Haematocrit, %	continuous	Hct_d180	Day 180	Omnifect Proimmune	19	43,99	7,99	42,10	39,00	49,45	29,30	58,20			
Haematology	Haematocrit, %	continuous	Hct_d180	Day 180	Placebo	18	42,07	8,98	43,55	38,53	47,20	16,40	53,10			
Haematology	Haematocrit, %	continuous	Hct_d360	Day 360	Total	31	44,66	8,07	45,70	40,95	49,90	22,00	60,90			
Haematology	Haematocrit, %	continuous	Hct_d360	Day 360	Omnifect Proimmune	16	45,61	7,18	44,35	40,98	48,60	35,40	60,90			
Haematology	Haematocrit, %	continuous	Hct_d360	Day 360	Placebo	15	43,65	9,07	47,00	42,05	49,90	22,00	51,40			
Haematology	Haemoglobin	continuous	Hb_d0	Day 0	Total	56	12,82	3,25	13,45	10,82	15,40	3,60	19,10			

Haematology	Haemoglobin	continuous	Hb_d0	Day 0	Omnifect Proimmune	27	13,11	3,48	13,50	11,40	15,30	3,60	19,10			
Haematology	Haemoglobin	continuous	Hb_d0	Day 0	Placebo	29	12,56	3,07	12,30	10,20	15,40	7,40	17,80			
Haematology	Haemoglobin	continuous	Hb_90	Day 90	Total	38	15,25	2,75	15,25	13,63	17,38	9,90	20,40			
Haematology	Haemoglobin	continuous	Hb_90	Day 90	Omnifect Proimmune	19	15,27	3,12	14,80	13,75	17,75	9,90	20,40			
Haematology	Haemoglobin	continuous	Hb_90	Day 90	Placebo	19	15,23	2,40	15,30	13,45	17,20	10,60	18,40			
Haematology	Haemoglobin	continuous	Hb_180	Day 180	Total	37	14,89	3,06	14,70	13,40	17,30	5,30	19,90			
Haematology	Haemoglobin	continuous	Hb_180	Day 180	Omnifect Proimmune	19	15,35	2,89	14,30	13,50	17,50	10,40	19,90			
Haematology	Haemoglobin	continuous	Hb_180	Day 180	Placebo	18	14,41	3,24	14,70	13,53	16,25	5,30	18,70			
Haematology	Haemoglobin	continuous	Hb_360	Day 360	Total	31	15,54	2,96	15,70	14,40	17,45	7,30	21,80			
Haematology	Haemoglobin	continuous	Hb_360	Day 360	Omnifect Proimmune	16	16,00	2,63	15,50	14,35	17,45	12,00	21,80			
Haematology	Haemoglobin	continuous	Hb_360	Day 360	Placebo	15	15,04	3,30	15,90	14,60	17,40	7,30	18,10			
Haematology	Mean corpuscular volume	continuous	VCM_d0	Day 0	Total	56	66,42	4,99	66,80	63,75	69,35	54,00	79,63			
Haematology	Mean corpuscular volume	continuous	VCM_d0	Day 0	Omnifect Proimmune	27	65,84	4,39	65,40	63,40	68,50	56,30	78,70			

Haematology	Mean corpuscular volume	continuous	VCM_d0	Day 0	Placebo	29	66,95	5,52	67,30	64,50	70,10	54,00	79,63			
Haematology	Mean corpuscular volume	continuous	VCM_90	Day 90	Total	38	65,92	4,16	65,95	63,45	68,93	51,00	72,50			
Haematology	Mean corpuscular volume	continuous	VCM_90	Day 90	Omnifect Proimmune	19	66,01	3,32	65,60	63,45	68,50	60,60	71,80			
Haematology	Mean corpuscular volume	continuous	VCM_90	Day 90	Placebo	19	65,84	4,96	67,40	63,55	68,80	51,00	72,50			
Haematology	Mean corpuscular volume	continuous	VCM_180	Day 180	Total	37	66,90	3,97	67,40	64,90	68,10	58,80	78,80			
Haematology	Mean corpuscular volume	continuous	VCM_180	Day 180	Omnifect Proimmune	19	65,84	3,44	66,70	63,70	67,95	58,80	71,10			
Haematology	Mean corpuscular volume	continuous	VCM_180	Day 180	Placebo	18	68,02	4,27	67,40	65,23	69,35	61,70	78,80			
Haematology	Mean corpuscular volume	continuous	VCM_360	Day 360	Total	31	66,38	4,52	66,60	63,50	68,80	57,50	80,70			
Haematology	Mean corpuscular volume	continuous	VCM_360	Day 360	Omnifect Proimmune	16	65,51	4,01	65,95	63,23	68,38	57,50	70,60			
Haematology	Mean corpuscular volume	continuous	VCM_360	Day 360	Placebo	15	67,31	4,98	66,60	63,90	68,80	60,70	80,70			
Haematology	Mean corpuscular haemoglob	continuous	CHCM_d0	Day 0	Total	56	33,57	1,78	34,00	32,93	34,83	29,16	35,80			

	in concentration															
Haematology	Mean corpuscular haemoglobin concentration	continuous	CHCM_d0	Day 0	Omnifect Proimmune	27	33,82	1,63	34,30	33,05	35,00	29,20	35,80			
Haematology	Mean corpuscular haemoglobin concentration	continuous	CHCM_d0	Day 0	Placebo	29	33,33	1,90	33,90	32,10	34,60	29,16	35,50			
Haematology	Mean corpuscular haemoglobin concentration	continuous	CHCM_d90	Day 90	Total	38	34,54	1,26	34,65	33,85	35,18	31,80	38,90			
Haematology	Mean corpuscular haemoglobin concentration	continuous	CHCM_d90	Day 90	Omnifect Proimmune	19	34,54	1,02	34,70	34,20	35,05	31,80	36,20			
Haematology	Mean corpuscular haemoglobin	continuous	CHCM_d90	Day 90	Placebo	19	34,54	1,50	34,50	33,70	35,20	32,10	38,90			

	concentration															
Haematology	Mean corpuscular haemoglobin concentration	continuous	CHCM_d180	Day 180	Total	37	34,22	2,28	34,80	33,80	35,50	22,50	36,10			
Haematology	Mean corpuscular haemoglobin concentration	continuous	CHCM_d180	Day 180	Omnifect Proimmune	19	34,96	1,05	35,30	34,30	35,75	32,10	36,10			
Haematology	Mean corpuscular haemoglobin concentration	continuous	CHCM_d180	Day 180	Placebo	18	33,43	2,92	34,15	33,20	34,88	22,50	35,70			
Haematology	Mean corpuscular haemoglobin concentration	continuous	CHCM_360	Day 360	Total	31	34,69	1,09	34,90	34,25	35,20	30,80	37,40			
Haematology	Mean corpuscular haemoglobin concentration	continuous	CHCM_360	Day 360	Omnifect Proimmune	16	34,98	0,87	35,05	34,50	35,20	33,50	37,40			

Haematology	Mean corpuscular haemoglobin concentration	continuous	CHCM_360	Day 360	Placebo	15	34,38	1,23	34,90	33,90	35,20	30,80	35,70			
Haematology	Reticulocytes	continuous	Ret_d0	Day 0	Total	56	0,05	0,04	0,04	0,02	0,06	0,00	0,27			
Haematology	Reticulocytes	continuous	Ret_d0	Day 0	Omnifect Proimmune	27	0,05	0,04	0,04	0,03	0,07	0,01	0,17			
Haematology	Reticulocytes	continuous	Ret_d0	Day 0	Placebo	29	0,04	0,05	0,03	0,02	0,05	0,00	0,27			
Haematology	Reticulocytes	continuous	Ret_d90	Day 90	Total	38	0,06	0,03	0,05	0,03	0,07	0,01	0,16			
Haematology	Reticulocytes	continuous	Ret_d90	Day 90	Omnifect Proimmune	19	0,06	0,04	0,06	0,04	0,07	0,02	0,16			
Haematology	Reticulocytes	continuous	Ret_d90	Day 90	Placebo	19	0,05	0,02	0,05	0,03	0,06	0,01	0,11			
Haematology	Reticulocytes	continuous	Ret_180	Day 180	Total	37	0,05	0,03	0,04	0,03	0,07	0,00	0,18			
Haematology	Reticulocytes	continuous	Ret_180	Day 180	Omnifect Proimmune	19	0,06	0,04	0,04	0,03	0,08	0,01	0,18			
Haematology	Reticulocytes	continuous	Ret_180	Day 180	Placebo	18	0,04	0,03	0,03	0,03	0,06	0,00	0,09			
Haematology	Reticulocytes	continuous	Ret_360	Day 360	Total	31	0,04	0,02	0,04	0,03	0,06	0,01	0,10			
Haematology	Reticulocytes	continuous	Ret_360	Day 360	Omnifect Proimmune	16	0,05	0,03	0,04	0,03	0,07	0,01	0,10			

Haematology	Reticulocytes	continuous	Ret_360	Day 360	Placebo	15	0,04	0,02	0,04	0,03	0,06	0,01	0,08			
Haematology	Reticulocyte haemoglobin	continuous	Hb_Reti_d0	Day 0	Total	10	24,45	3,28	25,65	21,73	26,20	19,10	29,40			
Haematology	Reticulocyte haemoglobin	continuous	Hb_Reti_d0	Day 0	Omnifect Proimmune	4	25,38	3,53	25,65	24,40	26,63	20,80	29,40			
Haematology	Reticulocyte haemoglobin	continuous	Hb_Reti_d0	Day 0	Placebo	6	23,83	3,28	25,20	21,43	26,20	19,10	26,80			
Haematology	Reticulocyte haemoglobin	continuous	Hb_Reti_d90	Day 90	Total	8	24,81	1,28	25,25	23,53	25,78	23,10	26,30			
Haematology	Reticulocyte haemoglobin	continuous	Hb_Reti_d90	Day 90	Omnifect Proimmune	2	23,45	0,21	23,45	23,38	23,53	23,30	23,60			
Haematology	Reticulocyte haemoglobin	continuous	Hb_Reti_d90	Day 90	Placebo	6	25,27	1,14	25,55	25,18	25,93	23,10	26,30			
Haematology	Reticulocyte haemoglobin	continuous	Hb_Reti_d180	Day 180	Total	4	24,83	1,92	25,20	23,88	26,15	22,30	26,60			
Haematology	Reticulocyte haemoglobin	continuous	Hb_Reti_d180	Day 180	Omnifect Proimmune	3	25,67	1,14	26,00	25,20	26,30	24,40	26,60			
Haematology	Reticulocyte	continuous	Hb_Reti_d180	Day 180	Placebo	1	22,30		22,30	22,30	22,30	22,30	22,30			

	haemoglobin															
Haematology	Reticulocyte haemoglobin	continuous	Hb_Reti_d360	Day 360	Total	9	25,42	1,14	25,30	25,00	26,00	23,00	27,00			
Haematology	Reticulocyte haemoglobin	continuous	Hb_Reti_d360	Day 360	Omnifect Proimmune	4	25,95	0,95	25,90	25,23	26,63	25,00	27,00			
Haematology	Reticulocyte haemoglobin	continuous	Hb_Reti_d360	Day 360	Placebo	5	25,00	1,20	25,30	24,90	25,80	23,00	26,00			
Haematology	Leukocytes	continuous	LEU_d0	Day 0	Total	56	10,64	5,49	9,22	6,68	11,92	4,04	25,41			
Haematology	Leukocytes	continuous	LEU_d0	Day 0	Omnifect Proimmune	27	11,35	5,30	10,57	7,27	13,98	4,04	24,93			
Haematology	Leukocytes	continuous	LEU_d0	Day 0	Placebo	29	9,98	5,68	7,32	6,56	10,21	4,42	25,41			
Haematology	Leukocytes	continuous	LEU_d90	Day 90	Total	38	9,84	3,80	9,26	7,31	10,88	4,88	19,13			
Haematology	Leukocytes	continuous	LEU_d90	Day 90	Omnifect Proimmune	19	11,09	4,07	10,32	7,94	13,29	4,88	19,13			
Haematology	Leukocytes	continuous	LEU_d90	Day 90	Placebo	19	8,60	3,15	8,18	6,56	9,37	4,95	17,90			
Haematology	Leukocytes	continuous	LEU_d180	Day 180	Total	37	10,32	8,88	8,08	6,86	9,88	2,97	57,01			
Haematology	Leukocytes	continuous	LEU_d180	Day 180	Omnifect Proimmune	19	9,77	4,96	8,46	7,16	9,76	5,87	26,58			

Haematology	Leukocytes	continuous	LEU_d180	Day 180	Placebo	18	10,90	11,84	7,86	6,45	10,01	2,97	57,01			
Haematology	Leukocytes	continuous	LEU_d360	Day 360	Total	31	9,26	3,88	8,07	6,38	10,08	5,36	20,03			
Haematology	Leukocytes	continuous	LEU_d360	Day 360	Omnifect Proimmune	16	10,10	4,79	8,04	6,67	14,84	5,36	20,03			
Haematology	Leukocytes	continuous	LEU_d360	Day 360	Placebo	15	8,36	2,44	8,51	6,38	9,92	5,60	14,05			
Haematology	Neutrophils	continuous	Neu_d0	Day 0	Total	56	7,63	4,92	5,59	4,23	8,34	2,44	21,14			
Haematology	Neutrophils	continuous	Neu_d0	Day 0	Omnifect Proimmune	27	8,09	4,77	6,32	5,01	10,43	2,44	17,97			
Haematology	Neutrophils	continuous	Neu_d0	Day 0	Placebo	29	7,20	5,09	5,17	4,00	7,66	2,77	21,14			
Haematology	Neutrophils	continuous	Neu_d90	Day 90	Total	38	6,54	3,44	5,37	4,33	7,22	2,45	14,58			
Haematology	Neutrophils	continuous	Neu_d90	Day 90	Omnifect Proimmune	19	7,46	3,65	6,09	4,82	9,24	2,78	14,58			
Haematology	Neutrophils	continuous	Neu_d90	Day 90	Placebo	19	5,61	3,03	4,97	3,95	5,75	2,45	14,41			
Haematology	Neutrophils	continuous	Neu_d180	Day 180	Total	37	7,10	8,53	5,14	4,04	6,31	1,46	53,59			
Haematology	Neutrophils	continuous	Neu_d180	Day 180	Omnifect Proimmune	19	6,40	3,93	5,37	4,27	5,99	2,58	17,91			
Haematology	Neutrophils	continuous	Neu_d180	Day 180	Placebo	18	7,84	11,69	4,61	3,84	6,32	1,46	53,59			
Haematology	Neutrophils	continuous	Neu_d360	Day 360	Total	31	6,38	3,67	4,99	4,03	6,78	3,26	18,43			

Haematology	Neutrophils	continuous	Neu_d360	Day 360	Omnifect Proimmune	16	7,03	4,54	4,73	4,09	9,86	3,26	18,43			
Haematology	Neutrophils	continuous	Neu_d360	Day 360	Placebo	15	5,68	2,39	4,99	3,94	6,03	3,65	11,61			
Haematology	Lymphocytes	continuous	Linf_d0	Day 0	Total	56	1,82	0,97	1,58	1,09	2,09	0,18	4,96			
Haematology	Lymphocytes	continuous	Linf_d0	Day 0	Omnifect Proimmune	27	2,02	1,08	1,82	1,22	2,28	0,38	4,96			
Haematology	Lymphocytes	continuous	Linf_d0	Day 0	Placebo	29	1,63	0,83	1,43	1,06	2,01	0,18	4,19			
Haematology	Lymphocytes	continuous	Linf_d90	Day 90	Total	38	2,94	5,61	1,85	1,43	2,33	0,82	36,20			
Haematology	Lymphocytes	continuous	Linf_d90	Day 90	Omnifect Proimmune	19	2,39	0,98	2,04	1,78	3,06	1,23	4,42			
Haematology	Lymphocytes	continuous	Linf_d90	Day 90	Placebo	19	3,49	7,94	1,65	1,28	1,98	0,82	36,20			
Haematology	Lymphocytes	continuous	Linf_d180	Day 180	Total	37	2,04	0,95	1,89	1,35	2,48	0,57	5,08			
Haematology	Lymphocytes	continuous	Linf_d180	Day 180	Omnifect Proimmune	19	2,18	1,02	1,99	1,47	2,46	0,81	5,08			
Haematology	Lymphocytes	continuous	Linf_d180	Day 180	Placebo	18	1,89	0,88	1,62	1,26	2,53	0,57	3,61			
Haematology	Lymphocytes	continuous	Linf_d360	Day 360	Total	31	1,80	0,72	1,63	1,33	2,31	0,40	3,29			
Haematology	Lymphocytes	continuous	Linf_d360	Day 360	Omnifect Proimmune	16	1,92	0,72	1,87	1,40	2,41	0,40	3,01			

Haematology	Lymphocytes	continuous	Linf_d360	Day 360	Placebo	15	1,67	0,73	1,53	1,18	1,91	0,64	3,29			
Haematology	Monocytes	continuous	Mono_d0	Day 0	Total	56	0,99	1,40	0,66	0,45	1,10	0,04	10,40			
Haematology	Monocytes	continuous	Mono_d0	Day 0	Omnifect Proimmune	27	0,80	0,47	0,81	0,38	1,13	0,04	1,82			
Haematology	Monocytes	continuous	Mono_d0	Day 0	Placebo	29	1,16	1,89	0,56	0,46	0,94	0,23	10,40			
Haematology	Monocytes	continuous	Mono_d90	Day 90	Total	38	0,74	0,44	0,60	0,44	0,89	0,05	1,77			
Haematology	Monocytes	continuous	Mono_d90	Day 90	Omnifect Proimmune	19	0,75	0,40	0,61	0,50	0,98	0,05	1,67			
Haematology	Monocytes	continuous	Mono_d90	Day 90	Placebo	19	0,74	0,48	0,58	0,38	0,89	0,31	1,77			
Haematology	Monocytes	continuous	Mono_d180	Day 180	Total	37	0,63	0,44	0,53	0,39	0,61	0,02	2,39			
Haematology	Monocytes	continuous	Mono_d180	Day 180	Omnifect Proimmune	19	0,70	0,55	0,52	0,42	0,63	0,02	2,39			
Haematology	Monocytes	continuous	Mono_d180	Day 180	Placebo	18	0,56	0,28	0,54	0,40	0,61	0,26	1,52			
Haematology	Monocytes	continuous	Mono_d360	Day 360	Total	31	0,59	0,30	0,50	0,38	0,64	0,28	1,23			
Haematology	Monocytes	continuous	Mono_d360	Day 360	Omnifect Proimmune	16	0,62	0,34	0,47	0,36	0,85	0,28	1,19			
Haematology	Monocytes	continuous	Mono_d360	Day 360	Placebo	15	0,56	0,26	0,51	0,43	0,56	0,32	1,23			
Haematology	Eosinophils	continuous	Eosi_d0	Day 0	Total	56	0,35	0,32	0,30	0,10	0,45	0,00	1,60			

Haematology	Eosinophils	continuous	Eosi_d0	Day 0	Omnifect Proimmune	27	0,43	0,40	0,34	0,20	0,47	0,00	1,60			
Haematology	Eosinophils	continuous	Eosi_d0	Day 0	Placebo	29	0,27	0,21	0,27	0,07	0,42	0,00	0,69			
Haematology	Eosinophils	continuous	Eosi_d90	Day 90	Total	38	0,47	0,40	0,37	0,19	0,66	0,00	1,93			
Haematology	Eosinophils	continuous	Eosi_d90	Day 90	Omnifect Proimmune	19	0,47	0,29	0,42	0,24	0,72	0,11	1,05			
Haematology	Eosinophils	continuous	Eosi_d90	Day 90	Placebo	19	0,46	0,49	0,36	0,18	0,46	0,00	1,93			
Haematology	Eosinophils	continuous	Eosi_d180	Day 180	Total	37	0,48	0,37	0,44	0,22	0,66	0,00	1,88			
Haematology	Eosinophils	continuous	Eosi_d180	Day 180	Omnifect Proimmune	19	0,48	0,30	0,47	0,28	0,67	0,08	1,14			
Haematology	Eosinophils	continuous	Eosi_d180	Day 180	Placebo	18	0,48	0,45	0,41	0,21	0,60	0,00	1,88			
Haematology	Eosinophils	continuous	Eosi_d360	Day 360	Total	31	0,48	0,36	0,42	0,30	0,63	0,00	1,70			
Haematology	Eosinophils	continuous	Eosi_d360	Day 360	Omnifect Proimmune	16	0,52	0,35	0,47	0,30	0,78	0,00	1,13			
Haematology	Eosinophils	continuous	Eosi_d360	Day 360	Placebo	15	0,45	0,38	0,41	0,32	0,45	0,00	1,70			
Haematology	Basophils	continuous	Baso_d0	Day 0	Total	56	0,02	0,04	0,01	0,00	0,02	0,00	0,26			
Haematology	Basophils	continuous	Baso_d0	Day 0	Omnifect Proimmune	27	0,02	0,05	0,01	0,01	0,02	0,00	0,26			

Haematology	Basophils	continuous	Baso_d0	Day 0	Placebo	29	0,01	0,01	0,01	0,00	0,01	0,00	0,05			
Haematology	Basophils	continuous	Baso_d90	Day 90	Total	38	0,01	0,01	0,01	0,01	0,02	0,00	0,04			
Haematology	Basophils	continuous	Baso_d90	Day 90	Omnifect Proimmune	19	0,01	0,01	0,01	0,01	0,02	0,00	0,04			
Haematology	Basophils	continuous	Baso_d90	Day 90	Placebo	19	0,01	0,01	0,01	0,01	0,02	0,00	0,02			
Haematology	Basophils	continuous	Baso_d180	Day 180	Total	37	0,01	0,01	0,01	0,01	0,02	0,00	0,05			
Haematology	Basophils	continuous	Baso_d180	Day 180	Omnifect Proimmune	19	0,01	0,01	0,01	0,01	0,02	0,00	0,05			
Haematology	Basophils	continuous	Baso_d180	Day 180	Placebo	18	0,01	0,01	0,01	0,00	0,02	0,00	0,02			
Haematology	Basophils	continuous	Baso_d360	Day 360	Total	31	0,01	0,03	0,01	0,00	0,02	0,00	0,14			
Haematology	Basophils	continuous	Baso_d360	Day 360	Omnifect Proimmune	16	0,02	0,03	0,01	0,00	0,02	0,00	0,14			
Haematology	Basophils	continuous	Baso_d360	Day 360	Placebo	15	0,01	0,01	0,01	0,00	0,01	0,00	0,02			
Haematology	Platelets, ×10³/µl	continuous	Plaq_d0	Day 0	Total	56	241,24	140,38	223,00	133,75	286,75	54,53	805,00			
Haematology	Platelets, ×10³/µl	continuous	Plaq_d0	Day 0	Omnifect Proimmune	27	247,07	155,90	214,00	158,00	279,50	86,00	805,00			
Haematology	Platelets, ×10³/µl	continuous	Plaq_d0	Day 0	Placebo	29	235,81	126,79	226,00	124,00	286,00	54,53	524,00			
Haematology	Platelets, ×10³/µl	continuous	Plaq_d90	Day 90	Total	38	312,42	149,84	292,00	229,25	352,75	99,00	749,00			

Haematology	Platelets, ×10³/µl	continuous	Plaq_d90	Day 90	Omnifect Proimmune	19	320,05	199,14	248,00	194,50	402,50	99,00	749,00			
Haematology	Platelets, ×10³/µl	continuous	Plaq_d90	Day 90	Placebo	19	304,79	79,81	315,00	263,00	340,50	158,00	436,00			
Haematology	Platelets, ×10³/µl	continuous	Plaq_d180	Day 180	Total	37	287,22	131,27	257,00	193,00	352,00	39,00	625,00			
Haematology	Platelets, ×10³/µl	continuous	Plaq_d180	Day 180	Omnifect Proimmune	19	307,21	157,77	248,00	188,50	410,00	39,00	625,00			
Haematology	Platelets, ×10³/µl	continuous	Plaq_d180	Day 180	Placebo	18	266,11	96,01	275,50	220,25	308,00	103,00	447,00			
Haematology	Platelets, ×10³/µl	continuous	Plaq_d360	Day 360	Total	31	312,90	130,35	319,00	219,50	399,00	97,00	641,00			
Haematology	Platelets, ×10³/µl	continuous	Plaq_d360	Day 360	Omnifect Proimmune	16	331,06	143,33	307,00	210,25	413,00	165,00	641,00			
Haematology	Platelets, ×10³/µl	continuous	Plaq_d360	Day 360	Placebo	15	293,53	116,72	325,00	230,50	376,00	97,00	468,00			
Biochemistry	Sodium	continuous	Na_d0	Day 0	Total	54	144,53	3,44	144,16	142,16	146,57	138,00	156,16			
Biochemistry	Sodium	continuous	Na_d0	Day 0	Omnifect Proimmune	27	144,08	3,43	144,07	141,09	146,11	138,86	153,92			
Biochemistry	Sodium	continuous	Na_d0	Day 0	Placebo	27	144,97	3,45	144,40	143,24	146,67	138,00	156,16			
Biochemistry	Sodium	continuous	Na_d90	Day 90	Total	38	146,03	3,39	145,35	144,25	146,72	142,06	159,66			
Biochemistry	Sodium	continuous	Na_d90	Day 90	Omnifect Proimmune	19	146,64	4,58	145,35	143,97	146,96	142,06	159,66			

Biochemistry	Sodium	continuous	Na_d90	Day 90	Placebo	19	145,42	1,37	145,35	144,57	146,19	143,02	147,75			
Biochemistry	Sodium	continuous	Na_d180	Day 180	Total	37	145,75	2,96	145,54	144,64	146,73	138,15	155,00			
Biochemistry	Sodium	continuous	Na_d180	Day 180	Omnifect Proimmune	19	146,21	3,51	146,00	144,93	146,86	138,15	155,00			
Biochemistry	Sodium	continuous	Na_d180	Day 180	Placebo	18	145,27	2,25	145,37	144,08	146,69	140,18	149,10			
Biochemistry	Sodium	continuous	Na_d360	Day 360	Total	31	141,71	18,70	145,59	142,65	146,92	42,50	151,00			
Biochemistry	Sodium	continuous	Na_d360	Day 360	Omnifect Proimmune	16	144,24	3,57	145,42	142,09	146,81	134,51	148,20			
Biochemistry	Sodium	continuous	Na_d360	Day 360	Placebo	15	139,02	26,84	146,20	143,87	147,53	42,50	151,00			
Biochemistry	Potassium	continuous	K_d0	Day 0	Total	54	4,38	0,49	4,28	4,05	4,64	3,50	5,76			
Biochemistry	Potassium	continuous	K_d0	Day 0	Omnifect Proimmune	27	4,41	0,56	4,20	4,05	4,84	3,50	5,76			
Biochemistry	Potassium	continuous	K_d0	Day 0	Placebo	27	4,36	0,41	4,41	4,05	4,59	3,63	5,35			
Biochemistry	Potassium	continuous	K_d90	Day 90	Total	38	4,27	0,38	4,24	3,96	4,52	3,55	5,07			
Biochemistry	Potassium	continuous	K_d90	Day 90	Omnifect Proimmune	19	4,28	0,35	4,26	4,00	4,52	3,77	5,07			
Biochemistry	Potassium	continuous	K_d90	Day 90	Placebo	19	4,26	0,41	4,19	3,96	4,57	3,55	4,96			
Biochemistry	Potassium	continuous	K_d180	Day 180	Total	37	4,26	0,41	4,22	3,95	4,60	3,53	5,08			

Biochemistry	Potassium	continuous	K_d180	Day 180	Omnifect Proimmune	19	4,23	0,42	4,15	3,97	4,53	3,67	5,08			
Biochemistry	Potassium	continuous	K_d180	Day 180	Placebo	18	4,29	0,41	4,31	3,97	4,67	3,53	4,83			
Biochemistry	Potassium	continuous	K_d360	Day 360	Total	31	4,40	0,42	4,34	4,09	4,70	3,71	5,20			
Biochemistry	Potassium	continuous	K_d360	Day 360	Omnifect Proimmune	16	4,44	0,42	4,39	4,08	4,76	3,90	5,12			
Biochemistry	Potassium	continuous	K_d360	Day 360	Placebo	15	4,36	0,42	4,33	4,10	4,58	3,71	5,20			
Biochemistry	Urea	continuous	Urea_d0	Day 0	Total	56	70,48	80,97	33,43	25,38	67,06	4,28	321,27			
Biochemistry	Urea	continuous	Urea_d0	Day 0	Omnifect Proimmune	27	78,15	85,79	39,13	24,33	80,27	16,62	321,27			
Biochemistry	Urea	continuous	Urea_d0	Day 0	Placebo	29	63,34	77,03	33,36	27,95	51,54	4,28	299,30			
Biochemistry	Urea	continuous	Urea_d90	Day 90	Total	38	37,23	18,15	32,14	28,30	43,55	10,80	105,51			
Biochemistry	Urea	continuous	Urea_d90	Day 90	Omnifect Proimmune	19	39,52	23,75	32,00	25,61	48,81	10,80	105,51			
Biochemistry	Urea	continuous	Urea_d90	Day 90	Placebo	19	34,94	10,11	32,90	28,31	40,53	17,97	61,00			
Biochemistry	Urea	continuous	Urea_d180	Day 180	Total	37	37,76	22,78	35,03	27,68	40,72	11,98	158,30			
Biochemistry	Urea	continuous	Urea_d180	Day 180	Omnifect Proimmune	19	37,67	30,85	31,06	24,50	40,80	11,98	158,30			

Biochemistry	Urea	continuous	Urea_d180	Day 180	Placebo	18	37,86	9,56	35,78	32,51	40,64	22,59	57,45			
Biochemistry	Urea	continuous	Urea_d360	Day 360	Total	30	55,38	86,20	36,62	28,43	46,39	15,90	496,75			
Biochemistry	Urea	continuous	Urea_d360	Day 360	Omnifect Proimmune	15	34,73	13,42	33,96	24,48	42,55	15,90	57,38			
Biochemistry	Urea	continuous	Urea_d360	Day 360	Placebo	15	76,04	119,58	37,37	32,49	49,05	19,14	496,75			
Biochemistry	BUN	continuous	BUN_d0	Day 0	Total	54	33,21	37,97	16,00	12,96	29,70	7,14	150,13			
Biochemistry	BUN	continuous	BUN_d0	Day 0	Omnifect Proimmune	27	36,51	40,09	18,29	11,37	37,51	7,77	150,13			
Biochemistry	BUN	continuous	BUN_d0	Day 0	Placebo	27	29,90	36,17	15,65	13,34	22,39	7,14	139,85			
Biochemistry	BUN	continuous	BUN_d90	Day 90	Total	38	17,39	8,48	15,02	13,21	20,34	5,02	49,30			
Biochemistry	BUN	continuous	BUN_d90	Day 90	Omnifect Proimmune	19	18,46	11,10	14,96	11,97	22,81	5,02	49,30			
Biochemistry	BUN	continuous	BUN_d90	Day 90	Placebo	19	16,32	4,72	15,37	13,23	18,94	8,40	28,48			
Biochemistry	BUN	continuous	BUN_d180	Day 180	Total	37	17,64	10,65	16,37	12,93	19,03	5,60	73,99			
Biochemistry	BUN	continuous	BUN_d180	Day 180	Omnifect Proimmune	19	17,56	14,44	14,51	11,05	19,07	5,60	73,99			
Biochemistry	BUN	continuous	BUN_d180	Day 180	Placebo	18	17,73	4,41	16,72	15,19	18,99	10,56	26,85			
Biochemistry	BUN	continuous	BUN_d360	Day 360	Total	31	29,25	43,80	17,44	13,58	22,92	7,43	232,13			

Biochemistry	BUN	continuous	BUN_d360	Day 360	Omnifect Proimmune	16	23,34	29,08	16,32	11,64	21,21	7,43	130,00			
Biochemistry	BUN	continuous	BUN_d360	Day 360	Placebo	15	35,55	55,87	17,46	15,18	22,92	8,94	232,13			
Biochemistry	Creatinine, mg/dl	continuous	Creat_d0	Day 0	Total	56	1,46	1,21	1,03	0,78	1,39	0,10	5,70			
Biochemistry	Creatinine, mg/dl	continuous	Creat_d0	Day 0	Omnifect Proimmune	27	1,48	1,16	0,97	0,79	1,59	0,51	5,70			
Biochemistry	Creatinine, mg/dl	continuous	Creat_d0	Day 0	Placebo	29	1,44	1,27	1,06	0,78	1,29	0,10	4,83			
Biochemistry	Creatinine, mg/dl	continuous	Creat_d90	Day 90	Total	38	0,95	0,34	0,83	0,69	1,21	0,50	2,00			
Biochemistry	Creatinine, mg/dl	continuous	Creat_d90	Day 90	Omnifect Proimmune	19	0,91	0,38	0,80	0,66	1,06	0,50	2,00			
Biochemistry	Creatinine, mg/dl	continuous	Creat_d90	Day 90	Placebo	19	0,99	0,31	0,86	0,76	1,24	0,57	1,56			
Biochemistry	Creatinine, mg/dl	continuous	Creat_d180	Day 180	Total	37	1,04	0,46	0,92	0,83	1,12	0,40	2,89			
Biochemistry	Creatinine, mg/dl	continuous	Creat_d180	Day 180	Omnifect Proimmune	19	0,99	0,53	0,86	0,80	1,00	0,40	2,89			
Biochemistry	Creatinine, mg/dl	continuous	Creat_d180	Day 180	Placebo	18	1,10	0,39	1,02	0,84	1,36	0,55	1,91			
Biochemistry	Creatinine, mg/dl	continuous	Creat_d360	Day 360	Total	31	1,60	2,23	0,95	0,79	1,51	0,44	12,23			
Biochemistry	Creatinine, mg/dl	continuous	Creat_d360	Day 360	Omnifect Proimmune	16	1,28	1,38	0,94	0,76	1,06	0,44	6,30			

Biochemistry	Creatinine, mg/dl	continuous	Creat_d360	Day 360	Placebo	15	1,94	2,89	1,09	0,89	1,52	0,60	12,23			
Biochemistry	Calcium	continuous	Ca_d0	Day 0	Total	54	10,19	0,82	10,22	9,79	10,73	7,08	11,78			
Biochemistry	Calcium	continuous	Ca_d0	Day 0	Omnifect Proimmune	27	10,24	0,64	10,22	9,83	10,57	8,56	11,78			
Biochemistry	Calcium	continuous	Ca_d0	Day 0	Placebo	27	10,15	0,98	10,21	9,74	10,79	7,08	11,74			
Biochemistry	Calcium	continuous	Ca_d90	Day 90	Total	38	10,31	0,60	10,38	10,09	10,57	8,41	11,75			
Biochemistry	Calcium	continuous	Ca_d90	Day 90	Omnifect Proimmune	19	10,28	0,63	10,18	10,02	10,53	8,88	11,75			
Biochemistry	Calcium	continuous	Ca_d90	Day 90	Placebo	19	10,35	0,58	10,44	10,23	10,57	8,41	11,30			
Biochemistry	Calcium	continuous	Ca_d180	Day 180	Total	37	10,43	0,48	10,42	10,06	10,68	9,14	11,50			
Biochemistry	Calcium	continuous	Ca_d180	Day 180	Omnifect Proimmune	19	10,42	0,43	10,36	10,03	10,64	9,90	11,50			
Biochemistry	Calcium	continuous	Ca_d180	Day 180	Placebo	18	10,44	0,54	10,56	10,26	10,70	9,14	11,31			
Biochemistry	Calcium	continuous	Ca_d360	Day 360	Total	31	10,32	0,77	10,42	10,14	10,79	6,92	11,34			
Biochemistry	Calcium	continuous	Ca_d360	Day 360	Omnifect Proimmune	16	10,07	0,96	10,18	9,92	10,56	6,92	11,34			
Biochemistry	Calcium	continuous	Ca_d360	Day 360	Placebo	15	10,59	0,37	10,74	10,28	10,84	9,79	11,07			
Biochemistry	Phosphorus	continuous	Fosf_d0	Day 0	Total	54	5,52	4,04	4,31	3,54	5,28	2,65	24,01			

Biochemistry	Phosphorus	continuous	Fosf_d0	Day 0	Omnifect Proimmune	27	5,63	4,15	4,39	3,72	5,70	2,65	24,01			
Biochemistry	Phosphorus	continuous	Fosf_d0	Day 0	Placebo	27	5,41	4,01	4,09	3,50	5,06	2,69	21,06			
Biochemistry	Phosphorus	continuous	Fosf_d90	Day 90	Total	38	3,71	0,79	3,72	3,34	4,08	1,21	5,73			
Biochemistry	Phosphorus	continuous	Fosf_d90	Day 90	Omnifect Proimmune	19	3,67	0,86	3,81	3,36	4,11	1,21	4,83			
Biochemistry	Phosphorus	continuous	Fosf_d90	Day 90	Placebo	19	3,75	0,74	3,48	3,34	4,08	2,59	5,73			
Biochemistry	Phosphorus	continuous	Fosf_d180	Day 180	Total	37	3,69	0,99	3,59	3,44	4,08	0,66	6,70			
Biochemistry	Phosphorus	continuous	Fosf_d180	Day 180	Omnifect Proimmune	19	3,65	0,85	3,74	3,32	4,03	1,81	5,34			
Biochemistry	Phosphorus	continuous	Fosf_d180	Day 180	Placebo	18	3,74	1,14	3,58	3,45	4,10	0,66	6,70			
Biochemistry	Phosphorus	continuous	Fosf_d360	Day 360	Total	31	4,46	3,23	3,53	3,18	4,22	2,42	16,28			
Biochemistry	Phosphorus	continuous	Fosf_d360	Day 360	Omnifect Proimmune	16	4,32	3,20	3,61	3,22	4,13	2,42	16,10			
Biochemistry	Phosphorus	continuous	Fosf_d360	Day 360	Placebo	15	4,60	3,37	3,46	3,20	4,22	2,89	16,28			
Biochemistry	Total protein, g/dl	continuous	Prot_d0	Day 0	Total	56	7,18	1,61	7,00	6,40	8,01	3,13	11,70			
Biochemistry	Total protein, g/dl	continuous	Prot_d0	Day 0	Omnifect Proimmune	27	7,09	1,71	7,02	6,10	7,81	4,44	11,70			

Biochemistry	Total protein, g/dl	continuous	Prot_d0	Day 0	Placebo	29	7,27	1,54	6,98	6,48	8,10	3,13	11,00			
Biochemistry	Total protein, g/dl	continuous	Prot_d90	Day 90	Total	38	6,40	0,64	6,50	6,00	6,76	5,05	8,01			
Biochemistry	Total protein, g/dl	continuous	Prot_d90	Day 90	Omnifect Proimmune	19	6,26	0,71	6,14	5,85	6,73	5,05	7,73			
Biochemistry	Total protein, g/dl	continuous	Prot_d90	Day 90	Placebo	19	6,53	0,55	6,50	6,31	6,71	5,42	8,01			
Biochemistry	Total protein, g/dl	continuous	Prot_d180	Day 180	Total	37	6,44	0,66	6,47	6,00	6,69	5,40	8,30			
Biochemistry	Total protein, g/dl	continuous	Prot_d180	Day 180	Omnifect Proimmune	19	6,42	0,75	6,20	6,00	6,72	5,40	8,30			
Biochemistry	Total protein, g/dl	continuous	Prot_d180	Day 180	Placebo	18	6,45	0,57	6,49	6,17	6,60	5,60	7,80			
Biochemistry	Total protein, g/dl	continuous	Prot_d360	Day 360	Total	31	6,52	0,63	6,43	6,15	6,76	5,21	8,82			
Biochemistry	Total protein, g/dl	continuous	Prot_d360	Day 360	Omnifect Proimmune	16	6,61	0,78	6,70	6,17	6,73	5,21	8,82			
Biochemistry	Total protein, g/dl	continuous	Prot_d360	Day 360	Placebo	15	6,42	0,42	6,30	6,10	6,76	5,85	7,10			
Biochemistry	Albumin, g/dl	continuous	Alb_d0	Day 0	Total	55	2,65	0,80	2,68	2,03	3,37	0,83	3,95			
Biochemistry	Albumin, g/dl	continuous	Alb_d0	Day 0	Omnifect	27	2,61	0,78	2,52	2,03	3,11	0,95	3,80			

					Proimmune											
Biochemistry	Albumin, g/dl	continuous	Alb_d0	Day 0	Placebo	28	2,69	0,83	2,78	2,02	3,40	0,83	3,95			
Biochemistry	Albumin, g/dl	continuous	Alb_d90	Day 90	Total	38	3,36	0,46	3,42	3,12	3,71	2,17	4,07			
Biochemistry	Albumin, g/dl	continuous	Alb_d90	Day 90	Omnifect Proimmune	19	3,24	0,49	3,18	3,04	3,66	2,17	3,91			
Biochemistry	Albumin, g/dl	continuous	Alb_d90	Day 90	Placebo	19	3,49	0,41	3,66	3,30	3,78	2,52	4,07			
Biochemistry	Albumin, g/dl	continuous	Alb_d180	Day 180	Total	37	3,35	0,45	3,42	3,20	3,63	2,07	4,07			
Biochemistry	Albumin, g/dl	continuous	Alb_d180	Day 180	Omnifect Proimmune	19	3,39	0,40	3,42	3,21	3,66	2,67	4,07			
Biochemistry	Albumin, g/dl	continuous	Alb_d180	Day 180	Placebo	18	3,30	0,50	3,41	3,20	3,60	2,07	3,85			
Biochemistry	Albumin, g/dl	continuous	Alb_d360	Day 360	Total	31	3,41	0,56	3,55	3,13	3,83	2,10	4,20			
Biochemistry	Albumin, g/dl	continuous	Alb_d360	Day 360	Omnifect Proimmune	16	3,21	0,58	3,25	2,73	3,63	2,10	4,13			
Biochemistry	Albumin, g/dl	continuous	Alb_d360	Day 360	Placebo	15	3,61	0,48	3,80	3,45	3,88	2,31	4,20			
Biochemistry	Globulins, g/dl	continuous	Glob_d0	Day 0	Total	55	4,53	1,82	4,44	3,11	5,49	1,08	9,18			
Biochemistry	Globulins, g/dl	continuous	Glob_d0	Day 0	Omnifect Proimmune	27	4,48	1,89	4,35	3,11	5,56	1,08	9,18			
Biochemistry	Globulins, g/dl	continuous	Glob_d0	Day 0	Placebo	28	4,58	1,77	4,48	3,11	5,48	2,27	8,96			

Biochemistry	Globulins, g/dl	continuous	Glob_d90	Day 90	Total	38	3,03	0,65	2,91	2,58	3,30	1,88	4,80			
Biochemistry	Globulins, g/dl	continuous	Glob_d90	Day 90	Omnifect Proimmune	19	3,02	0,66	2,93	2,68	3,29	1,88	4,72			
Biochemistry	Globulins, g/dl	continuous	Glob_d90	Day 90	Placebo	19	3,04	0,66	2,85	2,54	3,31	2,29	4,80			
Biochemistry	Globulins, g/dl	continuous	Glob_d180	Day 180	Total	37	3,09	0,65	2,97	2,74	3,41	1,98	5,57			
Biochemistry	Globulins, g/dl	continuous	Glob_d180	Day 180	Omnifect Proimmune	19	3,03	0,79	2,96	2,50	3,28	1,98	5,57			
Biochemistry	Globulins, g/dl	continuous	Glob_d180	Day 180	Placebo	18	3,15	0,47	3,05	2,91	3,49	2,16	4,04			
Biochemistry	Globulins, g/dl	continuous	Glob_d360	Day 360	Total	31	3,08	0,95	2,87	2,34	3,55	1,81	6,30			
Biochemistry	Globulins, g/dl	continuous	Glob_d360	Day 360	Omnifect Proimmune	16	3,33	1,07	3,18	2,65	3,96	1,81	6,30			
Biochemistry	Globulins, g/dl	continuous	Glob_d360	Day 360	Placebo	15	2,81	0,77	2,60	2,23	3,01	2,03	4,73			
Biochemistry	Albumin/globulin ratio	continuous	AlbGlob_d0	Day 0	Total	55	0,73	0,52	0,60	0,37	0,94	0,19	3,11			
Biochemistry	Albumin/globulin ratio	continuous	AlbGlob_d0	Day 0	Omnifect Proimmune	27	0,77	0,63	0,60	0,40	0,90	0,20	3,11			
Biochemistry	Albumin/globulin ratio	continuous	AlbGlob_d0	Day 0	Placebo	28	0,70	0,39	0,58	0,36	0,96	0,19	1,49			
Biochemistry	Albumin/globulin ratio	continuous	AlbGlob_d90	Day 90	Total	38	1,17	0,32	1,17	0,94	1,42	0,53	1,84			
Biochemistry	Albumin/globulin ratio	continuous	AlbGlob_d90	Day 90	Omnifect	19	1,13	0,34	1,08	0,89	1,32	0,64	1,84			

					Proimmune											
Biochemistry	Albumin/globulin ratio	continuous	AlbGlob_d90	Day 90	Placebo	19	1,21	0,30	1,30	1,01	1,40	0,53	1,67			
Biochemistry	Albumin/globulin ratio	continuous	AlbGlob_d180	Day 180	Total	37	1,13	0,28	1,12	0,98	1,27	0,49	1,73			
Biochemistry	Albumin/globulin ratio	continuous	AlbGlob_d180	Day 180	Omnifect Proimmune	19	1,19	0,31	1,23	1,01	1,37	0,49	1,73			
Biochemistry	Albumin/globulin ratio	continuous	AlbGlob_d180	Day 180	Placebo	18	1,08	0,25	1,12	0,98	1,25	0,59	1,59			
Biochemistry	Albumin/globulin ratio	continuous	AlbGlob_d360	Day 360	Total	31	1,22	0,46	1,29	0,87	1,63	0,40	1,96			
Biochemistry	Albumin/globulin ratio	continuous	AlbGlob_d360	Day 360	Omnifect Proimmune	16	1,06	0,45	0,92	0,71	1,43	0,40	1,88			
Biochemistry	Albumin/globulin ratio	continuous	AlbGlob_d360	Day 360	Placebo	15	1,39	0,42	1,59	1,10	1,68	0,49	1,96			
Biochemistry	Alkaline phosphatase	continuous	PAL_d0	Day 0	Total	54	103,67	167,26	49,35	36,66	84,50	11,67	934,26			
Biochemistry	Alkaline phosphatase	continuous	PAL_d0	Day 0	Omnifect Proimmune	27	97,90	153,69	49,11	36,80	69,29	11,67	687,00			
Biochemistry	Alkaline phosphatase	continuous	PAL_d0	Day 0	Placebo	27	109,44	182,59	49,54	38,55	86,53	13,24	934,26			
Biochemistry	Alkaline phosphatase	continuous	PAL_d90	Day 90	Total	37	95,09	93,51	60,89	46,24	105,06	12,46	431,00			
Biochemistry	Alkaline phosphatase	continuous	PAL_d90	Day 90	Omnifect Proimmune	19	85,22	79,96	59,04	47,41	94,91	12,46	361,96			

Biochemistry	Alkaline phosphatase	continuous	PAL_d90	Day 90	Placebo	18	105,52	107,34	62,47	42,53	112,78	25,63	431,00			
Biochemistry	Alkaline phosphatase	continuous	PAL_d180	Day 180	Total	36	89,25	202,31	45,73	32,70	76,83	12,28	125 0,34			
Biochemistry	Alkaline phosphatase	continuous	PAL_d180	Day 180	Omnifect Proimmune	19	111,65	277,86	40,92	30,01	60,73	12,28	125 0,34			
Biochemistry	Alkaline phosphatase	continuous	PAL_d180	Day 180	Placebo	17	64,22	37,54	53,20	35,43	92,07	14,35	139,42			
Biochemistry	Alkaline phosphatase	continuous	PAL_d360	Day 360	Total	31	85,12	112,93	51,27	37,56	70,46	10,00	605,14			
Biochemistry	Alkaline phosphatase	continuous	PAL_d360	Day 360	Omnifect Proimmune	16	80,62	142,14	46,30	34,06	60,62	10,00	605,14			
Biochemistry	Alkaline phosphatase	continuous	PAL_d360	Day 360	Placebo	15	89,93	75,08	56,08	39,78	138,23	11,00	260,00			
Biochemistry	ALT	continuous	ALT_d0	Day 0	Total	55	52,23	64,79	36,69	27,53	49,25	9,78	449,23			
Biochemistry	ALT	continuous	ALT_d0	Day 0	Omnifect Proimmune	27	62,70	87,59	39,66	28,46	52,71	12,11	449,23			
Biochemistry	ALT	continuous	ALT_d0	Day 0	Placebo	28	42,13	28,14	35,10	25,36	48,22	9,78	116,01			
Biochemistry	ALT	continuous	ALT_d90	Day 90	Total	38	83,60	92,20	48,78	35,86	91,99	10,77	522,37			
Biochemistry	ALT	continuous	ALT_d90	Day 90	Omnifect Proimmune	19	75,63	55,95	52,79	34,48	93,20	10,77	199,35			

Biochemistry	ALT	continuous	ALT_d90	Day 90	Placebo	19	91,57	119,21	43,62	36,85	76,28	22,86	522,37			
Biochemistry	ALT	continuous	ALT_180	Day 180	Total	36	67,88	68,00	42,22	30,23	81,00	11,32	388,83			
Biochemistry	ALT	continuous	ALT_180	Day 180	Omnifect Proimmune	19	62,42	45,21	42,85	26,49	82,94	11,32	145,50			
Biochemistry	ALT	continuous	ALT_180	Day 180	Placebo	17	73,98	87,99	41,58	31,27	77,08	23,07	388,83			
Biochemistry	ALT	continuous	ALT_d360	Day 360	Total	31	59,87	37,30	48,97	34,25	75,55	8,14	170,86			
Biochemistry	ALT	continuous	ALT_d360	Day 360	Omnifect Proimmune	16	59,66	35,57	53,74	43,46	70,16	8,14	141,50			
Biochemistry	ALT	continuous	ALT_d360	Day 360	Placebo	15	60,10	40,33	47,63	31,56	75,55	24,64	170,86			
Biochemistry	AST	continuous	AST_d0	Day 0	Total	53	54,36	51,20	36,96	24,54	56,34	11,58	261,97			
Biochemistry	AST	continuous	AST_d0	Day 0	Omnifect Proimmune	27	51,79	53,74	33,63	22,92	55,81	11,58	261,97			
Biochemistry	AST	continuous	AST_d0	Day 0	Placebo	26	57,02	49,34	38,04	28,35	58,80	15,47	191,44			
Biochemistry	AST	continuous	AST_d90	Day 90	Total	38	32,35	20,49	27,19	21,69	34,44	13,04	109,13			
Biochemistry	AST	continuous	AST_d90	Day 90	Omnifect Proimmune	19	31,23	20,43	27,32	20,70	31,97	13,04	109,13			
Biochemistry	AST	continuous	AST_d90	Day 90	Placebo	19	33,47	21,05	26,99	22,36	35,68	15,34	99,16			
Biochemistry	AST	continuous	AST_d180	Day 180	Total	36	30,22	15,70	26,94	21,39	34,12	13,59	100,20			

Biochemistry	AST	continuous	AST_d180	Day 180	Omnifect Proimmune	19	28,19	11,36	26,53	21,92	33,53	13,59	63,16			
Biochemistry	AST	continuous	AST_d180	Day 180	Placebo	17	32,49	19,59	27,38	21,46	34,16	14,65	100,20			
Biochemistry	AST	continuous	AST_d360	Day 360	Total	31	30,81	16,84	27,44	22,17	33,09	2,31	89,47			
Biochemistry	AST	continuous	AST_d360	Day 360	Omnifect Proimmune	15	31,24	15,62	28,89	23,68	30,51	20,88	85,34			
Biochemistry	AST	continuous	AST_d360	Day 360	Placebo	16	30,41	18,41	26,97	21,27	34,55	2,31	89,47			
Inflammation	C-reactive protein, mg/l	continuous	Prot_C_d0	Day 0	Total	42	34,07	43,59	11,15	2,12	58,11	0,00	141,32			
Inflammation	C-reactive protein, mg/l	continuous	Prot_C_d0	Day 0	Omnifect Proimmune	20	33,78	43,86	8,31	2,17	61,92	0,00	131,36			
Inflammation	C-reactive protein, mg/l	continuous	Prot_C_d0	Day 0	Placebo	22	34,33	44,38	12,96	2,07	44,36	0,00	141,32			
Inflammation	C-reactive protein, mg/l	continuous	Prot_C_d90	Day 90	Total	36	12,64	32,65	3,09	0,59	10,30	0,00	158,34			
Inflammation	C-reactive protein, mg/l	continuous	Prot_C_d90	Day 90	Omnifect Proimmune	18	13,86	36,40	3,62	1,19	10,53	0,00	158,34			
Inflammation	C-reactive protein, mg/l	continuous	Prot_C_d90	Day 90	Placebo	18	11,43	29,43	2,34	0,06	10,05	0,00	127,69			
Inflammation	C-reactive protein, mg/l	continuous	Prot_C_d180	Day 180	Total	34	11,60	23,82	2,93	0,79	12,47	0,00	130,98			

Inflammation	C-reactive protein, mg/l	continuous	Prot_C_d180	Day 180	Omnifect Proimmune	17	14,47	31,99	1,87	0,89	10,97	0,00	130,98			
Inflammation	C-reactive protein, mg/l	continuous	Prot_C_d180	Day 180	Placebo	17	8,72	11,38	4,76	0,10	12,97	0,00	43,26			
Inflammation	C-reactive protein, mg/l	continuous	Prot_C_d360	Day 360	Total	29	15,00	42,66	2,41	0,00	10,53	0,00	228,47			
Inflammation	C-reactive protein, mg/l	continuous	Prot_C_d360	Day 360	Omnifect Proimmune	14	22,64	59,71	8,27	0,05	10,35	0,00	228,47			
Inflammation	C-reactive protein, mg/l	continuous	Prot_C_d360	Day 360	Placebo	15	7,86	14,69	1,74	0,00	7,54	0,00	51,21			
Urinalysis	Urine specific gravity	continuous	USG_d0	Day 0	Total	55	1026,36	13,04	1024,00	1017,00	1034,00	1004,00	1050,00			
Urinalysis	Urine specific gravity	continuous	USG_d0	Day 0	Omnifect Proimmune	26	1025,00	13,38	1019,00	1016,00	1031,50	1004,00	1050,00			
Urinalysis	Urine specific gravity	continuous	USG_d0	Day 0	Placebo	29	1027,59	12,84	1024,00	1018,00	1036,00	1006,00	1050,00			
Urinalysis	Urine specific gravity	continuous	USG_d90	Day 90	Total	38	1028,74	13,41	1026,00	1017,50	1037,50	1008,00	1050,00			
Urinalysis	Urine specific gravity	continuous	USG_d90	Day 90	Omnifect Proimmune	19	1027,89	13,03	1026,00	1020,00	1036,00	1008,00	1050,00			
Urinalysis	Urine specific gravity	continuous	USG_d90	Day 90	Placebo	19	1029,58	14,09	1028,00	1019,00	1040,00	1008,00	1050,00			

Urinalysis	Urine specific gravity	continuous	USG_d180	Day 180	Total	37	1030,22	12,63	1030,00	1018,00	1040,00	1010,00	1050,00			
Urinalysis	Urine specific gravity	continuous	USG_d180	Day 180	Omnifect Proimmune	19	1032,74	11,89	1030,00	1026,00	1042,00	1012,00	1050,00			
Urinalysis	Urine specific gravity	continuous	USG_d180	Day 180	Placebo	18	1027,56	13,17	1025,00	1016,00	1036,00	1010,00	1050,00			
Urinalysis	Urine specific gravity	continuous	USG_d360	Day 360	Total	30	1027,77	15,01	1021,00	1015,25	1039,50	1004,00	1050,00			
Urinalysis	Urine specific gravity	continuous	USG_d360	Day 360	Omnifect Proimmune	16	1026,31	15,73	1019,00	1014,00	1041,00	1004,00	1050,00			
Urinalysis	Urine specific gravity	continuous	USG_d360	Day 360	Placebo	14	1029,43	14,54	1028,00	1018,00	1038,00	1010,00	1050,00			
Urinalysis	Urine pH	continuous	pH_d0	Day 0	Total	55	6,61	0,86	6,50	6,00	7,00	5,00	9,00			
Urinalysis	Urine pH	continuous	pH_d0	Day 0	Omnifect Proimmune	26	6,54	0,75	6,50	6,13	7,00	5,00	8,00			
Urinalysis	Urine pH	continuous	pH_d0	Day 0	Placebo	29	6,67	0,96	7,00	6,00	7,00	5,00	9,00			
Urinalysis	Urine pH	continuous	pH_d90	Day 90	Total	38	6,72	0,86	7,00	6,00	7,00	5,00	9,00			
Urinalysis	Urine pH	continuous	pH_d90	Day 90	Omnifect Proimmune	19	6,97	0,77	7,00	7,00	7,50	5,00	8,00			
Urinalysis	Urine pH	continuous	pH_d90	Day 90	Placebo	19	6,47	0,89	6,50	6,00	7,00	5,00	9,00			

Urinalysis	Urine pH	continuous	pH_d180	Day 180	Total	37	6,43	0,82	6,50	6,00	7,00	5,00	8,00			
Urinalysis	Urine pH	continuous	pH_d180	Day 180	Omnifect Proimmune	19	6,63	0,81	7,00	6,00	7,00	5,00	8,00			
Urinalysis	Urine pH	continuous	pH_d180	Day 180	Placebo	18	6,22	0,79	6,50	5,50	7,00	5,00	7,00			
Urinalysis	Urine pH	continuous	pH_d360	Day 360	Total	30	6,42	0,91	7,00	5,63	7,00	5,00	7,50			
Urinalysis	Urine pH	continuous	pH_d360	Day 360	Omnifect Proimmune	16	6,56	0,89	7,00	6,00	7,00	5,00	7,50			
Urinalysis	Urine pH	continuous	pH_d360	Day 360	Placebo	14	6,25	0,94	6,25	5,50	7,00	5,00	7,50			
Urinalysis	UPC	continuous	UPC_d0	Day 0	Total	56	2,54	3,48	0,51	0,18	4,10	0,06	13,71			
Urinalysis	UPC	continuous	UPC_d0	Day 0	Omnifect Proimmune	27	3,23	4,27	1,08	0,20	4,95	0,07	13,71			
Urinalysis	UPC	continuous	UPC_d0	Day 0	Placebo	29	1,90	2,44	0,36	0,16	3,03	0,06	8,72			
Urinalysis	UPC	continuous	UPC_d90	Day 90	Total	38	1,13	1,93	0,18	0,10	1,51	0,05	7,71			
Urinalysis	UPC	continuous	UPC_d90	Day 90	Omnifect Proimmune	19	1,47	2,06	0,35	0,11	2,00	0,05	6,97			
Urinalysis	UPC	continuous	UPC_d90	Day 90	Placebo	19	0,79	1,78	0,15	0,11	0,43	0,05	7,71			
Urinalysis	UPC	continuous	UPC_d180	Day 180	Total	37	0,88	1,61	0,24	0,08	0,58	0,04	7,44			
Urinalysis	UPC	continuous	UPC_d180	Day 180	Omnifect	19	1,06	1,49	0,34	0,11	1,05	0,07	4,61			

					Proimmune											
Urinalysis	UPC	continuous	UPC_d180	Day 180	Placebo	18	0,68	1,75	0,13	0,08	0,31	0,04	7,44			
Urinalysis	UPC	continuous	UPC_d360	Day 360	Total	30	0,98	1,46	0,22	0,08	1,01	0,05	5,15			
Urinalysis	UPC	continuous	UPC_d360	Day 360	Omnifect Proimmune	16	1,39	1,78	0,44	0,15	2,44	0,06	5,15			
Urinalysis	UPC	continuous	UPC_d360	Day 360	Placebo	14	0,51	0,82	0,18	0,07	0,40	0,05	2,83			
Protein electrophoresis	Alpha-1 globulin	continuous	alfa1glob_d0	Day 0	Total	53	0,37	0,19	0,31	0,27	0,40	0,09	0,92			
Protein electrophoresis	Alpha-1 globulin	continuous	alfa1glob_d0	Day 0	Omnifect Proimmune	26	0,40	0,19	0,33	0,27	0,50	0,14	0,80			
Protein electrophoresis	Alpha-1 globulin	continuous	alfa1glob_d0	Day 0	Placebo	27	0,35	0,19	0,31	0,26	0,38	0,09	0,92			
Protein electrophoresis	Alpha-1 globulin	continuous	alfa1glob_d90	Day 90	Total	38	0,45	0,60	0,35	0,28	0,41	0,12	3,98			
Protein electrophoresis	Alpha-1 globulin	continuous	alfa1glob_d90	Day 90	Omnifect Proimmune	19	0,36	0,16	0,32	0,29	0,39	0,12	0,76			
Protein electrophoresis	Alpha-1 globulin	continuous	alfa1glob_d90	Day 90	Placebo	19	0,55	0,84	0,35	0,29	0,46	0,15	3,98			
Protein electrophoresis	Alpha-1 globulin	continuous	alfa1glob_d180	Day 180	Total	37	0,33	0,13	0,33	0,28	0,37	0,16	0,92			

Protein electrophoresis	Alpha-1 globulin	continuous	alfa1glob_d180	Day 180	Omnifect Proimmune	19	0,31	0,09	0,31	0,28	0,37	0,17	0,47			
Protein electrophoresis	Alpha-1 globulin	continuous	alfa1glob_d180	Day 180	Placebo	18	0,36	0,16	0,35	0,28	0,38	0,16	0,92			
Protein electrophoresis	Alpha-1 globulin	continuous	alfa1glob_d360	Day 360	Total	31	0,33	0,15	0,30	0,27	0,36	0,16	0,79			
Protein electrophoresis	Alpha-1 globulin	continuous	alfa1glob_d360	Day 360	Omnifect Proimmune	16	0,32	0,16	0,28	0,21	0,32	0,16	0,78			
Protein electrophoresis	Alpha-1 globulin	continuous	alfa1glob_d360	Day 360	Placebo	15	0,36	0,13	0,31	0,30	0,36	0,24	0,79			
Protein electrophoresis	Alpha-2 globulin	continuous	alfa2glob_d0	Day 0	Total	53	0,87	0,28	0,81	0,70	1,06	0,33	1,59			
Protein electrophoresis	Alpha-2 globulin	continuous	alfa2glob_d0	Day 0	Omnifect Proimmune	26	0,88	0,29	0,85	0,72	1,02	0,33	1,59			
Protein electrophoresis	Alpha-2 globulin	continuous	alfa2glob_d0	Day 0	Placebo	27	0,87	0,29	0,81	0,70	1,08	0,35	1,50			
Protein electrophoresis	Alpha-2 globulin	continuous	alfa2glob_d90	Day 90	Total	38	0,92	0,36	0,87	0,60	1,18	0,29	1,63			
Protein electrophoresis	Alpha-2 globulin	continuous	alfa2glob_d90	Day 90	Omnifect Proimmune	19	0,90	0,39	0,86	0,56	1,16	0,29	1,63			
Protein electrophoresis	Alpha-2 globulin	continuous	alfa2glob_d90	Day 90	Placebo	19	0,94	0,34	0,88	0,64	1,20	0,49	1,49			

Protein electrophoresis	Alpha-2 globulin	continuous	alfa2glob_d180	Day 180	Total	37	0,81	0,30	0,77	0,64	0,98	0,11	1,73			
Protein electrophoresis	Alpha-2 globulin	continuous	alfa2glob_d180	Day 180	Omnifect Proimmune	19	0,85	0,32	0,86	0,65	1,01	0,37	1,73			
Protein electrophoresis	Alpha-2 globulin	continuous	alfa2glob_d180	Day 180	Placebo	18	0,76	0,28	0,74	0,61	0,88	0,11	1,32			
Protein electrophoresis	Alpha-2 globulin	continuous	alfa2glob_d360	Day 360	Total	31	0,77	0,35	0,65	0,56	0,87	0,11	2,09			
Protein electrophoresis	Alpha-2 globulin	continuous	alfa2glob_d360	Day 360	Omnifect Proimmune	16	0,87	0,41	0,74	0,58	1,03	0,52	2,09			
Protein electrophoresis	Alpha-2 globulin	continuous	alfa2glob_d360	Day 360	Placebo	15	0,67	0,26	0,64	0,54	0,85	0,11	1,26			
Protein electrophoresis	Beta globulin	continuous	betaglob_d0	Day 0	Total	53	1,47	0,47	1,43	1,13	1,85	0,61	2,58			
Protein electrophoresis	Beta globulin	continuous	betaglob_d0	Day 0	Omnifect Proimmune	26	1,45	0,55	1,36	0,99	1,90	0,61	2,58			
Protein electrophoresis	Beta globulin	continuous	betaglob_d0	Day 0	Placebo	27	1,50	0,39	1,47	1,22	1,78	0,93	2,44			
Protein electrophoresis	Beta globulin	continuous	betaglob_d90	Day 90	Total	38	1,15	0,36	1,08	0,92	1,47	0,32	1,89			
Protein electrophoresis	Beta globulin	continuous	betaglob_d90	Day 90	Omnifect Proimmune	19	1,18	0,31	1,16	0,94	1,44	0,68	1,74			

Protein electrophoresis	Beta globulin	continuous	betaglob_d90	Day 90	Placebo	19	1,13	0,41	1,03	0,90	1,45	0,32	1,89			
Protein electrophoresis	Beta globulin	continuous	betaglob_d180	Day 180	Total	37	1,20	0,29	1,18	0,98	1,39	0,72	1,82			
Protein electrophoresis	Beta globulin	continuous	betaglob_d180	Day 180	Omnifect Proimmune	19	1,24	0,28	1,22	1,04	1,41	0,74	1,82			
Protein electrophoresis	Beta globulin	continuous	betaglob_d180	Day 180	Placebo	18	1,16	0,31	1,18	0,89	1,37	0,72	1,81			
Protein electrophoresis	Beta globulin	continuous	betaglob_d360	Day 360	Total	31	1,18	0,46	1,05	0,89	1,38	0,11	2,37			
Protein electrophoresis	Beta globulin	continuous	betaglob_d360	Day 360	Omnifect Proimmune	16	1,37	0,48	1,35	0,99	1,69	0,73	2,37			
Protein electrophoresis	Beta globulin	continuous	betaglob_d360	Day 360	Placebo	15	0,98	0,37	0,95	0,89	1,05	0,11	2,01			
Protein electrophoresis	Gamma globulin	continuous	gammaglob_d0	Day 0	Total	53	2,03	1,53	1,51	0,80	2,58	0,23	5,99			
Protein electrophoresis	Gamma globulin	continuous	gammaglob_d0	Day 0	Omnifect Proimmune	26	1,96	1,51	1,65	0,84	2,46	0,23	5,99			
Protein electrophoresis	Gamma globulin	continuous	gammaglob_d0	Day 0	Placebo	27	2,09	1,57	1,49	0,79	2,65	0,68	5,80			
Protein electrophoresis	Gamma globulin	continuous	gammaglob_90	Day 90	Total	38	0,93	0,47	0,82	0,61	1,02	0,20	2,48			

Protein electrophoresis	Gamma globulin	continuous	gammaglob_90	Day 90	Omnifect Proimmune	19	0,93	0,52	0,75	0,60	1,21	0,34	2,48			
Protein electrophoresis	Gamma globulin	continuous	gammaglob_90	Day 90	Placebo	19	0,93	0,43	0,90	0,74	0,98	0,20	2,00			
Protein electrophoresis	Gamma globulin	continuous	gammaglob_180	Day 180	Total	37	0,91	0,43	0,89	0,61	1,04	0,34	2,85			
Protein electrophoresis	Gamma globulin	continuous	gammaglob_180	Day 180	Omnifect Proimmune	19	0,95	0,55	0,94	0,57	1,03	0,34	2,85			
Protein electrophoresis	Gamma globulin	continuous	gammaglob_180	Day 180	Placebo	18	0,88	0,28	0,86	0,74	1,07	0,36	1,47			
Protein electrophoresis	Gamma globulin	continuous	gammaglob_360	Day 360	Total	31	0,90	0,43	0,85	0,62	1,06	0,21	2,74			
Protein electrophoresis	Gamma globulin	continuous	gammaglob_360	Day 360	Omnifect Proimmune	16	1,01	0,53	0,93	0,67	1,19	0,44	2,74			
Protein electrophoresis	Gamma globulin	continuous	gammaglob_360	Day 360	Placebo	15	0,79	0,26	0,83	0,62	0,95	0,21	1,25			
Clinical signs	General clinical signs present	binary/categorical indicator	Sig_gen_d0	Day 0	Total	56								52	92,9	52/56 (92.9 %)
Clinical signs	General clinical signs present	binary/categorical indicator	Sig_gen_d0	Day 0	Omnifect Proimmune	27								25	92,6	25/27 (92.6 %)

Clinical signs	General clinical signs present	binary/categorical indicator	Sig_gen_d0	Day 0	Placebo	29								27	93,1	27/29 (93.1 %)
Clinical signs	General clinical signs present	binary/categorical indicator	Sig_gen_d90	Day 90	Total	38								23	60,5	23/38 (60.5 %)
Clinical signs	General clinical signs present	binary/categorical indicator	Sig_gen_d90	Day 90	Omnifect Proimmune	19								12	63,2	12/19 (63.2 %)
Clinical signs	General clinical signs present	binary/categorical indicator	Sig_gen_d90	Day 90	Placebo	19								11	57,9	11/19 (57.9 %)
Clinical signs	General clinical signs present	binary/categorical indicator	Sig_gen_d180	Day 180	Total	35								15	42,9	15/35 (42.9 %)
Clinical signs	General clinical signs present	binary/categorical indicator	Sig_gen_d180	Day 180	Omnifect Proimmune	17								6	35,3	6/17 (35.3 %)
Clinical signs	General clinical signs present	binary/categorical indicator	Sig_gen_d180	Day 180	Placebo	18								9	50,0	9/18 (50.0 %)
Clinical signs	General clinical signs present	binary/categorical indicator	Sig_gen_d360	Day 360	Total	32								16	50,0	16/32 (50.0 %)
Clinical signs	General clinical signs present	binary/categorical indicator	Sig_gen_d360	Day 360	Omnifect Proimmune	15								10	66,7	10/15 (66.7 %)

Clinical signs	General clinical signs present	binary/categorical indicator	Sig_gen_d360	Day 360	Placebo	17								6	35,3	6/17 (35.3%)
Clinical signs	Lethargy	binary/categorical indicator	Sig_gen_d0_letargo	Day 0	Total	56								25	44,6	25/56 (44.6%)
Clinical signs	Lethargy	binary/categorical indicator	Sig_gen_d0_letargo	Day 0	Omnifect Proimmune	27								11	40,7	11/27 (40.7%)
Clinical signs	Lethargy	binary/categorical indicator	Sig_gen_d0_letargo	Day 0	Placebo	29								14	48,3	14/29 (48.3%)
Clinical signs	Lethargy	binary/categorical indicator	Sig_gen_d90_letargo	Day 90	Total	38								3	7,9	3/38 (7.9%)
Clinical signs	Lethargy	binary/categorical indicator	Sig_gen_d90_letargo	Day 90	Omnifect Proimmune	19								1	5,3	1/19 (5.3%)
Clinical signs	Lethargy	binary/categorical indicator	Sig_gen_d90_letargo	Day 90	Placebo	19								2	10,5	2/19 (10.5%)
Clinical signs	Lethargy	binary/categorical indicator	Sig_gen_d180_letargo	Day 180	Total	36								2	5,6	2/36 (5.6%)
Clinical signs	Lethargy	binary/categorical indicator	Sig_gen_d180_letargo	Day 180	Omnifect Proimmune	18								1	5,6	1/18 (5.6%)
Clinical signs	Lethargy	binary/categorical indicator	Sig_gen_d180_letargo	Day 180	Placebo	18								1	5,6	1/18 (5.6%)
Clinical signs	Lethargy	binary/categorical indicator	Sig_gen_d360_letargo	Day 360	Total	31								2	6,5	2/31 (6.5%)

Clinical signs	Lethargy	binary/categorical indicator	Sig_gen_d360_letargo	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Clinical signs	Lethargy	binary/categorical indicator	Sig_gen_d360_letargo	Day 360	Placebo	16								2	12,5	2/16 (12.5%)
Clinical signs	Generalised lymphadenomegaly	binary/categorical indicator	Sig_gen_d0_aumentoganglios	Day 0	Total	56								39	69,6	39/56 (69.6%)
Clinical signs	Generalised lymphadenomegaly	binary/categorical indicator	Sig_gen_d0_aumentoganglios	Day 0	Omnifect Proimmune	27								20	74,1	20/27 (74.1%)
Clinical signs	Generalised lymphadenomegaly	binary/categorical indicator	Sig_gen_d0_aumentoganglios	Day 0	Placebo	29								19	65,5	19/29 (65.5%)
Clinical signs	Generalised lymphadenomegaly	binary/categorical indicator	Sig_gen_d90_aumentoganglios	Day 90	Total	38								6	15,8	6/38 (15.8%)
Clinical signs	Generalised lymphadenomegaly	binary/categorical indicator	Sig_gen_d90_aumentoganglios	Day 90	Omnifect Proimmune	19								3	15,8	3/19 (15.8%)
Clinical signs	Generalised lymphadenomegaly	binary/categorical indicator	Sig_gen_d90_aumentoganglios	Day 90	Placebo	19								3	15,8	3/19 (15.8%)
Clinical signs	Generalised lymphadenomegaly	binary/categorical indicator	Sig_gen_d180_aumentoganglios	Day 180	Total	36								3	8,3	3/36 (8.3%)

Clinical signs	Generalised lymphadenomegaly	binary/categorical indicator	Sig_gen_d180_aumentoganglios	Day 180	Omnifect Proimmune	18								2	11,1	2/18 (11.1%)
Clinical signs	Generalised lymphadenomegaly	binary/categorical indicator	Sig_gen_d180_aumentoganglios	Day 180	Placebo	18								1	5,6	1/18 (5.6%)
Clinical signs	Generalised lymphadenomegaly	binary/categorical indicator	Sig_gen_d360_aumentoganglios	Day 360	Total	31								7	22,6	7/31 (22.6%)
Clinical signs	Generalised lymphadenomegaly	binary/categorical indicator	Sig_gen_d360_aumentoganglios	Day 360	Omnifect Proimmune	15								3	20,0	3/15 (20.0%)
Clinical signs	Generalised lymphadenomegaly	binary/categorical indicator	Sig_gen_d360_aumentoganglios	Day 360	Placebo	16								4	25,0	4/16 (25.0%)
Clinical signs	Weight loss	binary/categorical indicator	Sig_gen_d0_perdidapeso	Day 0	Total	56								30	53,6	30/56 (53.6%)
Clinical signs	Weight loss	binary/categorical indicator	Sig_gen_d0_perdidapeso	Day 0	Omnifect Proimmune	27								14	51,9	14/27 (51.9%)
Clinical signs	Weight loss	binary/categorical indicator	Sig_gen_d0_perdidapeso	Day 0	Placebo	29								16	55,2	16/29 (55.2%)
Clinical signs	Weight loss	binary/categorical indicator	Sig_gen_d90_perdidapeso	Day 90	Total	38								8	21,1	8/38 (21.1%)
Clinical signs	Weight loss	binary/categorical indicator	Sig_gen_d90_pe	Day 90	Omnifect	19								4	21,1	4/19 (21.1%)

			rdidapeso		Proimmune											
Clinical signs	Weight loss	binary/categorical indicator	Sig_gen_d90_perdidapeso	Day 90	Placebo	19								4	21,1	4/19 (21.1%)
Clinical signs	Weight loss	binary/categorical indicator	Sig_gen_d180_perdidapeso	Day 180	Total	36								7	19,4	7/36 (19.4%)
Clinical signs	Weight loss	binary/categorical indicator	Sig_gen_d180_perdidapeso	Day 180	Omnifect Proimmune	18								3	16,7	3/18 (16.7%)
Clinical signs	Weight loss	binary/categorical indicator	Sig_gen_d180_perdidapeso	Day 180	Placebo	18								4	22,2	4/18 (22.2%)
Clinical signs	Weight loss	binary/categorical indicator	Sig_gen_d360_perdidapeso	Day 360	Total	31								6	19,4	6/31 (19.4%)
Clinical signs	Weight loss	binary/categorical indicator	Sig_gen_d360_perdidapeso	Day 360	Omnifect Proimmune	15								3	20,0	3/15 (20.0%)
Clinical signs	Weight loss	binary/categorical indicator	Sig_gen_d360_perdidapeso	Day 360	Placebo	16								3	18,8	3/16 (18.8%)
Clinical signs	Reduced appetite	binary/categorical indicator	Sig_gen_d0_péridiaapetito	Day 0	Total	56								23	41,1	23/56 (41.1%)
Clinical signs	Reduced appetite	binary/categorical indicator	Sig_gen_d0_pér	Day 0	Omnifect	27								11	40,7	11/27 (40.7%)

			didaapetito		Proimmune											
Clinical signs	Reduced appetite	binary/categorical indicator	Sig_gen_d0_péridaapetito	Day 0	Placebo	29								12	41,4	12/29 (41.4%)
Clinical signs	Reduced appetite	binary/categorical indicator	Sig_gen_d90_péridaapetito	Day 90	Total	38								3	7,9	3/38 (7.9%)
Clinical signs	Reduced appetite	binary/categorical indicator	Sig_gen_d90_péridaapetito	Day 90	Omnifect Proimmune	19								2	10,5	2/19 (10.5%)
Clinical signs	Reduced appetite	binary/categorical indicator	Sig_gen_d90_péridaapetito	Day 90	Placebo	19								1	5,3	1/19 (5.3%)
Clinical signs	Reduced appetite	binary/categorical indicator	Sig_gen_d180_pérdidaapetito	Day 180	Total	36								3	8,3	3/36 (8.3%)
Clinical signs	Reduced appetite	binary/categorical indicator	Sig_gen_d180_pérdidaapetito	Day 180	Omnifect Proimmune	18								0	0,0	0/18 (0.0%)
Clinical signs	Reduced appetite	binary/categorical indicator	Sig_gen_d180_pérdidaapetito	Day 180	Placebo	18								3	16,7	3/18 (16.7%)
Clinical signs	Reduced appetite	binary/categorical indicator	Sig_gen_d360_pérdidaapetito	Day 360	Total	31								3	9,7	3/31 (9.7%)
Clinical signs	Reduced appetite	binary/categorical indicator	Sig_gen_d360_p	Day 360	Omnifect	15								1	6,7	1/15 (6.7%)

			érdidaapetito		Proimmune											
Clinical signs	Reduced appetite	binary/categorical indicator	Sig_gen_d360_pérdidaapetito	Day 360	Placebo	16								2	12,5	2/16 (12.5%)
Clinical signs	Pale mucous membranes	binary/categorical indicator	Sig_gen_d0_mucosaspálidas	Day 0	Total	56								8	14,3	8/56 (14.3%)
Clinical signs	Pale mucous membranes	binary/categorical indicator	Sig_gen_d0_mucosaspálidas	Day 0	Omnifect Proimmune	27								4	14,8	4/27 (14.8%)
Clinical signs	Pale mucous membranes	binary/categorical indicator	Sig_gen_d0_mucosaspálidas	Day 0	Placebo	29								4	13,8	4/29 (13.8%)
Clinical signs	Pale mucous membranes	binary/categorical indicator	Sig_gen_d90_mucosaspálidas	Day 90	Total	38								2	5,3	2/38 (5.3%)
Clinical signs	Pale mucous membranes	binary/categorical indicator	Sig_gen_d90_mucosaspálidas	Day 90	Omnifect Proimmune	19								1	5,3	1/19 (5.3%)
Clinical signs	Pale mucous membranes	binary/categorical indicator	Sig_gen_d90_mucosaspálidas	Day 90	Placebo	19								1	5,3	1/19 (5.3%)
Clinical signs	Pale mucous membranes	binary/categorical indicator	Sig_gen_d180_mucosaspálidas	Day 180	Total	36								2	5,6	2/36 (5.6%)
Clinical signs	Pale mucous	binary/categorical indicator	Sig_gen_d180_	Day 180	Omnifect	18								0	0,0	0/18 (0.0%)

	membranes		mucosas pálidas		Proimmune											
Clinical signs	Pale mucous membranes	binary/categorical indicator	Sig_gen_d180_mucosas pálidas	Day 180	Placebo	18								2	11,1	2/18 (11.1%)
Clinical signs	Pale mucous membranes	binary/categorical indicator	Sig_gen_d360_mucosas pálidas	Day 360	Total	31								1	3,2	1/31 (3.2%)
Clinical signs	Pale mucous membranes	binary/categorical indicator	Sig_gen_d360_mucosas pálidas	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Clinical signs	Pale mucous membranes	binary/categorical indicator	Sig_gen_d360_mucosas pálidas	Day 360	Placebo	16								1	6,3	1/16 (6.2%)
Clinical signs	Polyuria/polydipsia	binary/categorical indicator	Sig_gen_d0_PUPD	Day 0	Total	56								19	33,9	19/56 (33.9%)
Clinical signs	Polyuria/polydipsia	binary/categorical indicator	Sig_gen_d0_PUPD	Day 0	Omnifect Proimmune	27								10	37,0	10/27 (37.0%)
Clinical signs	Polyuria/polydipsia	binary/categorical indicator	Sig_gen_d0_PUPD	Day 0	Placebo	29								9	31,0	9/29 (31.0%)
Clinical signs	Polyuria/polydipsia	binary/categorical indicator	Sig_gen_d90_PUPD	Day 90	Total	38								7	18,4	7/38 (18.4%)
Clinical signs	Polyuria/polydipsia	binary/categorical indicator	Sig_gen_d90_PUPD	Day 90	Omnifect Proimmune	19								3	15,8	3/19 (15.8%)

Clinical signs	Polyuria/polydipsia	binary/categorical indicator	Sig_gen_d90_PUPD	Day 90	Placebo	19								4	21,1	4/19 (21.1%)
Clinical signs	Polyuria/polydipsia	binary/categorical indicator	Sig_gen_d180_PUPD	Day 180	Total	36								3	8,3	3/36 (8.3%)
Clinical signs	Polyuria/polydipsia	binary/categorical indicator	Sig_gen_d180_PUPD	Day 180	Omnifect Proimmune	18								1	5,6	1/18 (5.6%)
Clinical signs	Polyuria/polydipsia	binary/categorical indicator	Sig_gen_d180_PUPD	Day 180	Placebo	18								2	11,1	2/18 (11.1%)
Clinical signs	Polyuria/polydipsia	binary/categorical indicator	Sig_gen_d360_PUPD	Day 360	Total	31								5	16,1	5/31 (16.1%)
Clinical signs	Polyuria/polydipsia	binary/categorical indicator	Sig_gen_d360_PUPD	Day 360	Omnifect Proimmune	15								4	26,7	4/15 (26.7%)
Clinical signs	Polyuria/polydipsia	binary/categorical indicator	Sig_gen_d360_PUPD	Day 360	Placebo	16								1	6,3	1/16 (6.2%)
Clinical signs	Vomiting	binary/categorical indicator	Sig_gen_d0_vómitos	Day 0	Total	56								7	12,5	7/56 (12.5%)
Clinical signs	Vomiting	binary/categorical indicator	Sig_gen_d0_vómitos	Day 0	Omnifect Proimmune	27								6	22,2	6/27 (22.2%)
Clinical signs	Vomiting	binary/categorical indicator	Sig_gen_d0_vómitos	Day 0	Placebo	29								1	3,4	1/29 (3.4%)
Clinical signs	Vomiting	binary/categorical indicator	Sig_gen_d90_vómitos	Day 90	Total	38								3	7,9	3/38 (7.9%)

Clinical signs	Vomiting	binary/categorical indicator	Sig_gen_d90_vómitos	Day 90	Omnifect Proimmune	19								2	10,5	2/19 (10.5%)
Clinical signs	Vomiting	binary/categorical indicator	Sig_gen_d90_vómitos	Day 90	Placebo	19								1	5,3	1/19 (5.3%)
Clinical signs	Vomiting	binary/categorical indicator	Sig_gen_d180_vómitos	Day 180	Total	36								1	2,8	1/36 (2.8%)
Clinical signs	Vomiting	binary/categorical indicator	Sig_gen_d180_vómitos	Day 180	Omnifect Proimmune	18								1	5,6	1/18 (5.6%)
Clinical signs	Vomiting	binary/categorical indicator	Sig_gen_d180_vómitos	Day 180	Placebo	18								0	0,0	0/18 (0.0%)
Clinical signs	Vomiting	binary/categorical indicator	Sig_gen_d360_vómitos	Day 360	Total	31								1	3,2	1/31 (3.2%)
Clinical signs	Vomiting	binary/categorical indicator	Sig_gen_d360_vómitos	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Clinical signs	Vomiting	binary/categorical indicator	Sig_gen_d360_vómitos	Day 360	Placebo	16								1	6,3	1/16 (6.2%)
Clinical signs	Diarrhoea	binary/categorical indicator	Sig_gen_d0_diarrea	Day 0	Total	56								8	14,3	8/56 (14.3%)
Clinical signs	Diarrhoea	binary/categorical indicator	Sig_gen_d0_diarrea	Day 0	Omnifect Proimmune	27								5	18,5	5/27 (18.5%)
Clinical signs	Diarrhoea	binary/categorical indicator	Sig_gen_d0_diarrea	Day 0	Placebo	29								3	10,3	3/29 (10.3%)

Clinical signs	Diarrhoea	binary/categorical indicator	Sig_gen_d90_diarrea	Day 90	Total	38								3	7,9	3/38 (7.9%)
Clinical signs	Diarrhoea	binary/categorical indicator	Sig_gen_d90_diarrea	Day 90	Omnifect Proimmune	19								2	10,5	2/19 (10.5%)
Clinical signs	Diarrhoea	binary/categorical indicator	Sig_gen_d90_diarrea	Day 90	Placebo	19								1	5,3	1/19 (5.3%)
Clinical signs	Diarrhoea	binary/categorical indicator	Sig_gen_d180_diarrea	Day 180	Total	36								0	0,0	0/36 (0.0%)
Clinical signs	Diarrhoea	binary/categorical indicator	Sig_gen_d180_diarrea	Day 180	Omnifect Proimmune	18								0	0,0	0/18 (0.0%)
Clinical signs	Diarrhoea	binary/categorical indicator	Sig_gen_d180_diarrea	Day 180	Placebo	18								0	0,0	0/18 (0.0%)
Clinical signs	Diarrhoea	binary/categorical indicator	Sig_gen_d360_diarrea	Day 360	Total	31								0	0,0	0/31 (0.0%)
Clinical signs	Diarrhoea	binary/categorical indicator	Sig_gen_d360_diarrea	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Clinical signs	Diarrhoea	binary/categorical indicator	Sig_gen_d360_diarrea	Day 360	Placebo	16								0	0,0	0/16 (0.0%)
Clinical signs	Fever	binary/categorical indicator	Sig_gen_d0_fiebre	Day 0	Total	56								3	5,4	3/56 (5.4%)
Clinical signs	Fever	binary/categorical indicator	Sig_gen_d0_fiebre	Day 0	Omnifect Proimmune	27								3	11,1	3/27 (11.1%)

Clinical signs	Fever	binary/categorical indicator	Sig_gen_d0_fibre	Day 0	Placebo	29								0	0,0	0/29 (0.0%)
Clinical signs	Fever	binary/categorical indicator	Sig_gen_d90_fibre	Day 90	Total	38								0	0,0	0/38 (0.0%)
Clinical signs	Fever	binary/categorical indicator	Sig_gen_d90_fibre	Day 90	Omnifect Proimmune	19								0	0,0	0/19 (0.0%)
Clinical signs	Fever	binary/categorical indicator	Sig_gen_d90_fibre	Day 90	Placebo	19								0	0,0	0/19 (0.0%)
Clinical signs	Fever	binary/categorical indicator	Sig_gen_d180_fibre	Day 180	Total	36								0	0,0	0/36 (0.0%)
Clinical signs	Fever	binary/categorical indicator	Sig_gen_d180_fibre	Day 180	Omnifect Proimmune	18								0	0,0	0/18 (0.0%)
Clinical signs	Fever	binary/categorical indicator	Sig_gen_d180_fibre	Day 180	Placebo	18								0	0,0	0/18 (0.0%)
Clinical signs	Fever	binary/categorical indicator	Sig_gen_d360_fibre	Day 360	Total	31								0	0,0	0/31 (0.0%)
Clinical signs	Fever	binary/categorical indicator	Sig_gen_d360_fibre	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Clinical signs	Fever	binary/categorical indicator	Sig_gen_d360_fibre	Day 360	Placebo	16								0	0,0	0/16 (0.0%)
Clinical signs	Splenomegaly	binary/categorical indicator	Sig_gen_d0_splenomegalia	Day 0	Total	56								4	7,1	4/56 (7.1%)

Clinical signs	Splenomegaly	binary/categorical indicator	Sig_gen_d0_esplenomegalia	Day 0	Omnifect Proimmune	27								2	7,4	2/27 (7.4%)
Clinical signs	Splenomegaly	binary/categorical indicator	Sig_gen_d0_esplenomegalia	Day 0	Placebo	29								2	6,9	2/29 (6.9%)
Clinical signs	Splenomegaly	binary/categorical indicator	Sig_gen_d90_esplenomegalia	Day 90	Total	38								0	0,0	0/38 (0.0%)
Clinical signs	Splenomegaly	binary/categorical indicator	Sig_gen_d90_esplenomegalia	Day 90	Omnifect Proimmune	19								0	0,0	0/19 (0.0%)
Clinical signs	Splenomegaly	binary/categorical indicator	Sig_gen_d90_esplenomegalia	Day 90	Placebo	19								0	0,0	0/19 (0.0%)
Clinical signs	Splenomegaly	binary/categorical indicator	Sig_gen_d180_esplenomegalia	Day 180	Total	36								0	0,0	0/36 (0.0%)
Clinical signs	Splenomegaly	binary/categorical indicator	Sig_gen_d180_esplenomegalia	Day 180	Omnifect Proimmune	18								0	0,0	0/18 (0.0%)
Clinical signs	Splenomegaly	binary/categorical indicator	Sig_gen_d180_esplenomegalia	Day 180	Placebo	18								0	0,0	0/18 (0.0%)
Clinical signs	Splenomegaly	binary/categorical indicator	Sig_gen_d360_esplenomegalia	Day 360	Total	31								0	0,0	0/31 (0.0%)

Clinical signs	Splenomegaly	binary/categorical indicator	Sig_gen_d360_esplenomegalia	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Clinical signs	Splenomegaly	binary/categorical indicator	Sig_gen_d360_esplenomegalia	Day 360	Placebo	16								0	0,0	0/16 (0.0%)
Clinical signs	Exercise intolerance	binary/categorical indicator	Sig_gen_d0_int_ejercicio	Day 0	Total	56								5	8,9	5/56 (8.9%)
Clinical signs	Exercise intolerance	binary/categorical indicator	Sig_gen_d0_int_ejercicio	Day 0	Omnifect Proimmune	27								2	7,4	2/27 (7.4%)
Clinical signs	Exercise intolerance	binary/categorical indicator	Sig_gen_d0_int_ejercicio	Day 0	Placebo	29								3	10,3	3/29 (10.3%)
Clinical signs	Exercise intolerance	binary/categorical indicator	Sig_gen_d90_int_ejercicio	Day 90	Total	38								2	5,3	2/38 (5.3%)
Clinical signs	Exercise intolerance	binary/categorical indicator	Sig_gen_d90_int_ejercicio	Day 90	Omnifect Proimmune	19								0	0,0	0/19 (0.0%)
Clinical signs	Exercise intolerance	binary/categorical indicator	Sig_gen_d90_int_ejercicio	Day 90	Placebo	19								2	10,5	2/19 (10.5%)
Clinical signs	Exercise intolerance	binary/categorical indicator	Sig_gen_d180_int_ejercicio	Day 180	Total	36								3	8,3	3/36 (8.3%)
Clinical signs	Exercise intolerance	binary/categorical indicator	Sig_gen_d180_i	Day 180	Omnifect	18								0	0,0	0/18 (0.0%)

			nt_ejercicio		Proimmune											
Clinical signs	Exercise intolerance	binary/categorical indicator	Sig_gen_d180_int_ejercicio	Day 180	Placebo	18								3	16,7	3/18 (16.7%)
Clinical signs	Exercise intolerance	binary/categorical indicator	Sig_gen_d360_int_ejercicio	Day 360	Total	31								0	0,0	0/31 (0.0%)
Clinical signs	Exercise intolerance	binary/categorical indicator	Sig_gen_d360_int_ejercicio	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Clinical signs	Exercise intolerance	binary/categorical indicator	Sig_gen_d360_int_ejercicio	Day 360	Placebo	16								0	0,0	0/16 (0.0%)
Clinical signs	Cough	binary/categorical indicator	Sig_gen_d0_tos	Day 0	Total	56								1	1,8	1/56 (1.8%)
Clinical signs	Cough	binary/categorical indicator	Sig_gen_d0_tos	Day 0	Omnifect Proimmune	27								1	3,7	1/27 (3.7%)
Clinical signs	Cough	binary/categorical indicator	Sig_gen_d0_tos	Day 0	Placebo	29								0	0,0	0/29 (0.0%)
Clinical signs	Cough	binary/categorical indicator	Sig_gen_d90_tos	Day 90	Total	38								1	2,6	1/38 (2.6%)
Clinical signs	Cough	binary/categorical indicator	Sig_gen_d90_tos	Day 90	Omnifect Proimmune	19								0	0,0	0/19 (0.0%)

Clinical signs	Cough	binary/categorical indicator	Sig_gen_d90_tos	Day 90	Placebo	19								1	5,3	1/19 (5.3%)
Clinical signs	Cough	binary/categorical indicator	Sig_gen_d180_tos	Day 180	Total	36								0	0,0	0/36 (0.0%)
Clinical signs	Cough	binary/categorical indicator	Sig_gen_d180_tos	Day 180	Omnifect Proimmune	18								0	0,0	0/18 (0.0%)
Clinical signs	Cough	binary/categorical indicator	Sig_gen_d180_tos	Day 180	Placebo	18								0	0,0	0/18 (0.0%)
Clinical signs	Cough	binary/categorical indicator	Sig_gen_d360_tos	Day 360	Total	31								0	0,0	0/31 (0.0%)
Clinical signs	Cough	binary/categorical indicator	Sig_gen_d360_tos	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Clinical signs	Cough	binary/categorical indicator	Sig_gen_d360_tos	Day 360	Placebo	16								0	0,0	0/16 (0.0%)
Cutaneous signs	Cutaneous signs present	binary/categorical indicator	Sig_cutan_d0	Day 0	Total	56								23	41,1	23/56 (41.1%)
Cutaneous signs	Cutaneous signs present	binary/categorical indicator	Sig_cutan_d0	Day 0	Omnifect Proimmune	27								8	29,6	8/27 (29.6%)
Cutaneous signs	Cutaneous signs present	binary/categorical indicator	Sig_cutan_d0	Day 0	Placebo	29								15	51,7	15/29 (51.7%)
Cutaneous signs	Cutaneous signs present	binary/categorical indicator	Sig_cutan_d90	Day 90	Total	38								9	23,7	9/38 (23.7%)

Cutaneous signs	Cutaneous signs present	binary/categorical indicator	Sig_cutan_d90	Day 90	Omnifect Proimmune	19								6	31,6	6/19 (31.6%)
Cutaneous signs	Cutaneous signs present	binary/categorical indicator	Sig_cutan_d90	Day 90	Placebo	19								3	15,8	3/19 (15.8%)
Cutaneous signs	Cutaneous signs present	binary/categorical indicator	Sig_cutan_d180	Day 180	Total	36								5	13,9	5/36 (13.9%)
Cutaneous signs	Cutaneous signs present	binary/categorical indicator	Sig_cutan_d180	Day 180	Omnifect Proimmune	18								2	11,1	2/18 (11.1%)
Cutaneous signs	Cutaneous signs present	binary/categorical indicator	Sig_cutan_d180	Day 180	Placebo	18								3	16,7	3/18 (16.7%)
Cutaneous signs	Cutaneous signs present	binary/categorical indicator	Sig_cutan_d360	Day 360	Total	31								4	12,9	4/31 (12.9%)
Cutaneous signs	Cutaneous signs present	binary/categorical indicator	Sig_cutan_d360	Day 360	Omnifect Proimmune	15								2	13,3	2/15 (13.3%)
Cutaneous signs	Cutaneous signs present	binary/categorical indicator	Sig_cutan_d360	Day 360	Placebo	16								2	12,5	2/16 (12.5%)
Cutaneous signs	Alopecia	binary/categorical indicator	Sig_cutan_d0_alopecia	Day 0	Total	56								8	14,3	8/56 (14.3%)
Cutaneous signs	Alopecia	binary/categorical indicator	Sig_cutan_d0_alopecia	Day 0	Omnifect Proimmune	27								1	3,7	1/27 (3.7%)
Cutaneous signs	Alopecia	binary/categorical indicator	Sig_cutan_d0_alopecia	Day 0	Placebo	29								7	24,1	7/29 (24.1%)

Cutaneous signs	Alopecia	binary/categorical indicator	Sig_cutan_d90_alopecia	Day 90	Total	38								4	10,5	4/38 (10.5%)
Cutaneous signs	Alopecia	binary/categorical indicator	Sig_cutan_d90_alopecia	Day 90	Omnifect Proimmune	19								3	15,8	3/19 (15.8%)
Cutaneous signs	Alopecia	binary/categorical indicator	Sig_cutan_d90_alopecia	Day 90	Placebo	19								1	5,3	1/19 (5.3%)
Cutaneous signs	Alopecia	binary/categorical indicator	Sig_cutan_d180_alopecia	Day 180	Total	36								1	2,8	1/36 (2.8%)
Cutaneous signs	Alopecia	binary/categorical indicator	Sig_cutan_d180_alopecia	Day 180	Omnifect Proimmune	18								1	5,6	1/18 (5.6%)
Cutaneous signs	Alopecia	binary/categorical indicator	Sig_cutan_d180_alopecia	Day 180	Placebo	18								0	0,0	0/18 (0.0%)
Cutaneous signs	Alopecia	binary/categorical indicator	Sig_cutan_d360_alopecia	Day 360	Total	31								2	6,5	2/31 (6.5%)
Cutaneous signs	Alopecia	binary/categorical indicator	Sig_cutan_d360_alopecia	Day 360	Omnifect Proimmune	15								1	6,7	1/15 (6.7%)
Cutaneous signs	Alopecia	binary/categorical indicator	Sig_cutan_d360_alopecia	Day 360	Placebo	16								1	6,3	1/16 (6.2%)
Cutaneous signs	Exfoliative dermatitis	binary/categorical indicator	Sig_cutan_d0_D_exfoliativa	Day 0	Total	56								8	14,3	8/56 (14.3%)
Cutaneous signs	Exfoliative dermatitis	binary/categorical indicator	Sig_cutan_d0_D_	Day 0	Omnifect	27								2	7,4	2/27 (7.4%)

			exfoliativa		Proimmune											
Cutaneous signs	Exfoliative dermatitis	binary/categorical indicator	Sig_cutan_d0_D_exfoliativa	Day 0	Placebo	29								6	20,7	6/29 (20.7%)
Cutaneous signs	Exfoliative dermatitis	binary/categorical indicator	Sig_cutan_d90_D_exfoliativa	Day 90	Total	38								1	2,6	1/38 (2.6%)
Cutaneous signs	Exfoliative dermatitis	binary/categorical indicator	Sig_cutan_d90_D_exfoliativa	Day 90	Omnifect Proimmune	19								0	0,0	0/19 (0.0%)
Cutaneous signs	Exfoliative dermatitis	binary/categorical indicator	Sig_cutan_d90_D_exfoliativa	Day 90	Placebo	19								1	5,3	1/19 (5.3%)
Cutaneous signs	Exfoliative dermatitis	binary/categorical indicator	Sig_cutan_d180_D_exfoliativa	Day 180	Total	36								3	8,3	3/36 (8.3%)
Cutaneous signs	Exfoliative dermatitis	binary/categorical indicator	Sig_cutan_d180_D_exfoliativa	Day 180	Omnifect Proimmune	18								1	5,6	1/18 (5.6%)
Cutaneous signs	Exfoliative dermatitis	binary/categorical indicator	Sig_cutan_d180_D_exfoliativa	Day 180	Placebo	18								2	11,1	2/18 (11.1%)
Cutaneous signs	Exfoliative dermatitis	binary/categorical indicator	Sig_cutan_d360_D_exfoliativa	Day 360	Total	31								1	3,2	1/31 (3.2%)
Cutaneous signs	Exfoliative dermatitis	binary/categorical indicator	Sig_cutan_d360_	Day 360	Omnifect	15								0	0,0	0/15 (0.0%)

			D_exfoliativa		Proimmune											
Cutaneous signs	Exfoliative dermatitis	binary/categorical indicator	Sig_cutan_d360_D_exfoliativa	Day 360	Placebo	16								1	6,3	1/16 (6.2%)
Cutaneous signs	Erosive/ulcerative dermatitis	binary/categorical indicator	Sig_cutan_d0_D_erosivaulcerativa	Day 0	Total	56								10	17,9	10/56 (17.9%)
Cutaneous signs	Erosive/ulcerative dermatitis	binary/categorical indicator	Sig_cutan_d0_D_erosivaulcerativa	Day 0	Omnifect Proimmune	27								4	14,8	4/27 (14.8%)
Cutaneous signs	Erosive/ulcerative dermatitis	binary/categorical indicator	Sig_cutan_d0_D_erosivaulcerativa	Day 0	Placebo	29								6	20,7	6/29 (20.7%)
Cutaneous signs	Erosive/ulcerative dermatitis	binary/categorical indicator	Sig_cutan_d90_D_erosivaulcerativ	Day 90	Total	38								0	0,0	0/38 (0.0%)
Cutaneous signs	Erosive/ulcerative dermatitis	binary/categorical indicator	Sig_cutan_d90_D_erosivaulcerativ	Day 90	Omnifect Proimmune	19								0	0,0	0/19 (0.0%)
Cutaneous signs	Erosive/ulcerative dermatitis	binary/categorical indicator	Sig_cutan_d90_D_erosivaulcerativ	Day 90	Placebo	19								0	0,0	0/19 (0.0%)
Cutaneous signs	Erosive/ulcerative dermatitis	binary/categorical indicator	Sig_cutan_d180_D_erosivaulcerati	Day 180	Total	36								1	2,8	1/36 (2.8%)
Cutaneous signs	Erosive/ulcerative dermatitis	binary/categorical indicator	Sig_cutan_d180_	Day 180	Omnifect	18								1	5,6	1/18 (5.6%)

			D_erosivaulcerati		Proimmune												
Cutaneous signs	Erosive/ulcerative dermatitis	binary/categorical indicator	Sig_cutan_d180_D_erosivaulcerati	Day 180	Placebo	18								0	0,0	0/18 (0.0%)	
Cutaneous signs	Erosive/ulcerative dermatitis	binary/categorical indicator	Sig_cutan_d360_D_erosivaulcerati	Day 360	Total	31								1	3,2	1/31 (3.2%)	
Cutaneous signs	Erosive/ulcerative dermatitis	binary/categorical indicator	Sig_cutan_d360_D_erosivaulcerati	Day 360	Omnifect Proimmune	15								1	6,7	1/15 (6.7%)	
Cutaneous signs	Erosive/ulcerative dermatitis	binary/categorical indicator	Sig_cutan_d360_D_erosivaulcerati	Day 360	Placebo	16								0	0,0	0/16 (0.0%)	
Cutaneous signs	Nodular dermatitis	binary/categorical indicator	Sig_cutan_d0_D_nodular	Day 0	Total	56								1	1,8	1/56 (1.8%)	
Cutaneous signs	Nodular dermatitis	binary/categorical indicator	Sig_cutan_d0_D_nodular	Day 0	Omnifect Proimmune	27								1	3,7	1/27 (3.7%)	
Cutaneous signs	Nodular dermatitis	binary/categorical indicator	Sig_cutan_d0_D_nodular	Day 0	Placebo	29								0	0,0	0/29 (0.0%)	
Cutaneous signs	Nodular dermatitis	binary/categorical indicator	Sig_cutan_d90_D_nodular	Day 90	Total	38								0	0,0	0/38 (0.0%)	
Cutaneous signs	Nodular dermatitis	binary/categorical indicator	Sig_cutan_d90_D_nodular	Day 90	Omnifect Proimmune	19								0	0,0	0/19 (0.0%)	

Cutaneous signs	Nodular dermatitis	binary/categorical indicator	Sig_cutan_d90_D_nodular	Day 90	Placebo	19								0	0,0	0/19 (0.0%)
Cutaneous signs	Nodular dermatitis	binary/categorical indicator	Sig_cutan_d180_D_nodular	Day 180	Total	36								0	0,0	0/36 (0.0%)
Cutaneous signs	Nodular dermatitis	binary/categorical indicator	Sig_cutan_d180_D_nodular	Day 180	Omnifect Proimmune	18								0	0,0	0/18 (0.0%)
Cutaneous signs	Nodular dermatitis	binary/categorical indicator	Sig_cutan_d180_D_nodular	Day 180	Placebo	18								0	0,0	0/18 (0.0%)
Cutaneous signs	Nodular dermatitis	binary/categorical indicator	Sig_cutan_d360_D_nodular	Day 360	Total	31								0	0,0	0/31 (0.0%)
Cutaneous signs	Nodular dermatitis	binary/categorical indicator	Sig_cutan_d360_D_nodular	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Cutaneous signs	Nodular dermatitis	binary/categorical indicator	Sig_cutan_d360_D_nodular	Day 360	Placebo	16								0	0,0	0/16 (0.0%)
Cutaneous signs	Papular dermatitis	binary/categorical indicator	Sig_cutan_d0_D_papular	Day 0	Total	56								1	1,8	1/56 (1.8%)
Cutaneous signs	Papular dermatitis	binary/categorical indicator	Sig_cutan_d0_D_papular	Day 0	Omnifect Proimmune	27								0	0,0	0/27 (0.0%)
Cutaneous signs	Papular dermatitis	binary/categorical indicator	Sig_cutan_d0_D_papular	Day 0	Placebo	29								1	3,4	1/29 (3.4%)

Cutaneous signs	Papular dermatitis	binary/categorical indicator	Sig_cutan_d90_D_papular	Day 90	Total	38								1	2,6	1/38 (2.6%)
Cutaneous signs	Papular dermatitis	binary/categorical indicator	Sig_cutan_d90_D_papular	Day 90	Omnifect Proimmune	19								0	0,0	0/19 (0.0%)
Cutaneous signs	Papular dermatitis	binary/categorical indicator	Sig_cutan_d90_D_papular	Day 90	Placebo	19								1	5,3	1/19 (5.3%)
Cutaneous signs	Papular dermatitis	binary/categorical indicator	Sig_cutan_d180_D_papular	Day 180	Total	36								0	0,0	0/36 (0.0%)
Cutaneous signs	Papular dermatitis	binary/categorical indicator	Sig_cutan_d180_D_papular	Day 180	Omnifect Proimmune	18								0	0,0	0/18 (0.0%)
Cutaneous signs	Papular dermatitis	binary/categorical indicator	Sig_cutan_d180_D_papular	Day 180	Placebo	18								0	0,0	0/18 (0.0%)
Cutaneous signs	Papular dermatitis	binary/categorical indicator	Sig_cutan_d360_D_papular	Day 360	Total	31								0	0,0	0/31 (0.0%)
Cutaneous signs	Papular dermatitis	binary/categorical indicator	Sig_cutan_d360_D_papular	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Cutaneous signs	Papular dermatitis	binary/categorical indicator	Sig_cutan_d360_D_papular	Day 360	Placebo	16								0	0,0	0/16 (0.0%)
Cutaneous signs	Pustular dermatitis	binary/categorical indicator	Sig_cutan_d0_D_pustular	Day 0	Total	56								1	1,8	1/56 (1.8%)

Cutaneous signs	Pustular dermatitis	binary/categorical indicator	Sig_cutan_d0_D_pustular	Day 0	Omnifect Proimmune	27								0	0,0	0/27 (0.0%)
Cutaneous signs	Pustular dermatitis	binary/categorical indicator	Sig_cutan_d0_D_pustular	Day 0	Placebo	29								1	3,4	1/29 (3.4%)
Cutaneous signs	Pustular dermatitis	binary/categorical indicator	Sig_cutan_d90_D_pustular	Day 90	Total	38								0	0,0	0/38 (0.0%)
Cutaneous signs	Pustular dermatitis	binary/categorical indicator	Sig_cutan_d90_D_pustular	Day 90	Omnifect Proimmune	19								0	0,0	0/19 (0.0%)
Cutaneous signs	Pustular dermatitis	binary/categorical indicator	Sig_cutan_d90_D_pustular	Day 90	Placebo	19								0	0,0	0/19 (0.0%)
Cutaneous signs	Pustular dermatitis	binary/categorical indicator	Sig_cutan_d180_D_pustular	Day 180	Total	36								1	2,8	1/36 (2.8%)
Cutaneous signs	Pustular dermatitis	binary/categorical indicator	Sig_cutan_d180_D_pustular	Day 180	Omnifect Proimmune	18								1	5,6	1/18 (5.6%)
Cutaneous signs	Pustular dermatitis	binary/categorical indicator	Sig_cutan_d180_D_pustular	Day 180	Placebo	18								0	0,0	0/18 (0.0%)
Cutaneous signs	Pustular dermatitis	binary/categorical indicator	Sig_cutan_d360_D_pustular	Day 360	Total	31								0	0,0	0/31 (0.0%)

Cutaneous signs	Pustular dermatitis	binary/categorical indicator	Sig_cutan_d360_D_pustular	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Cutaneous signs	Pustular dermatitis	binary/categorical indicator	Sig_cutan_d360_D_pustular	Day 360	Placebo	16								0	0,0	0/16 (0.0%)
Cutaneous signs	Onychogryphosis	binary/categorical indicator	Sig_cutan_d0_Onicogrifosis	Day 0	Total	56								1	1,8	1/56 (1.8%)
Cutaneous signs	Onychogryphosis	binary/categorical indicator	Sig_cutan_d0_Onicogrifosis	Day 0	Omnifect Proimmune	27								0	0,0	0/27 (0.0%)
Cutaneous signs	Onychogryphosis	binary/categorical indicator	Sig_cutan_d0_Onicogrifosis	Day 0	Placebo	29								1	3,4	1/29 (3.4%)
Cutaneous signs	Onychogryphosis	binary/categorical indicator	Sig_cutan_d90_Onicogrifosis	Day 90	Total	38								1	2,6	1/38 (2.6%)
Cutaneous signs	Onychogryphosis	binary/categorical indicator	Sig_cutan_d90_Onicogrifosis	Day 90	Omnifect Proimmune	19								1	5,3	1/19 (5.3%)
Cutaneous signs	Onychogryphosis	binary/categorical indicator	Sig_cutan_d90_Onicogrifosis	Day 90	Placebo	19								0	0,0	0/19 (0.0%)
Cutaneous signs	Onychogryphosis	binary/categorical indicator	Sig_cutan_d180_Onicogrifosis	Day 180	Total	36								0	0,0	0/36 (0.0%)

Cutaneous signs	Onychogryphosis	binary/categorical indicator	Sig_cutan_d180_Onicogrifosis	Day 180	Omnifect Proimmune	18								0	0,0	0/18 (0.0%)
Cutaneous signs	Onychogryphosis	binary/categorical indicator	Sig_cutan_d180_Onicogrifosis	Day 180	Placebo	18								0	0,0	0/18 (0.0%)
Cutaneous signs	Onychogryphosis	binary/categorical indicator	Sig_cutan_d360_Onicogrifosis	Day 360	Total	31								0	0,0	0/31 (0.0%)
Cutaneous signs	Onychogryphosis	binary/categorical indicator	Sig_cutan_d360_Onicogrifosis	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Cutaneous signs	Onychogryphosis	binary/categorical indicator	Sig_cutan_d360_Onicogrifosis	Day 360	Placebo	16								0	0,0	0/16 (0.0%)
Cutaneous signs	Hyperkeratosis	binary/categorical indicator	Sig_cutan_d0_Hiperqueratosis	Day 0	Total	56								6	10,7	6/56 (10.7%)
Cutaneous signs	Hyperkeratosis	binary/categorical indicator	Sig_cutan_d0_Hiperqueratosis	Day 0	Omnifect Proimmune	27								1	3,7	1/27 (3.7%)
Cutaneous signs	Hyperkeratosis	binary/categorical indicator	Sig_cutan_d0_Hiperqueratosis	Day 0	Placebo	29								5	17,2	5/29 (17.2%)
Cutaneous signs	Hyperkeratosis	binary/categorical indicator	Sig_cutan_d90_Hiperqueratosis	Day 90	Total	38								1	2,6	1/38 (2.6%)

Cutaneous signs	Hyperkeratosis	binary/categorical indicator	Sig_cutan_d90_Hiperqueratosis	Day 90	Omnifect Proimmune	19								0	0,0	0/19 (0.0%)
Cutaneous signs	Hyperkeratosis	binary/categorical indicator	Sig_cutan_d90_Hiperqueratosis	Day 90	Placebo	19								1	5,3	1/19 (5.3%)
Cutaneous signs	Hyperkeratosis	binary/categorical indicator	Sig_cutan_d180_Hiperqueratosis	Day 180	Total	36								1	2,8	1/36 (2.8%)
Cutaneous signs	Hyperkeratosis	binary/categorical indicator	Sig_cutan_d180_Hiperqueratosis	Day 180	Omnifect Proimmune	18								0	0,0	0/18 (0.0%)
Cutaneous signs	Hyperkeratosis	binary/categorical indicator	Sig_cutan_d180_Hiperqueratosis	Day 180	Placebo	18								1	5,6	1/18 (5.6%)
Cutaneous signs	Hyperkeratosis	binary/categorical indicator	Sig_cutan_d360_Hiperqueratosis	Day 360	Total	31								0	0,0	0/31 (0.0%)
Cutaneous signs	Hyperkeratosis	binary/categorical indicator	Sig_cutan_d360_Hiperqueratosis	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Cutaneous signs	Hyperkeratosis	binary/categorical indicator	Sig_cutan_d360_Hiperqueratosis	Day 360	Placebo	16								0	0,0	0/16 (0.0%)
Cutaneous signs	Pruritus	binary/categorical indicator	Sig_cutan_d90_prurito	Day 90	Total	38								1	2,6	1/38 (2.6%)

Cutaneous signs	Pruritus	binary/categorical indicator	Sig_cutan_d90_prurito	Day 90	Omnifect Proimmune	19								1	5,3	1/19 (5.3%)
Cutaneous signs	Pruritus	binary/categorical indicator	Sig_cutan_d90_prurito	Day 90	Placebo	19								0	0,0	0/19 (0.0%)
Cutaneous signs	Pruritus	binary/categorical indicator	Sig_cutan_d180_prurito	Day 180	Total	36								0	0,0	0/36 (0.0%)
Cutaneous signs	Pruritus	binary/categorical indicator	Sig_cutan_d180_prurito	Day 180	Omnifect Proimmune	18								0	0,0	0/18 (0.0%)
Cutaneous signs	Pruritus	binary/categorical indicator	Sig_cutan_d180_prurito	Day 180	Placebo	18								0	0,0	0/18 (0.0%)
Cutaneous signs	Pruritus	binary/categorical indicator	Sig_cutan_d360_prurito	Day 360	Total	31								0	0,0	0/31 (0.0%)
Cutaneous signs	Pruritus	binary/categorical indicator	Sig_cutan_d360_prurito	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Cutaneous signs	Pruritus	binary/categorical indicator	Sig_cutan_d360_prurito	Day 360	Placebo	16								0	0,0	0/16 (0.0%)
Other signs	Ocular signs	binary/categorical indicator	Sig_ocu_d0	Day 0	Total	56								6	10,7	6/56 (10.7%)
Other signs	Ocular signs	binary/categorical indicator	Sig_ocu_d0	Day 0	Omnifect Proimmune	27								2	7,4	2/27 (7.4%)
Other signs	Ocular signs	binary/categorical indicator	Sig_ocu_d0	Day 0	Placebo	29								4	13,8	4/29 (13.8%)

Other signs	Ocular signs	binary/categorical indicator	Sig_ocu_d90	Day 90	Total	38								0	0,0	0/38 (0.0%)
Other signs	Ocular signs	binary/categorical indicator	Sig_ocu_d90	Day 90	Omnifect Proimmune	19								0	0,0	0/19 (0.0%)
Other signs	Ocular signs	binary/categorical indicator	Sig_ocu_d90	Day 90	Placebo	19								0	0,0	0/19 (0.0%)
Other signs	Ocular signs	binary/categorical indicator	Sig_ocu_d180	Day 180	Total	36								3	8,3	3/36 (8.3%)
Other signs	Ocular signs	binary/categorical indicator	Sig_ocu_d180	Day 180	Omnifect Proimmune	18								1	5,6	1/18 (5.6%)
Other signs	Ocular signs	binary/categorical indicator	Sig_ocu_d180	Day 180	Placebo	18								2	11,1	2/18 (11.1%)
Other signs	Ocular signs	binary/categorical indicator	Sig_ocu_d360	Day 360	Total	31								1	3,2	1/31 (3.2%)
Other signs	Ocular signs	binary/categorical indicator	Sig_ocu_d360	Day 360	Omnifect Proimmune	15								1	6,7	1/15 (6.7%)
Other signs	Ocular signs	binary/categorical indicator	Sig_ocu_d360	Day 360	Placebo	16								0	0,0	0/16 (0.0%)
Other signs	Neurological signs	binary/categorical indicator	Sig_neuro_d0	Day 0	Total	56								3	5,4	3/56 (5.4%)
Other signs	Neurological signs	binary/categorical indicator	Sig_neuro_d0	Day 0	Omnifect Proimmune	27								2	7,4	2/27 (7.4%)

Other signs	Neurological signs	binary/categorical indicator	Sig_neuro_d0	Day 0	Placebo	29								1	3,4	1/29 (3.4%)
Other signs	Neurological signs	binary/categorical indicator	Sig_neuro_d90	Day 90	Total	38								1	2,6	1/38 (2.6%)
Other signs	Neurological signs	binary/categorical indicator	Sig_neuro_d90	Day 90	Omnifect Proimmune	19								0	0,0	0/19 (0.0%)
Other signs	Neurological signs	binary/categorical indicator	Sig_neuro_d90	Day 90	Placebo	19								1	5,3	1/19 (5.3%)
Other signs	Neurological signs	binary/categorical indicator	Sig_neuro_d180	Day 180	Total	36								1	2,8	1/36 (2.8%)
Other signs	Neurological signs	binary/categorical indicator	Sig_neuro_d180	Day 180	Omnifect Proimmune	18								1	5,6	1/18 (5.6%)
Other signs	Neurological signs	binary/categorical indicator	Sig_neuro_d180	Day 180	Placebo	18								0	0,0	0/18 (0.0%)
Other signs	Neurological signs	binary/categorical indicator	Sig_neuro_d360	Day 360	Total	31								1	3,2	1/31 (3.2%)
Other signs	Neurological signs	binary/categorical indicator	Sig_neuro_d360	Day 360	Omnifect Proimmune	15								0	0,0	0/15 (0.0%)
Other signs	Neurological signs	binary/categorical indicator	Sig_neuro_d360	Day 360	Placebo	16								1	6,3	1/16 (6.2%)
Other signs	Other signs present	binary/categorical indicator	Otrossig_d0	Day 0	Total	56								21	37,5	21/56 (37.5%)

Other signs	Other signs present	binary/categorical indicator	Otrossig_d0	Day 0	Omnifect Proimmune	27								12	44,4	12/27 (44.4%)
Other signs	Other signs present	binary/categorical indicator	Otrossig_d0	Day 0	Placebo	29								9	31,0	9/29 (31.0%)
Other signs	Other signs present	binary/categorical indicator	Otrossig_d90	Day 90	Total	38								11	28,9	11/38 (28.9%)
Other signs	Other signs present	binary/categorical indicator	Otrossig_d90	Day 90	Omnifect Proimmune	19								3	15,8	3/19 (15.8%)
Other signs	Other signs present	binary/categorical indicator	Otrossig_d90	Day 90	Placebo	19								8	42,1	8/19 (42.1%)
Other signs	Other signs present	binary/categorical indicator	Otrossig_d180	Day 180	Total	36								8	22,2	8/36 (22.2%)
Other signs	Other signs present	binary/categorical indicator	Otrossig_d180	Day 180	Omnifect Proimmune	18								3	16,7	3/18 (16.7%)
Other signs	Other signs present	binary/categorical indicator	Otrossig_d180	Day 180	Placebo	18								5	27,8	5/18 (27.8%)
Other signs	Other signs present	binary/categorical indicator	Otrossig_d360	Day 360	Total	31								6	19,4	6/31 (19.4%)
Other signs	Other signs present	binary/categorical indicator	Otrossig_d360	Day 360	Omnifect Proimmune	15								1	6,7	1/15 (6.7%)
Other signs	Other signs present	binary/categorical indicator	Otrossig_d360	Day 360	Placebo	16								5	31,3	5/16 (31.2%)

Urinalysis	Urine dipstick blood positive	binary/categorical indicator	dipstick_d0_sangre	Day 0	Total	55								26	47,3	26/55 (47.3 %)
Urinalysis	Urine dipstick blood positive	binary/categorical indicator	dipstick_d0_sangre	Day 0	Omnifect Proimmune	26								15	57,7	15/26 (57.7 %)
Urinalysis	Urine dipstick blood positive	binary/categorical indicator	dipstick_d0_sangre	Day 0	Placebo	29								11	37,9	11/29 (37.9 %)
Urinalysis	Urine dipstick blood positive	binary/categorical indicator	dipstick_d90_sangre	Day 90	Total	38								14	36,8	14/38 (36.8 %)
Urinalysis	Urine dipstick blood positive	binary/categorical indicator	dipstick_d90_sangre	Day 90	Omnifect Proimmune	19								7	36,8	7/19 (36.8 %)
Urinalysis	Urine dipstick blood positive	binary/categorical indicator	dipstick_d90_sangre	Day 90	Placebo	19								7	36,8	7/19 (36.8 %)
Urinalysis	Urine dipstick blood positive	binary/categorical indicator	dipstick_d180_sangre	Day 180	Total	37								12	32,4	12/37 (32.4 %)
Urinalysis	Urine dipstick blood positive	binary/categorical indicator	dipstick_d180_sangre	Day 180	Omnifect Proimmune	19								5	26,3	5/19 (26.3 %)
Urinalysis	Urine dipstick blood positive	binary/categorical indicator	dipstick_d180_sangre	Day 180	Placebo	18								7	38,9	7/18 (38.9 %)

Urinalysis	Urine dipstick blood positive	binary/categorical indicator	dipstick_d360_sangre	Day 360	Total	30								12	40,0	12/30 (40.0%)
Urinalysis	Urine dipstick blood positive	binary/categorical indicator	dipstick_d360_sangre	Day 360	Omnifect Proimmune	16								6	37,5	6/16 (37.5%)
Urinalysis	Urine dipstick blood positive	binary/categorical indicator	dipstick_d360_sangre	Day 360	Placebo	14								6	42,9	6/14 (42.9%)
Urinalysis	Urine culture positive	binary/categorical indicator	urocult_d0	Day 0	Total	56								6	10,7	6/56 (10.7%)
Urinalysis	Urine culture positive	binary/categorical indicator	urocult_d0	Day 0	Omnifect Proimmune	27								3	11,1	3/27 (11.1%)
Urinalysis	Urine culture positive	binary/categorical indicator	urocult_d0	Day 0	Placebo	29								3	10,3	3/29 (10.3%)
Urinalysis	Urine culture positive	binary/categorical indicator	urocult_d90	Day 90	Total	37								3	8,1	3/37 (8.1%)
Urinalysis	Urine culture positive	binary/categorical indicator	urocult_d90	Day 90	Omnifect Proimmune	19								2	10,5	2/19 (10.5%)
Urinalysis	Urine culture positive	binary/categorical indicator	urocult_d90	Day 90	Placebo	18								1	5,6	1/18 (5.6%)
Urinalysis	Urine culture positive	binary/categorical indicator	urocult_d180	Day 180	Total	37								2	5,4	2/37 (5.4%)

Urinalysis	Urine culture positive	binary/categorical indicator	urocult_d180	Day 180	Omnifect Proimmune	19								1	5,3	1/19 (5.3%)
Urinalysis	Urine culture positive	binary/categorical indicator	urocult_d180	Day 180	Placebo	18								1	5,6	1/18 (5.6%)
Urinalysis	Urine culture positive	binary/categorical indicator	urocult_d360	Day 360	Total	29								2	6,9	2/29 (6.9%)
Urinalysis	Urine culture positive	binary/categorical indicator	urocult_d360	Day 360	Omnifect Proimmune	15								2	13,3	2/15 (13.3%)
Urinalysis	Urine culture positive	binary/categorical indicator	urocult_d360	Day 360	Placebo	14								0	0,0	0/14 (0.0%)
Urinalysis	Xanthine crystals	binary/categorical indicator	dipstick_d0_sedimento_cristalesx	Day 0	Total	55								2	3,6	2/55 (3.6%)
Urinalysis	Xanthine crystals	binary/categorical indicator	dipstick_d0_sedimento_cristalesx	Day 0	Omnifect Proimmune	26								2	7,7	2/26 (7.7%)
Urinalysis	Xanthine crystals	binary/categorical indicator	dipstick_d0_sedimento_cristalesx	Day 0	Placebo	29								0	0,0	0/29 (0.0%)
Urinalysis	Xanthine crystals	binary/categorical indicator	dipstick_d90_sedimento_cristales	Day 90	Total	38								7	18,4	7/38 (18.4%)
Urinalysis	Xanthine crystals	binary/categorical indicator	dipstick_d90_sedimento_cristales	Day 90	Omnifect Proimmune	19								3	15,8	3/19 (15.8%)

Urinalysis	Xanthine crystals	binary/categorical indicator	dipstick_d90_sedimento_cristales	Day 90	Placebo	19								4	21,1	4/19 (21.1%)
Urinalysis	Xanthine crystals	binary/categorical indicator	dipstick_d180_sedimento_cristale	Day 180	Total	37								7	18,9	7/37 (18.9%)
Urinalysis	Xanthine crystals	binary/categorical indicator	dipstick_d180_sedimento_cristale	Day 180	Omnifect Proimmune	19								3	15,8	3/19 (15.8%)
Urinalysis	Xanthine crystals	binary/categorical indicator	dipstick_d180_sedimento_cristale	Day 180	Placebo	18								4	22,2	4/18 (22.2%)
Urinalysis	Xanthine crystals	binary/categorical indicator	dipstick_d360_sedimento_cristale	Day 360	Total	30								7	23,3	7/30 (23.3%)
Urinalysis	Xanthine crystals	binary/categorical indicator	dipstick_d360_sedimento_cristale	Day 360	Omnifect Proimmune	16								5	31,3	5/16 (31.2%)
Urinalysis	Xanthine crystals	binary/categorical indicator	dipstick_d360_sedimento_cristale	Day 360	Placebo	14								2	14,3	2/14 (14.3%)

Supplementary Table S4. Full serological, molecular and individual cytokine outcomes

Domain	Outcome	Scale	Variable	Visit	Treatment group	n	mean	sd	median	q1	q3	min	max	n_positive	percent_positive	formatted

Serology	**IFI titre/category**	**ordinal titre code (0–7)**	**IFI_leish_d0**	**Day 0**	**Total**	54	4,33	1,96	4,00	3,00	6,00	0,00	7,00			
Serology	IFI titre/category	ordinal titre code (0–7)	IFI_leish_d0	Day 0	Omnifect Proimmune	26	4,12	1,95	4,00	3,00	5,75	1,00	7,00			
Serology	IFI titre/category	ordinal titre code (0–7)	IFI_leish_d0	Day 0	Placebo	28	4,54	1,99	5,00	4,00	6,00	0,00	7,00			
Serology	IFI titre/category	ordinal titre code (0–7)	IFI_leish_d90	Day 90	Total	38	2,84	1,79	3,00	2,00	4,00	0,00	7,00			
Serology	IFI titre/category	ordinal titre code (0–7)	IFI_leish_d90	Day 90	Omnifect Proimmune	19	2,89	1,70	3,00	2,00	3,50	0,00	7,00			
Serology	IFI titre/category	ordinal titre code (0–7)	IFI_leish_d90	Day 90	Placebo	19	2,79	1,93	3,00	1,50	4,00	0,00	6,00			
Serology	IFI titre/category	ordinal titre code (0–7)	IFI_leish_d180	Day 180	Total	37	3,05	1,96	3,00	2,00	4,00	0,00	7,00			
Serology	IFI titre/category	ordinal titre code (0–7)	IFI_leish_d180	Day 180	Omnifect Proimmune	19	3,16	1,71	3,00	2,50	3,50	0,00	7,00			
Serology	IFI titre/category	ordinal titre code (0–7)	IFI_leish_d180	Day 180	Placebo	18	2,94	2,24	3,00	1,00	4,75	0,00	7,00			

Serology	IFI titre/category	ordinal titre code (0–7)	IFI_leish_d360	Day 360	Total	31	2,29	2,08	2,00	0,50	3,00	0,00	6,00			
Serology	IFI titre/category	ordinal titre code (0–7)	IFI_leish_d360	Day 360	Omnifect Proimmune	16	2,88	2,13	2,50	1,00	5,00	0,00	6,00			
Serology	IFI titre/category	ordinal titre code (0–7)	IFI_leish_d360	Day 360	Placebo	15	1,67	1,91	1,00	0,00	2,50	0,00	6,00			
Molecular	**TaqMan qPCR positivity**	**n/N (%)**	**TaqMan_qPCR_positive_d0**	**Day 0**	**Total**	43								36	83,7	36/43 (83.7%)
Molecular	TaqMan qPCR positivity	n/N (%)	TaqMan_qPCR_positive_d0	Day 0	Omnifect Proimmune	21								19	90,5	19/21 (90.5%)
Molecular	TaqMan qPCR positivity	n/N (%)	TaqMan_qPCR_positive_d0	Day 0	Placebo	22								17	77,3	17/22 (77.3%)
Molecular	TaqMan qPCR positivity	n/N (%)	TaqMan_qPCR_positive_d90	Day 90	Total	27								3	11,1	3/27 (11.1%)
Molecular	TaqMan qPCR positivity	n/N (%)	TaqMan_qPCR_positive_d90	Day 90	Omnifect Proimmune	15								2	13,3	2/15 (13.3%)
Molecular	TaqMan qPCR positivity	n/N (%)	TaqMan_qPCR_positive_d90	Day 90	Placebo	12								1	8,3	1/12 (8.3%)
Molecular	TaqMan qPCR positivity	n/N (%)	TaqMan_qPCR_positive_d180	Day 180	Total	20								2	10,0	2/20 (10.0%)
Molecular	TaqMan qPCR positivity	n/N (%)	TaqMan_qPCR_positive_d180	Day 180	Omnifect Proimmune	12								2	16,7	2/12 (16.7%)

Molecular	TaqMan qPCR positivity	n/N (%)	TaqMan_qPCR_positive_d180	Day 180	Placebo	8								0	0,0	0/8 (0.0%)
Molecular	TaqMan qPCR positivity	n/N (%)	TaqMan_qPCR_positive_d360	Day 360	Total	18								2	11,1	2/18 (11.1%)
Molecular	TaqMan qPCR positivity	n/N (%)	TaqMan_qPCR_positive_d360	Day 360	Omnifect Proimmune	9								1	11,1	1/9 (11.1%)
Molecular	TaqMan qPCR positivity	n/N (%)	TaqMan_qPCR_positive_d360	Day 360	Placebo	9								1	11,1	1/9 (11.1%)
Molecular	**TaqMan qPCR Ct**	**Ct cycles**	**NºCtqPCR_SND_d0**	**Day 0**	**Total**	36	33,30	2,62	35,00	30,62	35,00	26,14	35,00			
Molecular	TaqMan qPCR Ct	Ct cycles	NºCtqPCR_SND_d0	Day 0	Omnifect Proimmune	17	33,20	2,38	35,00	30,58	35,00	29,02	35,00			
Molecular	TaqMan qPCR Ct	Ct cycles	NºCtqPCR_SND_d0	Day 0	Placebo	19	33,39	2,88	35,00	32,82	35,00	26,14	35,00			
Molecular	TaqMan qPCR Ct	Ct cycles	NºCtqPCR_SND_d90	Day 90	Total	27	34,56	1,61	35,00	35,00	35,00	28,16	35,00			
Molecular	TaqMan qPCR Ct	Ct cycles	NºCtqPCR_SND_d90	Day 90	Omnifect Proimmune	15	34,66	1,31	35,00	35,00	35,00	29,93	35,00			
Molecular	TaqMan qPCR Ct	Ct cycles	NºCtqPCR_SND_d90	Day 90	Placebo	12	34,43	1,97	35,00	35,00	35,00	28,16	35,00			
Molecular	TaqMan qPCR Ct	Ct cycles	NºCtqPCR_SND_d180	Day 180	Total	20	34,34	2,06	35,00	35,00	35,00	27,58	35,00			
Molecular	TaqMan qPCR Ct	Ct cycles	NºCtqPCR_SND_d180	Day 180	Omnifect Proimmune	12	33,89	2,60	35,00	35,00	35,00	27,58	35,00			
Molecular	TaqMan qPCR Ct	Ct cycles	NºCtqPCR_SND_d180	Day 180	Placebo	8	35,00	0,00	35,00	35,00	35,00	35,00	35,00			
Molecular	TaqMan qPCR Ct	Ct cycles	NºCtqPCR_SND_d360	Day 360	Total	18	33,83	3,42	35,00	35,00	35,00	24,41	35,00			
Molecular	TaqMan qPCR Ct	Ct cycles	NºCtqPCR_SND_d360	Day 360	Omnifect Proimmune	9	33,82	3,53	35,00	35,00	35,00	24,41	35,00			
Molecular	TaqMan qPCR Ct	Ct cycles	NºCtqPCR_SND_d360	Day 360	Placebo	9	33,83	3,51	35,00	35,00	35,00	24,46	35,00			

Molecular	**SYBR Green qPCR positivity**	**n/N (%)**	**SYBR_qPCR_positive_d0**	**Day 0**	**Total**	39								25	64,1	25/39 (64.1%)
Molecular	SYBR Green qPCR positivity	n/N (%)	SYBR_qPCR_positive_d0	Day 0	Omnifect Proimmune	19								9	47,4	9/19 (47.4%)
Molecular	SYBR Green qPCR positivity	n/N (%)	SYBR_qPCR_positive_d0	Day 0	Placebo	20								16	80,0	16/20 (80.0%)
Molecular	SYBR Green qPCR positivity	n/N (%)	SYBR_qPCR_positive_d90	Day 90	Total	23								15	65,2	15/23 (65.2%)
Molecular	SYBR Green qPCR positivity	n/N (%)	SYBR_qPCR_positive_d90	Day 90	Omnifect Proimmune	10								8	80,0	8/10 (80.0%)
Molecular	SYBR Green qPCR positivity	n/N (%)	SYBR_qPCR_positive_d90	Day 90	Placebo	13								7	53,8	7/13 (53.8%)
Molecular	SYBR Green qPCR positivity	n/N (%)	SYBR_qPCR_positive_d180	Day 180	Total	20								15	75,0	15/20 (75.0%)
Molecular	SYBR Green qPCR positivity	n/N (%)	SYBR_qPCR_positive_d180	Day 180	Omnifect Proimmune	12								10	83,3	10/12 (83.3%)
Molecular	SYBR Green qPCR positivity	n/N (%)	SYBR_qPCR_positive_d180	Day 180	Placebo	8								5	62,5	5/8 (62.5%)
Molecular	SYBR Green qPCR positivity	n/N (%)	SYBR_qPCR_positive_d360	Day 360	Total	18								8	44,4	8/18 (44.4%)
Molecular	SYBR Green qPCR positivity	n/N (%)	SYBR_qPCR_positive_d360	Day 360	Omnifect Proimmune	9								7	77,8	7/9 (77.8%)
Molecular	SYBR Green qPCR positivity	n/N (%)	SYBR_qPCR_positive_d360	Day 360	Placebo	9								1	11,1	1/9 (11.1%)

Molecular	**SYBR Green qPCR Ct**	**Ct cycles**	**NºCtqPCR_SYB_d0**	**Day 0**	**Total**	25	34,65	3,45	34,15	33,24	38,00	28,62	38,00			
Molecular	SYBR Green qPCR Ct	Ct cycles	NºCtqPCR_SYB_d0	Day 0	Omnifect Proimmune	9	34,67	3,68	34,45	33,37	38,00	28,67	38,00			
Molecular	SYBR Green qPCR Ct	Ct cycles	NºCtqPCR_SYB_d0	Day 0	Placebo	16	34,64	3,45	33,97	32,99	38,00	28,62	38,00			
Molecular	SYBR Green qPCR Ct	Ct cycles	NºCtqPCR_SYB_d90	Day 90	Total	23	34,77	2,72	34,11	32,96	38,00	28,02	38,00			
Molecular	SYBR Green qPCR Ct	Ct cycles	NºCtqPCR_SYB_d90	Day 90	Omnifect Proimmune	10	34,34	2,04	33,98	32,92	34,24	32,42	38,00			
Molecular	SYBR Green qPCR Ct	Ct cycles	NºCtqPCR_SYB_d90	Day 90	Placebo	13	35,11	3,19	34,38	32,99	38,00	28,02	38,00			
Molecular	SYBR Green qPCR Ct	Ct cycles	NºCtqPCR_SYB_d180	Day 180	Total	20	33,95	2,88	33,30	32,68	35,40	27,76	38,00			
Molecular	SYBR Green qPCR Ct	Ct cycles	NºCtqPCR_SYB_d180	Day 180	Omnifect Proimmune	12	33,26	2,98	33,30	32,51	34,09	27,76	38,00			
Molecular	SYBR Green qPCR Ct	Ct cycles	NºCtqPCR_SYB_d180	Day 180	Placebo	8	35,00	2,55	33,86	32,83	38,00	32,66	38,00			
Molecular	SYBR Green qPCR Ct	Ct cycles	NºCtqPCR_SYB_d360	Day 360	Total	18	34,69	4,66	38,00	32,77	38,00	23,43	38,00			
Molecular	SYBR Green qPCR Ct	Ct cycles	NºCtqPCR_SYB_d360	Day 360	Omnifect Proimmune	9	33,00	4,01	32,87	32,73	33,03	24,14	38,00			
Molecular	SYBR Green qPCR Ct	Ct cycles	NºCtqPCR_SYB_d360	Day 360	Placebo	9	36,38	4,86	38,00	38,00	38,00	23,43	38,00			
Cytokines	**IFN-gamma**	**pg/ml**	**IFN_d0**	**Day 0**	**Total**	20	196,77	781,05	0,00	0,00	3,80	0,00	3503,80			
Cytokines	IFN-gamma	pg/ml	IFN_d0	Day 0	Omnifect Proimmune	10	352,39	1107,30	0,00	0,00	2,85	0,00	3503,80			
Cytokines	IFN-gamma	pg/ml	IFN_d0	Day 0	Placebo	10	41,14	88,92	0,00	0,00	2,85	0,00	253,80			
Cytokines	IFN-gamma	pg/ml	IFN_90	Day 90	Total	19	124,28	481,13	0,00	0,00	0,00	0,00	2103,75			
Cytokines	IFN-gamma	pg/ml	IFN_90	Day 90	Omnifect Proimmune	10	210,38	665,26	0,00	0,00	0,00	0,00	2103,75			
Cytokines	IFN-gamma	pg/ml	IFN_90	Day 90	Placebo	9	28,61	58,13	0,00	0,00	0,00	0,00	153,75			

Cytokines	IFN-gamma	pg/ml	IFN_180	Day 180	Total	0										
Cytokines	IFN-gamma	pg/ml	IFN_180	Day 180	Omnifect Proimmune	0										
Cytokines	IFN-gamma	pg/ml	IFN_180	Day 180	Placebo	0										
Cytokines	IFN-gamma	pg/ml	IFN_360	Day 360	Total	0										
Cytokines	IFN-gamma	pg/ml	IFN_360	Day 360	Omnifect Proimmune	0										
Cytokines	IFN-gamma	pg/ml	IFN_360	Day 360	Placebo	0										
Cytokines	IL-12	pg/ml	IL12_d0	Day 0	Total	20	5622,75	7221,68	2457,75	1379,63	4839,00	639,00	22351,50			
Cytokines	IL-12	pg/ml	IL12_d0	Day 0	Omnifect Proimmune	10	4561,50	6155,24	1445,25	1126,50	4164,00	639,00	18376,50			
Cytokines	IL-12	pg/ml	IL12_d0	Day 0	Placebo	10	6684,00	8349,27	2607,75	2242,13	5214,00	676,50	22351,50			
Cytokines	IL-12	pg/ml	IL12_90	Day 90	Total	20	3663,38	5119,79	2139,00	1004,63	4060,88	1,50	22839,00			
Cytokines	IL-12	pg/ml	IL12_90	Day 90	Omnifect Proimmune	10	1835,25	1729,20	1164,00	760,88	2364,00	226,50	5889,00			
Cytokines	IL-12	pg/ml	IL12_90	Day 90	Placebo	10	5491,50	6702,24	2607,75	1932,75	7276,50	1,50	22839,00			
Cytokines	IL-12	pg/ml	IL12_180	Day 180	Total	0										
Cytokines	IL-12	pg/ml	IL12_180	Day 180	Omnifect Proimmune	0										
Cytokines	IL-12	pg/ml	IL12_180	Day 180	Placebo	0										
Cytokines	IL-12	pg/ml	IL12_360	Day 360	Total	0										
Cytokines	IL-12	pg/ml	IL12_360	Day 360	Omnifect Proimmune	0										
Cytokines	IL-12	pg/ml	IL12_360	Day 360	Placebo	0										

Cytokines	IL-4	pg/ml	IL4_d0	Day 0	Total	27	512,50	252,99	509,40	282,90	734,40	28,70	994,30			
Cytokines	IL-4	pg/ml	IL4_d0	Day 0	Omnifect Proimmune	14	497,19	288,62	482,10	271,05	693,50	28,70	994,30			
Cytokines	IL-4	pg/ml	IL4_d0	Day 0	Placebo	13	528,98	218,78	536,60	395,20	741,20	186,10	786,60			
Cytokines	IL-4	pg/ml	IL4_90	Day 90	Total	26	574,26	292,77	516,20	408,38	801,43	18,40	1227,50			
Cytokines	IL-4	pg/ml	IL4_90	Day 90	Omnifect Proimmune	14	579,14	343,54	547,35	329,70	845,75	18,40	1227,50			
Cytokines	IL-4	pg/ml	IL4_90	Day 90	Placebo	12	568,57	235,06	500,30	451,88	782,10	141,20	913,90			
Cytokines	IL-4	pg/ml	IL4_180	Day 180	Total	26	457,57	298,90	394,20	250,05	645,05	44,30	1000,00			
Cytokines	IL-4	pg/ml	IL4_180	Day 180	Omnifect Proimmune	15	414,31	318,66	337,30	247,40	425,10	44,30	1000,00			
Cytokines	IL-4	pg/ml	IL4_180	Day 180	Placebo	11	516,55	273,05	478,40	381,30	719,10	85,00	1000,00			
Cytokines	IL-4	pg/ml	IL4_360	Day 360	Total	0										
Cytokines	IL-4	pg/ml	IL4_360	Day 360	Omnifect Proimmune	0										
Cytokines	IL-4	pg/ml	IL4_360	Day 360	Placebo	0										
Cytokines	IL-10	pg/ml	IL10_d0	Day 0	Total	20	1,52	4,11	0,00	0,00	0,00	0,00	14,90			
Cytokines	IL-10	pg/ml	IL10_d0	Day 0	Omnifect Proimmune	10	0,00	0,00	0,00	0,00	0,00	0,00	0,00			
Cytokines	IL-10	pg/ml	IL10_d0	Day 0	Placebo	10	3,03	5,52	0,00	0,00	3,08	0,00	14,90			
Cytokines	IL-10	pg/ml	IL10_90	Day 90	Total	19	0,00	0,00	0,00	0,00	0,00	0,00	0,00			
Cytokines	IL-10	pg/ml	IL10_90	Day 90	Omnifect Proimmune	10	0,00	0,00	0,00	0,00	0,00	0,00	0,00			
Cytokines	IL-10	pg/ml	IL10_90	Day 90	Placebo	9	0,00	0,00	0,00	0,00	0,00	0,00	0,00			

Cytokines	IL-10	pg/ml	IL10_180	Day 180	Total	0										
Cytokines	IL-10	pg/ml	IL10_180	Day 180	Omnifect Proimmune	0										
Cytokines	IL-10	pg/ml	IL10_180	Day 180	Placebo	0										
Cytokines	IL-10	pg/ml	IL10_360	Day 360	Total	0										
Cytokines	IL-10	pg/ml	IL10_360	Day 360	Omnifect Proimmune	0										
Cytokines	IL-10	pg/ml	IL10_360	Day 360	Placebo	0										
Cytokines	IL-17	pg/ml	IL17_d0	Day 0	Total	25	28,46	42,76	15,60	15,60	20,68	15,60	226,00			
Cytokines	IL-17	pg/ml	IL17_d0	Day 0	Omnifect Proimmune	12	33,93	60,52	15,60	15,60	16,70	15,60	226,00			
Cytokines	IL-17	pg/ml	IL17_d0	Day 0	Placebo	13	23,41	15,58	15,60	15,60	20,76	15,60	60,82			
Cytokines	IL-17	pg/ml	IL17_d90	Day 90	Total	29	18,46	10,89	15,60	15,60	15,60	15,60	73,72			
Cytokines	IL-17	pg/ml	IL17_d90	Day 90	Omnifect Proimmune	15	19,93	14,91	15,60	15,60	16,43	15,60	73,72			
Cytokines	IL-17	pg/ml	IL17_d90	Day 90	Placebo	14	16,89	3,27	15,60	15,60	15,60	15,60	27,43			
Cytokines	IL-17	pg/ml	IL17_180	Day 180	Total	34	18,18	5,25	15,60	15,60	17,97	15,60	37,10			
Cytokines	IL-17	pg/ml	IL17_180	Day 180	Omnifect Proimmune	18	18,57	6,01	15,60	15,60	17,97	15,60	37,10			
Cytokines	IL-17	pg/ml	IL17_180	Day 180	Placebo	16	17,74	4,38	15,60	15,60	16,66	15,60	28,54			
Cytokines	IL-17	pg/ml	IL17_360	Day 360	Total	0										
Cytokines	IL-17	pg/ml	IL17_360	Day 360	Omnifect Proimmune	0										
Cytokines	IL-17	pg/ml	IL17_360	Day 360	Placebo	0										

Cytokines	IL-21	pg/ml	IL21_d0	Day 0	Total	35	18,54	9,81	15,60	15,60	15,60	15,60	69,79			
Cytokines	IL-21	pg/ml	IL21_d0	Day 0	Omnifect Proimmune	18	19,63	12,73	15,60	15,60	16,16	15,60	69,79			
Cytokines	IL-21	pg/ml	IL21_d0	Day 0	Placebo	17	17,40	5,43	15,60	15,60	15,60	15,60	36,36			
Cytokines	IL-21	pg/ml	IL21_d90	Day 90	Total	34	16,77	2,73	15,60	15,60	15,67	15,60	27,18			
Cytokines	IL-21	pg/ml	IL21_d90	Day 90	Omnifect Proimmune	18	17,74	3,50	15,60	15,60	19,20	15,60	27,18			
Cytokines	IL-21	pg/ml	IL21_d90	Day 90	Placebo	16	15,68	0,29	15,60	15,60	15,60	15,60	16,76			
Cytokines	IL-21	pg/ml	IL21_d180	Day 180	Total	34	17,54	10,12	15,60	15,60	15,60	15,60	74,61			
Cytokines	IL-21	pg/ml	IL21_d180	Day 180	Omnifect Proimmune	18	19,05	13,88	15,60	15,60	15,60	15,60	74,61			
Cytokines	IL-21	pg/ml	IL21_d180	Day 180	Placebo	16	15,84	0,96	15,60	15,60	15,60	15,60	19,44			
Cytokines	IL-21	pg/ml	IL21_d360	Day 360	Total	0										
Cytokines	IL-21	pg/ml	IL21_d360	Day 360	Omnifect Proimmune	0										
Cytokines	IL-21	pg/ml	IL21_d360	Day 360	Placebo	0										

Notes. Group A corresponded to conventional treatment plus Omnifect Proimmune, and Group B to conventional treatment plus placebo. qPCR positivity and Ct summaries are presented using available observations; Ct denominators may be smaller because a recorded Ct was not available for every qualitative result. TaqMan qPCR was prespecified as the primary molecular endpoint; SYBR Green qPCR was interpreted as complementary. Cytokine concentrations are reported in pg/ml. No ELISA determinations were available at day 360. IFI is shown using the ordinal titre code in the source dataset; analytical categories were low (≤ 1:800), intermediate (1:1600–1:3200) and high (≥ 1:6400).

Supplementary Table S5. Exploratory pooled-serum membrane-array substudy: summary by functional axis

Functional axis	**Analytes, n**	**Median ΔΔ**	**IQR lower**	**IQR upper**	**Nominal p value**	**qFDR**
Growth/angiogenesis	8,00	-0,98	-1,96	-0,71	0.008	0.070

Other/miscellaneous	11,00	-0,94	-1,27	-0,15	0.065	0.290
Th1/pro-inflammatory	7,00	-0,59	-0,91	-0,15	0.125	0.380
Chemokines	2,00	-2,08	-3,59	-0,57	0.500	0.750
Th2/regulatory	2,00	-0,76	-1,35	-0,17	0.500	0.759
Classic Th1	2,00	-0,31	-0,57	-0,06	0.500	0.750
Renal/metabolic	4,00	-1,91	-2,45	2,16	0.630	0.800
Th17	1,00	-2,68	-2,68	-2,68	1.000	1.000
Fibrosis/remodelling	3,00	-1,77	-2,09	0,29	1.000	1.000

Note. ΔΔ = log2FC placebo − log2FC Omnifect Proimmune, where log2FC is the log2-transformed fold change from day 90 to baseline. Values below zero indicate a larger relative increase, or a smaller relative decrease, in the Omnifect Proimmune group than in the placebo group. Nominal p values derive from axis-level directionality testing and qFDR values from Benjamini–Hochberg false-discovery-rate correction across axes. Each treatment group and time point were represented by one pooled serum sample from six dogs; therefore, the substudy had no biological replication and does not support individual-level or formal treatment-group inference.


Supplementary Table S6. Complementary Cox proportional-hazards models

Model+A3:H14	**N dogs**	**Events**	**Covariate**	**Hazard ratio**	**95% CI**	**p value**	**Notes**
Main model: treatment + creatinine + albumin	55	16	Treatment group: placebo vs Omnifect Proimmune	1,42	(0.49–4.11)	0.518	Main model is shown for reference.
Main model: treatment + creatinine + albumin	55	16	Baseline serum creatinine, per 1 mg/dl increase	2,43	(1.47–4.00)	<0.001	Main model is shown for reference.
Main model: treatment + creatinine + albumin	55	16	Baseline serum albumin, per 1 g/dl increase	0,31	(0.13–0.75)	0.009	Main model is shown for reference.
Complementary model: main model + grouped baseline LeishVet stage	55	16	Treatment group: placebo vs Omnifect Proimmune	1,28	(0.43–3.82)	0.661	Complementary model.
Complementary model: main model + grouped baseline LeishVet stage	55	16	Baseline serum creatinine, per 1 mg/dl increase	2,82	(1.55–5.14)	<0.001	Complementary model.
Complementary model: main model + grouped baseline LeishVet stage	55	16	Baseline serum albumin, per 1 g/dl increase	0,24	(0.09–0.65)	0.005	Complementary model.
Complementary model: main model + grouped baseline LeishVet stage	55	16	Grouped baseline LeishVet stage III–IV vs I–II	0,40	(0.07–2.21)	0.295	Complementary model.
Complementary model: main model + log baseline UPC	55	16	Treatment group: placebo vs Omnifect Proimmune	1,29	(0.43–3.80)	0.649	Complementary model.

Complementary model: main model + log baseline UPC	55	16	Baseline serum creatinine, per 1 mg/dl increase	2,86	(1.58–5.16)	<0.001	Complementary model.
Complementary model: main model + log baseline UPC	55	16	Baseline serum albumin, per 1 g/dl increase	0,18	(0.05–0.64)	0.008	Complementary model.
Complementary model: main model + log baseline UPC	55	16	Baseline log(UPC)	0,71	(0.40–1.26)	0.240	Complementary model.


Note. Models used administrative censoring at day 360 and Efron's method for tied event times. Omnifect Proimmune was the reference treatment category. Hazard ratios for creatinine and albumin are expressed per 1 mg/dl and 1 g/dl increase, respectively. The main model corresponds to the primary Cox model reported in Table 3; the remaining rows show complementary exploratory Cox models. OP, Omnifect Proimmune; UPC, urinary protein-to-creatinine ratio; HR, hazard ratio; CI, confidence interval.

Supplementary Figures



Group-by-time interaction p values: lethargy p = 0.018; generalised lymphadenomegaly p < 0.001; weight loss p = 0.022; alopecia p = 0.036.

Supplementary Figure S1. Longitudinal trajectories of clinical signs with nominally significant group-by-time interactions. Percentages indicate the proportion of dogs with each clinical sign among those with an available clinical assessment at each visit. Nominal group-by-time interaction p values from mixed-effects logistic models adjusted for grouped baseline LeishVet stage were: lethargy, $p = 0.018$; generalised lymphadenomegaly, $p < 0.001$; weight loss, $p = 0.022$; and alopecia, $p = 0.036$. Frequencies decreased over time in both groups; these sign-specific interactions were not accompanied by a differential longitudinal trajectory in global LeishVet stage.



Supplementary Figure S2. Exploratory pooled-serum membrane-array analysis by functional axis. Points represent the median Delta-Delta (ΔΔ) for each functional axis; where available, horizontal bars represent the interquartile range of the analyte-level ΔΔ values within that axis. Delta-Delta was defined as log2FC placebo − log2FC Omnifect Proimmune. The vertical dashed line at zero represents no between-group difference in change. Values below zero indicate a larger relative increase, or a smaller relative decrease, in the Omnifect Proimmune group than in the placebo group between baseline and day 90. The growth/angiogenesis axis, highlighted in black, showed the largest descriptive between-group difference [median ΔΔ −0.98, interquartile range −1.96 to

−0.71; qFDR approximately 0.07]. Because the substudy was based on one pooled serum sample from six dogs per treatment group and time point, it provided no biological replication and did not allow individual-level or formal between-group inference. The findings should therefore be considered hypothesis-generating and require confirmation in individual samples.